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5We are proud to present this, the thirteenth, annual report
of the European Monitoring Centre for Drugs and Drug
Addiction. This report is only possible through the hard
work and dedication of our partners in the Reitox network
of national focal points and the experts throughout
Europe who have contributed to the analysis. We also
are indebted to those EU agencies and international
organisations working in the drugs ﬁeld. Our report is a
collective endeavour and we thank all those who have
contributed to it. The rationale behind this work is that a
cool-headed analysis of what we know about the drug
situation is a condition for an informed, productive and
reasoned debate. It ensures that opinions are enlightened
by facts, and that those making difﬁcult policy choices can
have a clear understanding of the costs and beneﬁts of the
options available.
This year has been an exceptionally busy time for drug
policy, and the EMCDDA has been honoured to have
supported both the ﬁnal evaluation of the current EU
action plan on drugs and the review of the 1998 United
Nations General Assembly Special Session on the drug
problem. It is gratifying to note that, by international
standards, Europe stands out as one of the parts of the
world where monitoring capacities are most developed.
Nonetheless, we are aware of the limitations of our current
information resources, and are constantly working with our
partners to improve the quality and relevance of the data
available.
An underlying theme of the policy debate on drugs is
the costs, both hidden and more visible, of Europe’s drug
problem. This issue is addressed in various parts of this
report. The EMCDDA has been working to develop an
understanding of the public expenditures associated with
tackling drug use in EU Member States. This work is in
its infancy, and estimates derived are indicative rather
than precise. Nonetheless, they point to considerable
sums being spent, with preliminary ﬁgures of between
EUR 28 billion and EUR 40 billion. Less easy to express
in economic terms is the harm caused by drug use.
What costs do we count in looking at the tragic loss
of life caused by drugs in Europe, the negative impact
on communities where drugs are produced or sold, or
in the way that drug trafﬁcking undermines the social
development and political stability of producer and
transit countries? One has only to consider the worrying
developments resulting from the transiting of cocaine
through West Africa to be reminded of the collateral
damage that this problem can cause.
On a positive note, drug use in Europe appears to be
stabilising, and progress can be noted in the way in which
EU Member States are addressing this issue. For most
forms of drug use, our overall assessment is that we are
not seeing increases, and in some areas the trends appear
to be downward. In terms of responses, we have seen
virtually all Member States adopt a strategic approach,
and greater cohesion is visible at the European level.
Treatment availability continues to grow, and in some
countries it has reached the point where the majority of
heroin users, once considered a hidden population, are
now in contact with services of one sort or another. Not
many years ago, HIV infection among drug injectors was
a central concern in the drug policy debate. Since then,
a pragmatic mixture of prevention, treatment and harm-
reduction measures has become the norm in Europe, and
rates of new infection attributed to drug use have fallen
and continue to do so.
Good news makes poor headlines and can be overlooked.
However, it is important to recognise progress where
it has been made. Increasingly, in Europe, we have
an understanding of what measures can be effective
in addressing drug problems. An acceptance that our
activities can, and do, make a difference is a prerequisite
to securing investment and policy support. This is not to say
that our report does not highlight many areas of concern
for the European Union. Examples include the continuing
increases in cocaine use and the considerable differences
that still exist between countries in the availability and
quality of services for those with problems. We must
therefore conclude that, even if progress has been made,
the journey remains far from ﬁnished. However, today
in Europe, more than at any time in the past, we have a
stronger agreement on the direction we should take.
Marcel Reimen
Chairman, EMCDDA Management Board
Wolfgang Götz
Director, EMCDDA
Foreword
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Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points
in the EU Member States, Norway, the candidate countries and at the European Commission. Under the responsibility of their
governments, the focal points are the national authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at:
http://www.emcdda.europa.eu/about/partners/reitox-network

9This annual report is based on information provided to the EMCDDA by the EU Member States and candidate countries
and Norway (participating in the work of the EMCDDA since 2001) in the form of a national report. The statistical data
reported here relate to the year 2006 (or the last year available). Graphics and tables in this report may reﬂect a subset
of EU countries: the selection is made on the basis of those countries from which data are available for the period of
interest.
Retail prices of drugs reported to the EMCDDA reﬂect the price to the user. Reports on purity or potency, from most
countries, are based on a sample of all drugs seized, and it is generally not possible to relate the reported data to a
speciﬁc level of the drug market. For purity or potency and retail prices, all analyses are based on typical (modal) values
or, in their absence, mean (or median) values.
Reports of the prevalence of drug use based on general population surveys mostly refer to the national population aged
15–64 years. Countries using different upper or lower age limits include: Bulgaria (18–60), the Czech Republic (18),
Denmark (16), Germany (18), Hungary (18–59), Malta (18), Sweden (16) and the United Kingdom (16–59).
In reports on treatment demand, ‘new clients’ refers to those who have entered treatment for the ﬁrst time in their lives and
‘all clients’ refers to all those entering treatment. Clients in continuous treatment at the start of the year in question are
not included in the data. Where the proportion of treatment demands for a primary drug is given, the denominator is the
number of cases for which the primary drug is known.
Analysis of trends is based only on those countries providing sufﬁcient data to describe changes over the time period in
question. Figures for 2005 may substitute for missing 2006 values in trend analysis of drug market data; for the analysis
of other trends, missing data may be interpolated. Trends in price are adjusted for inﬂation at national level.
The term ‘reports’ for drug law offences may describe different concepts in different countries.
Further information on the data and analytical methods is available in the 2008 statistical bulletin.
The annual report is available for downloading in 23 languages (http://www.emcdda.europa.eu/publications/annual-
report/2008).
The 2008 statistical bulletin (http://www.emcdda.europa.eu/stats08) presents the full set of source tables on which the
statistical analysis in the annual report is based. It also provides further detail on the methodology used and about 100
additional statistical graphs.
Country overviews (http://www.emcdda.europa.eu/publications/country-overviews) provide a summary of key aspects of
the drug situation for each country.
The national reports of the Reitox focal points give a detailed description and analysis of the drugs problem in each
country and are available on the EMCDDA website (http://www.emcdda.europa.eu/publications/national-reports).
Introductory note
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A strong voice from Europe in an important year for
reﬂection and policy formation
In Europe, 2008 has seen the evaluation of the 2005–08
drug action plan, together with work to prepare a new
plan to take forward the EU drug strategy during its
second period (2009–12). At the same time, 13 Member
States are redrafting or reviewing their national drug
strategies or action plans. Internationally, this year
also marks the 10-year review point of the declarations
and action plans adopted at the 20th UN General
Assembly Special Session (Ungass). This makes 2008 an
unprecedented year for European and global reﬂections
on how drug policies have performed to date, and what
directions should be pursued in the future.
A growing European consensus can be seen in the way
Member States have adopted national drug strategies and
in their contribution to the global debate on drugs. All
but one of the EU Member States now have national drug
policy documents, and around half of them now structure
their national policy documents along lines similar to those
found in the EU action plan — an indication of a growing
policy convergence in Europe on how the drug problem
should be addressed. EU Member States, supported by the
Commission, have put forward an increasingly united EU
position in the ongoing discussions that have accompanied
the Ungass review. In the European contributions to the
debates, emphasis has been placed on the need for
comprehensive, balanced and evidence-based policies and
actions, and on the value of improved monitoring of the
global drug problem in the post-Ungass period.
Drug use and the application of criminal sanctions: a
mixed picture
In recent years, the EMCDDA has reported a tendency
among European countries to make a stronger distinction
in their drug laws between those who are trafﬁcking or
selling drugs and those using them. This distinction has
been reﬂected in a reduction of penalties for drug use
in some countries, though others have rejected moves
to reduce penalties or have even increased them. In
practice, making a distinction between the supplier and
the user is often difﬁcult, and Member States vary greatly
in how they have drawn the line between these two
categories.
The idea that European countries are now making less
use of criminal sanctions for drug use is not borne out by
the available data. During the past ﬁve years, the number
of reported drug law offences has increased in Europe.
Most of the reported drug law offences are related to use
and possession for use rather than supply, and whereas
offences related to supply have increased by 12%, those
related to possession have increased by over 50%.
Cannabis continues to be the drug most often associated
with drug law offences.
The reasons for the increase in the number of drug law
offences related to drug use are unclear, and could even
be related to the possibility that, in some countries, it may
have become administratively simpler to issue a conviction
for possession. However, the view held by some that, for
drug users and particularly cannabis users, the likelihood
of being charged with drug offences has decreased in
recent years is not supported by the data. Furthermore,
the extent to which sanctions applied for drug possession
have changed is not clear, and the EMCDDA will explore
this question in a selected issue next year.
New survey explores young people’s attitudes to drug use
A recent Eurobarometer survey explored young
people’s attitudes and perceptions on drugs and found
considerable consensus among countries. Overall,
the risks associated with using drugs such as heroin,
cocaine and ecstasy were rated as high by between
81% and 96% of those surveyed. The vast majority of
respondents (95%) felt that these drugs should continue
to be controlled in Europe. Views on cannabis, however,
were more divided, with 40% feeling that the drug
posed a high risk, while about the same number (43%)
considered that cannabis use represented a ‘medium
health risk’, broadly similar to the risks associated
with smoking tobacco. The perceptions of health risks
associated with cannabis use were reﬂected in the lower
level of support for continuing the ban on cannabis
Commentary
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(67%) and the view held by a substantial minority (31%)
that cannabis should be regulated in a similar way to
alcohol and tobacco products.
Drug use prevention: evidence base grows but practice is
slow to change
Despite the almost universal support for drug use
prevention, formal evaluations in this area are
methodologically challenging and, historically, the
evidence available for demonstrating the effectiveness of
interventions in this area has been limited. This situation
is changing as the scientiﬁc basis for drug prevention
continues to grow and more rigorous studies are carried
out. Although inference must still often be drawn from the
results of US studies, whose relevance to the European
context may be questionable, there is now a growing
body of European work. Together, the information now
available allows for a greater understanding of what
types of activities are likely to prove effective and how to
target those most at risk. Nevertheless, new data suggests
that in many countries, the predominant approaches
are often still those that lack a strong evidence base
and, in some cases, include activities that may even be
counterproductive. The challenge for policymakers may be
that those programmes that are known to deliver beneﬁts
often require both a greater investment of resources and
more attention to training and quality control.
To support knowledge transfer and best practice in the
drugs ﬁeld, in 2008 the EMCDDA launched an internet
portal on best practice. The portal, which includes a
prevention module, provides an overview of the latest
evidence on programme efﬁcacy and effectiveness as well
as tools and standards aimed at improving the quality
of interventions. Examples of evaluated practices across
Europe are also provided.
Drug treatment: more emphasis on outcomes
and client needs
The number of drug users receiving treatment for their
dependency has grown considerably in recent years, and
many countries now have a signiﬁcant proportion of their
problem opioid users in long-term substitution treatment.
This trend has led to a widening of the available
pharmaceutical options and has resulted in an increased
focus on treatment quality and outcome, as opposed
to treatment uptake, as a primary policy concern. In
particular, the debate has moved on to discussions about
what constitutes realistic long-term goals for substitution
treatment and to what extent clients may be socially
reintegrated and return to a normal lifestyle. Taking
up employment is one of the key elements of achieving
reintegration into society, and it has been shown to be of
high prognostic value. However, re-entry into the labour
market is often difﬁcult to achieve given the poor skills and
low educational status that characterise many of those
found among an overall ageing population of chronic
drug users in long-term treatment in Europe. Arriving
at a consensus on what constitutes successful outcomes
for those with long-term drug problems and as to what
extent members of this population can be successfully
reintegrated back into society are becoming increasingly
important questions for European drug treatment services.
Although Europe continues to see an expansion of drug
treatment provision, considerable variation still exists
between countries in the availability of care or the
extent to which services address different types of drug
problems. Moreover, widespread recognition of the value
of providing drug treatment options to users in prison
has yet to be matched by investments in services in this
area, which in most countries remain poorly developed.
An important challenge for drug treatment services in
Europe is the need to develop models of care tailored to
the needs of a more heterogeneous population of drug
users. Against the general background where evidence
does not point to a single best approach, some European
countries are developing interesting new methods to
treat cannabis or cocaine users. The complex problems
caused by different patterns of polydrug use, including
alcohol, constitute a challenge for service development.
It is therefore likely that European drug treatment services
will have to develop an increasingly differentiated set of
responses in the future if they are to match the increasingly
differentiated needs of their clients.
Stronger signals that the popularity of cannabis
use may be declining
Recent data from school and adult population surveys
suggest that overall cannabis use has stabilised or is
declining in some countries. Different national trends
are still apparent and marked differences exist between
countries. This is reﬂected in the medium-term trends, which
have seen increases reported often by lower prevalence
countries, a stable situation for many others and declines
noted among some higher prevalence countries.
Declines in prevalence are most apparent among younger
age groups. New school survey data from the latest HBSC
(Health behaviour in school-aged children) study reveal a
stable or decreasing trend in drug use among 15-year-old
students in most countries during the 2001–2006 period
and preliminary reports suggest that this picture may be
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conﬁrmed by the latest round of ESPAD (European school
project on alcohol and other drugs), which is due to be
published at the end of 2008. In the United Kingdom,
a country that used to stand out in terms of its high
prevalence of cannabis use, a steady downward trend is
now visible, and is most evident in the 16–24 age group.
The reasons why cannabis use might be becoming less
popular among young people are not well-documented,
though they may be related to possible changes in the
perceptions of the risks associated with the use of this
drug. Some commentators have suggested that declines
in the popularity of cannabis use may be associated
with changing attitudes to cigarette smoking. Cannabis
in Europe is often smoked in combination with tobacco,
and drug prevention programmes increasingly address
together the health implications of using both illegal and
legal substances.
Despite recent trends, levels of cannabis use in Europe
remain high by historical standards, and considerable
numbers of regular and intensive users, mostly young
males, exist in many countries. Trends in the numbers
of regular and intensive users of cannabis may move
independently of the prevalence of use of the drug among
the general population, and more focus on these patterns
of use and associated problems is required.
Domestic cannabis production: the big unknown
Cannabis resin has historically been the dominant product
in many EU Member States, and western Europe remains
overall the major global consumer of this form of the drug.
However, and to a large extent undetected, domestic
production of herbal cannabis has been increasing in
Europe. Most countries now report local production,
which can range from a few plants grown for personal
consumption to large-scale plantations grown for
commercial purposes.
The extent and relative market share of domestically
produced herbal cannabis remains unknown, and in
response to this the EMCDDA is carrying out a study on
mapping the cannabis market in Europe. There is also a
growing debate about the implications of the evolving
cannabis market. Concerns being voiced include the
negative impact of cannabis production sites on local
communities through increased levels of criminality, and
that domestically produced cannabis is typically of high
potency. Local production also poses a challenge for law
enforcement bodies, as production sites are located close
to the consumer, relatively easy to conceal and do not
necessitate the transportation of drugs across national
borders.
Cocaine use still growing in a segmented
European market for stimulant drugs
Stimulant drugs play an important role not only in patterns
of drug use found among the chronic and marginalised
At a glance — estimates of drug use in Europe
The estimates presented here relate to the adult population
(15–64 years old) and are based on the most recent data
available. For the complete set of data and information on
the methodology see the accompanying statistical bulletin.
Cannabis
Lifetime prevalence: at least 71 million
(22% of European adults)
Last year use: about 23 million European adults or
one-third of lifetime users
Last month use: over 12 million Europeans
Country variation in last year use:
overall range 0.8% to 11.2%
Cocaine
Lifetime prevalence: at least 12 million
(3.6% of European adults)
Last year use: 4 million European adults or one-third of
lifetime users
Last month use: around 2 million
Country variation in last year use:
overall range 0.1% to 3.0%
Ecstasy
Lifetime prevalence: about 9.5 million
(2.8% of European adults)
Last year use: over 2.6 million or one-third of lifetime users
Last month use: more than 1 million
Country variation in last year use:
overall range 0.2% to 3.5%
Amphetamines
Lifetime prevalence: almost 11 million
(3.3% of European adults)
Last year use: around 2 million or one-ﬁfth of lifetime users
Last month use: less than 1 million
Country variation in last year use:
overall range 0.0% to 1.3%
Opioids
Problem opioid use: between one and six cases per 1 000
adult population
In 2005–06, drug-induced deaths accounted for 3.5%
of all deaths of Europeans 15–39 years old, with opioids
being found in around 70% of them
Principal drug in around 50% of all drug treatment requests
More than 600 000 opioid users received substitution
treatment in 2006
14
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population of problem drug users in Europe, but also
among the better socially integrated groups of young
people who use drugs on a more recreational basis.
However, patterns of stimulant use differ across Europe:
cocaine is now the most commonly used stimulant in
many countries in the south and west of Europe, and
its use continues to grow. In contrast, the indicators for
amphetamine and ecstasy use suggest an overall stable or
declining picture. Nonetheless, amphetamines remain the
most used stimulants in most countries in central, northern
and eastern Europe, where in some cases they represent
an important part of the drug problem. Methamphetamine
use remains rare outside the Czech Republic and Slovakia,
although the availability or use of the drug is sporadically
reported by other countries.
As similarities exist in both the settings in which different
stimulant drugs are used and in the rationales offered
for their use, to some extent these substances can be
regarded as competing products on the European drug
market. This would imply that, as well as targeting
individual substances, interventions need to consider
stimulant drugs as a group rather than only as individual
problems. This point is important, as measures to impact
on the availability of one of these substances may be
undermined if they simply result in consumers switching to
alternative products.
Developments in synthetic drug production in Europe
increases concerns about environmental costs
European countries remain major producers of
amphetamines and MDMA, although the relative
importance of Europe may have declined as production
has increased elsewhere. Typically, between 70 and
90 production units are detected each year, mainly
concentrated in a few countries in western and eastern
Europe. Law enforcement data suggest that the production
of synthetic drugs, including methamphetamine, may
be becoming more sophisticated, with production runs
increasing in scale through the use of larger reaction
vessels, industrial and custom-made equipment and mobile
units.
The increase in the size of typical production runs
may be exacerbating the problem of waste dumping.
Typically, the production of one kilogram of amphetamine
or MDMA results in around 15–20 kilograms of waste
material, including toxic and inﬂammable chemicals
which constitute an environmental hazard. The costs in
terms of environmental damage and clearing up of sites
that have been used for the illegal disposal of chemical
wastes resulting from synthetic drug production can be
considerable.
Cocaine trafﬁcking through west Africa:
an area of concern and action
As cocaine use continues to rise in Europe, increased
efforts are being focused on cocaine interdiction. Both
the volume and number of cocaine seizures continue
to increase, with annual seizures now in excess of 120
tonnes, of which more than three quarters are accounted
for by Spain and Portugal. Efforts to counter the
trafﬁcking in cocaine into Europe have been bolstered
by the establishment, in Lisbon, of the Maritime Analysis
and Operations Centre–Narcotics (MAOC-N), which
is playing an important role in the coordination of
interdiction activities and the sharing of intelligence
among participating Member States.
Although cocaine enters Europe by a number of routes,
trafﬁcking through west African countries has dramatically
increased and now represents a major route for cocaine
destined to the European market. This situation has the
potential to destabilise and undermine development efforts
in a region already facing many social, health and political
challenges. In particular, the income generated by cocaine
trafﬁcking has considerable potential to undermine criminal
justice systems and encourage corruption. The European
Union and its Member States are working together with
west African countries to develop a range of measures to
address this growing threat.
Heroin problems not diminishing alongside reports of
increased use of synthetic opioids
The most recent estimates show that, at an estimated
733 tonnes, potential global heroin production has
continued to increase. However, the impact of this
increase on the availability and use of this drug in
Europe is difﬁcult to gauge. The available data make
drawing conclusions in this area difﬁcult. For example,
the quantity of heroin seized in the European Union has
declined slightly, but this has been counterbalanced by
considerable increases in Turkey.
No strong evidence exists to suggest an epidemic growth
in heroin problems similar to the one many parts of Europe
experienced in 1990s; overall, the data point to a stable
but no longer a diminishing problem. As such, heroin use
in Europe remains a serious public health issue and still
accounts for a large proportion of the overall health and
social costs associated with drug use. Data suggest that
opioid use, mostly heroin, accounts for around 60% of those
in drug treatment in Europe. Among those new to treatment,
15
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the relative proportion of opioid users — but not their actual
numbers — had been falling, but this trend now appears
to have levelled out. And, although there is evidence that
Europe’s opioid-using population is slowly ageing, the data
suggest that new recruitment is still occurring at a rate that
will ensure that the extent of the problem will not signiﬁcantly
decline in the foreseeable future.
Perhaps counter-intuitively, given the situation in
Afghanistan, problems with both diverted and illicitly
produced synthetic opioids appear to be increasingly
common in some countries. In Latvia, Lithuania and
Estonia, for example, there are indications of a growing
problem caused by the availability of 3-methylfentanyl
that is illicitly manufactured outside the EU. Due to its
strength (fentanyl is considerably more potent than heroin),
using this drug can be extremely dangerous, as reﬂected
in over 70 fentanyl-related fatal poisonings reported in
Estonia in 2006. Other countries note a growing number
of individuals seeking help with problems related to the
use of opioids that appear to have been diverted from
therapeutic purposes, and this contributes to the growing
polydrug use problem that now characterises chronic drug
use in parts of Europe.
Drug injecting and HIV: overall picture positive but
important national differences
Over 40% of all heroin users entering outpatient treatment
report injecting, underlining that this particularly harmful
route of administration remains an important health issue
in Europe. Injecting is associated with a range of problems
including, but not limited to, the spread of blood-borne
infections including HIV and hepatitis C. Changes in the
proportion of injectors among those entering treatment
suggest that, in many countries, the overall trend has been
away from injecting, although distinct regional and national
differences can be seen in the data. In some countries,
particularly in eastern Europe, drug injection remains the
principal route of heroin administration and is reported by
over 80% of heroin users entering treatment. Relatively high
levels of initiation also appear to be still occurring in some
Member States, as indicated by studies among injecting
drug users that show a relatively high proportion of young
and new injectors.
Overall, the rate of newly acquired HIV infections in
Europe has been falling since a localised epidemic
in some countries caused a peak at the beginning of
this decade. Declines in injecting together with the
increasing availability of treatment and harm-reduction
services appear to have resulted in a generally improving
situation; and where some increases in new infection are
observed, these have been small. However, there remain
important differences between countries. Although data
point to an improving situation in Estonia, Latvia and
Portugal, these countries still report disproportionately
high rates of new infection and account for a signiﬁcant
proportion of all new HIV cases in Europe attributed to
drug use. Data from regional or local studies also suggest
that transmission of HIV infection remains an issue in
Spain and Italy, although the absence of national case
reporting data makes tracking trends in these countries
difﬁcult. Elsewhere, risk behaviour continues and the
potential for new epidemics remains, strongly suggesting
the need to remain vigilant: for example, Bulgaria
reported 34 new cases in 2006, but was reporting
virtually no infections in the years 2000–03.
Drug-related deaths: a major burden on public health
The EMCDDA monitors fatal poisonings directly attributable
to drug use (drug-induced deaths). There are, on average,
around 7 000–8 000 drug-induced deaths reported in
Europe each year, and due to known underreporting this
ﬁgure represents a minimum estimate. Opioids, principally
heroin, are the drugs most often associated with overdose,
although other drugs and alcohol are commonly present.
After falling for some years in the early part of this decade,
the trend in drug-induced deaths has now levelled out. The
reasons for this are unclear, indicating a need for more
research on both the factors associated with overdose and
on the effectiveness of prevention measures. Drug users
leaving prison may be at particular risk, with a recent study
reporting mortality rates eight to ten times higher than
expected. Overall, overdose prevention remains an area
requiring increased investment.
Studies have also shown that overall mortality, when
diseases, accidents and violence are also taken into
consideration, among drug users is up to ﬁfty times higher
than that found among the general population. Therefore,
investment in well-designed cohort studies is needed to
provide a better understanding of the causes and extent of
overall drug-related mortality and to examine differential
risks such as those experienced by prisoners on release
and treatment drop-outs.
Internet and market innovation pose challenges
to drug policy
A recent EMCDDA survey has shown that more than
200 natural, semi-synthetic and synthetic psychoactive
products are sold by online shops in Europe. Many
of the substances are categorised as ‘legal highs’ or
‘herbal highs’ and advertised as alternatives to controlled
16
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substances, although their actual legal status may vary
considerably across Europe. Reports suggest that the
number of online retailers of these products is growing
and that they adapt rapidly to attempts to control the
market, for example through the launch of new products.
In addition, online pharmacies and online retailers
selling psychoactive substances for ostensibly legitimate
purposes also potentially provide new avenues for illicit
drug supply. Taken together, Internet sales now represent
a considerable challenge to both international and
national drug policies and control mechanisms. Given
the speed at which new products can appear and be
distributed, the monitoring of online activities is becoming
an important area for development.
Growing recognition of the importance
of dialogue with civil society
Drug problems are intertwined with a range of other social
and health issues. Consequently, successful interventions
in this area require the involvement of a broad alliance
of participants and can beneﬁt from the support of
the communities in which they are implemented. This
understanding is reﬂected in a growing recognition that
the policy debate needs to be informed by a dialogue
with civil society. With this aim in mind, several actions
have recently been taken within the European discourse
on drugs. Among the most notable of these is the
establishment by the European Commission of a civil
society forum, which provides an opportunity to ensure that
frontline experiences are fed into the process leading to
the new EU drug strategy and inform the evaluation of the
EU action plan on drugs. The importance of consulting with
representatives of non-governmental organisations and
local communities has also been recognised in the EU drug
strategy and echoed in a report adopted by the European
Parliament in March 2008 acknowledging the fundamental
role of civil society in the development, implementation,
evaluation and monitoring of drug policies.
European drug research and the need
for transnational cooperation
Over the last decade, drug-related research and the
infrastructure that supports it (research centres, scientiﬁc
journals, funding mechanisms) has developed greatly
in Europe, as shown in a selected issue on research
published by the EMCDDA in 2008. Less positively, this
progress has not been accompanied by a comparable
increase in the cooperation and coordination of drug-
related research efforts among EU Member States.
Increasing attention is being paid to this issue, and the
European Commission has commissioned a new study to
provide an inventory of research activity together with a
comparative analysis of infrastructures available in Europe
and in other regions of the world. The report will include
recommendations on how to improve cooperation at EU
level and contribute to a discussion on how to improve the
links between European research funding opportunities
and needs of research and policy.
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Introduction
Drug policy is set to be an important issue in 2008. In this
year, both the United Nations and the European Union
assess the results of their drug policies on the use of, and
harms caused by, illicit drugs. The United Nations reviews
the progress made in implementing the measures and
reaching the goals decided during the 1998 UN General
Assembly Special Session (Ungass) on the world drug
problem. In Europe, 2008 sees the ﬁnal evaluation of
the current EU action plan on drugs (2005–08) and the
drafting of the action plan for 2009–12. Furthermore, an
unprecedented number of EU Member States also review
their national drug strategies and action plans and draft
new drug-policy documents (1) during this year.
The EMCDDA will discuss the ﬁndings and developments
made during 2008 in its next annual report. This year,
Chapter 1 focuses on recent changes in drug policy,
presents new data on drug-related public expenditure,
explores three speciﬁc dimensions of drug laws —
possession for personal use, alternatives to punishment,
and the focus on protecting the public — and highlights
the latest trends in drug-related offences. The chapter
ends with an overview of drug-related research in EU
Member States.
International and EU policy developments
Ungass 10-year review
In June 1998, the 20th UN General Assembly Special
Session (Ungass) convened in New York to debate the
world drug problem. This ‘drug summit’ set a new agenda
for the international community through the adoption
of three key documents (2): a political declaration; a
declaration on the guiding principles of drug demand
reduction; and a ﬁve-part resolution with measures to
enhance international cooperation. In adopting the
political declaration, UN Member States committed
themselves to achieving measurable results in reducing the
supply and demand for illicit drugs by 2008.
This year’s session of the United Nations Commission
on Narcotic Drugs (CND) has launched the 10-year
review of the progress made in reaching the goals
and targets set during the 1998 Ungass. A report
presented by the United Nations Ofﬁce on Drugs and
Crime (UNODC) argued that signiﬁcant progress has
been achieved in the last 10 years, though, in some
areas and regions, UN Member States have not fully
attained the goals and targets mentioned in the political
declaration (3). This assessment is to be followed by a
one-year reﬂection period, during which discussions will
ﬁrst be held among intergovernmental expert working
groups and then in intersessional meetings. This will
allow preparations to be made for a dedicated two-
day, high-level, segment at the 2009 CND, which will
decide upon a possible future political declaration and
measures.
The European Union is playing an active role in the
Ungass review. Resolutions prepared by the EU were
adopted at the 2006 (49/1), 2007 (50/12) and 2008
(51/4) sessions of the CND, all of which call for a
scientiﬁc and transparent review process. The EMCDDA
has also been involved in expert consultations funded by
the European Commission and held by the UNODC, and
in this context has provided an overview of drug strategies
and responses in Europe since 1998.
Evaluation of the EU action plan on drugs
In December 2007, the European Commission presented
its second progress review on the implementation of the
EU action plan on drugs (2005–08). The report, which
includes data from the EU Member States, the EMCDDA,
Europol and the European Commission, assesses the extent
to which the measures planned for 2007 were carried out.
One of the main conclusions of the review was that there
are signs of convergence between Member States’ drug
policies. It also highlighted difﬁculties in collecting data
Chapter 1
Policies and laws
(1) The term ‘national drug-policy document’ means any ofﬁcial document approved by a government that deﬁnes general principles and speciﬁc
interventions or objectives in the ﬁeld of drugs, where ofﬁcially represented as a drug strategy, action plan, programme or other policy document.
(2) http://www.un.org/ga/20special/
(3) http://www.unodc.org/unodc/en/commissions/CND/session/51.html
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on supply-reduction activities and in linking some of the
planned actions with the indicator chosen to assess their
implementation.
The ﬁnal evaluation of the current EU action plan on
drugs took place in 2008, with input from the EU Member
States, Europol and the EMCDDA. The evaluation report
is due to be published by the Commission in autumn
2008, and its ﬁndings will contribute to the shaping of
the second action plan (2009–12) under the current EU
strategy on drugs (2005–12).
Other EU developments
In September 2007, the Council and the European
Parliament adopted the ’Drug prevention and
information’ programme (4) under the ﬁnancial
framework 2007–13 and the general programme
for civil justice and fundamental rights. The general
objectives of the programme are: the prevention and
reduction of drug use, dependence and drug-related
harm; to contribute to the improvement of information
on drug use; and to support actions taken under the
EU drug strategy (2005–12). Under the programme,
EUR 21.35 million will be available for Commission
studies, operational costs of European non-governmental
organisations in the drugs ﬁeld, and transnational
projects. Joint actions may also be undertaken with
other Community programmes, for example the second
programme of Community action in the ﬁeld of health
(2008–13) (5), which, in the part related to health
promotion dealing with different health determinants,
includes actions on illicit drugs in speciﬁc settings, such
as schools and workplaces.
In June 2006, the European Commission issued a Green
Paper on the role of civil society in drug policy, as called
for in the current drug action plan. This was followed
in 2007 by the selection process for a new civil society
forum on drugs. The purpose of the forum is to serve
as a platform for the informal exchange of views and
information between the Commission and civil society
organisations in the EU, candidate countries and, as
appropriate, European neighbourhood policy countries.
The forum includes 26 organisations representing a wide
spectrum of views. It met for the ﬁrst time in December
2007 and again in May 2008 to discuss the evaluation
of the current EU action plan on drugs and the new
action plan.
National drug strategies
New developments
New drug action plans or programmes were adopted
by four EU Member States (Czech Republic, Estonia,
Hungary, Finland), Turkey and Norway in the second
half of 2007. All of these documents cover a time span of
three to four years and, with the exception of the Turkish
action plan, they have been preceded by previous plans
or programmes. In the same year, Spain also adopted
a complementary national action programme against
cocaine (2007–10).
In early 2008, three more Member States adopted new
policy documents. Italy’s ﬁrst drug action plan has a time
frame of one year, and is to be followed by a four-year
action plan (2009–12), which will be synchronised with the
new EU action plan on drugs. Malta’s ﬁrst ever national
drug-policy document, while not deﬁning the time frame,
includes almost 50 actions to be implemented in the coming
years. Finally, the United Kingdom’s new 10-year drug
strategy (2008–18) is, for the ﬁrst time, complemented by a
three-year action plan (2008–11), which deﬁnes key actions
to be implemented in the near future.
The majority of national drug-policy documents adopted
in late 2007 and early 2008 focus mainly on illicit drugs,
with some also addressing other substances such as
alcohol, tobacco, medicines and performance-enhancing
drugs. This reﬂects a tendency among European countries,
whereby the existence of links and similarities between
the use of illicit and licit substances is acknowledged, but
drug-policy documents rarely comprehensively address
substances other than illicit drugs (6). Norway continues to
be one of the exceptions to this pattern, with illicit drugs
and alcohol fully integrated in its recently adopted action
plan. The numerous national drug strategies and action
plans to be developed for 2009, together with those
recently adopted, will allow the EMCDDA to examine
whether the trend towards increasing integration of licit
and illicit drugs in national drug policies, identiﬁed in the
2006 selected issue, has continued.
General situation
Austria is now the only EU Member State that has not
adopted a national drug strategy or action plan, though
each of its provinces has a regional drug or addiction
strategy or action plan. In the other 26 Member States,
as well as in Croatia, Turkey and Norway, drug policy is
(4) Decision No 1150/2007/EC of the European Parliament and of the Council of 25 September 2007 establishing for the period 2007–13 the speciﬁc
programme ‘drug prevention and information’ as part of the general programme ‘Fundamental rights and justice’ (OJ L 257, 3.10.2007, p. 23).
(5) Decision No 1350/2007/EC of the European Parliament and of the Council of 23 October 2007 establishing a second programme of Community
action in the ﬁeld of health (2008–13) (OJ L 301, 20.11.2007, p. 3).
(6) See the 2006 selected issue European drug policies: extended beyond illicit drugs?
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set out in national drug-policy documents. As a point of
comparison, in 1995, only 10 of these 30 countries had
developed such an instrument (Figure 1).
Convergence can also be seen in the format of drug
strategies and action plans. Fourteen countries now
structure their national drug-policy documents along
lines similar to those of the current EU drug strategy and
action plan. Moreover, the same number of countries
now organise their national drug policies using two
complementary instruments: a strategic framework and
an action plan (Figure 1). In 2000, when the European
Union used this approach for the ﬁrst time, only two
Member States had two complementary drug-policy
documents.
The content of national drug-policy documents is another
area in which there are signs of convergence among
the EU Member States, Croatia, Turkey and Norway,
with gradually more evidence of common objectives and
common interventions in the national drug strategies and
action plans adopted by different countries. However, as
European countries differ in their drug problem as well
as in their political, social and economic contexts, the
diversity that exists among national drug policies, though
diminishing, is likely to remain to some degree in the
future. Some examples of this diversity are highlighted in
Chapter 2.
Evaluation
In 2008, 13 EU Member States have already redrafted
or are due to review and redraft their national drug-
policy documents, making this a year of unprecedented
activity in policymaking at national level. Following Italy,
Malta and the United Kingdom, Ireland will renew its
drug strategy in 2008; France, Portugal and Romania
will renew their drug action plans; Bulgaria, Spain,
Cyprus, Lithuania and Slovakia will renew both their drug
strategies and their action plans. Finally, the Netherlands,
which has the oldest national drug-policy document in
Europe, intends to compose a new one during 2008.
There is a growing recognition in Europe of the need
to include monitoring and evaluation as an essential
component in national drug strategies and action
plans. Almost all of the countries mentioned above have
produced or plan to produce a progress review of the
implementation of their drug strategies or action plans,
and some of them, for example Ireland, Cyprus and
Portugal, could produce more in-depth evaluations in
2008.
EU Member States differ, however, in their methods and
approaches for evaluating national drug strategies and
action plans; and there is a need to identify best practices
in this ﬁeld. This was highlighted at a conference on
evaluation organised by the Portuguese Presidency of
the EU in September 2007. To respond to this challenge,
the EMCDDA, in collaboration with Member States,
is exploring the possibility of developing European
guidelines in this ﬁeld.
Drug-related public expenditure
For 2006, four EU Member States (Czech Republic,
Ireland, Poland, Portugal) provided detailed information
on public expenditure associated with tackling drugs
(summarised in Table 1). Information on the division of
drug-related expenditure between central government and
regional or local government was provided by two of the
four countries, allowing a comparison of the role played
by the different sectors of government. In the countries
for which data are available, the bulk of reported drug-
related public expenditure is allocated to activities that are
funded by central government.
Sources: Reitox national focal points.
Figure 1: Trend in the number of countries with national drug-
policy documents among the 27 EU Member States, Croatia,
Turkey and Norway
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Eleven Member States gave details of expenditure by the
State on certain activities undertaken in response to the
drug problem. A further two countries provided rough
estimates of overall public expenditure related to the drug
problem (Spain, Malta), though with no information on the
activities on which the money was spent.
In 2005, the total drug-related public expenditure by
European countries was calculated to lie somewhere
between EUR 13 billion and EUR 36 billion (EMCDDA,
2007a). This ﬁgure was estimated by extrapolating the
total drug-related expenditures of six countries (Belgium,
Hungary, Netherlands, Finland, Sweden, United Kingdom)
to the other States. A revised estimate, which includes
data from additional countries (Czech Republic, France,
Luxembourg, Poland, Slovakia), has recently been
proposed (EMCDDA, 2008d). The new estimate of drug-
related public expenditure in Europe is EUR 34 billion
(95% conﬁdence interval, EUR 28–40 billion), which
is equivalent to 0.3% of the combined gross domestic
product of all EU Member States. This suggests that State
expenditure on the drug problem costs the average EU
citizen EUR 60 a year. These ﬁgures must, however, still be
taken as indicative because of the limited data on which
they are based.
Reports on the social cost of drug use
Data on the social cost of drug use (direct and indirect
costs caused by drug use) were reported by four Member
States. While these reports may provide useful insights into
the impact of drug use in the country in which they were
conducted, differences in methods and in the way results
are reported mean that it is not possible to compare the
countries. The lack of comparability in the data from different
countries highlights the need to adopt a common approach
towards monitoring the social cost of drug use in Europe.
In Italy, the social cost of illicit drug use was estimated
at EUR 6 473 million, with law enforcement activities
accounting for the largest share of the total (43%), and
the remainder divided between healthcare and social
services (27%) and loss of productivity of drug users
and people indirectly affected by drug use (30%).
In addition, it was estimated that drug users spent
EUR 3 980 million for the purchase of illicit drugs. On
the basis of these data, the cost of drug use in Italy
is estimated to represent 0.7% of the national gross
domestic product. In data reported for Austria, in 2004,
the division between direct and indirect costs was the
opposite of that reported for Italy: of the estimated
social cost of drug use of EUR 1 444 million, 72% was
accounted for by indirect costs.
The United Kingdom reported that, in 2003/04, the
economic and social costs of Class A (7) drug use in
England and Wales was EUR 22.26 billion, representing
an annual cost of EUR 63 940 for each problem drug
user. It was suggested that problem drug use accounted
for 99% of the total costs. Costs due to drug-related crime,
including law enforcement and costs to the victims of drug-
related crimes, accounted for the largest proportion of the
overall cost (90%, or EUR 20.1 billion).
Development of national legislation
Examining the changes in drug legislation that have been
made since the 1998 Ungass on drugs is of particular
interest in this year of international, European and national
reviews and evaluations of drug-policy documents.
Observing the changes in three key areas, this section
Table 1: Drug-labelled public expenditure (1) by selected EU Member States
Country Labelled expenditures reported by government sector (EUR) Total as a
proportion of
total public
expenditure (2) (%)Central Regional Local Total
Czech Republic 12 821 000 3 349 000 1 699 000 17 869 000 0.04
Ireland (3) 214 687 000 – – 214 687 000 0.39
Poland 68 476 000 644 000 13 253 000 82 373 000 0.08
Portugal 75 195 175 – – 75 195 175 0.11
(1) Public expenditures explicitly ‘labelled’ as drug-related in ofﬁcial accountancy documents.
(2) Total general government expenditure in the year.
(3) In Ireland, government departments and State agencies are invited to report their annual drug-related expenditure to the coordinating Department
of Community, Rural and Gaeltacht Affairs. These expenditures are not necessarily labelled as drug-related in ofﬁcial accountancy documents.
Sources: Reitox national focal points and Eurostat (http://epp.eurostat.ec.europa.eu/).
(7) Class A drugs are deﬁned as those considered to be the most harmful.
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asks the question: Do the changes in legal deﬁnitions and
responses to drug users indicate a new, wider trend in
how countries view users of drugs?
Possession for personal use
During the past 10 years, most European countries have
moved towards an approach that distinguishes between
the drug trafﬁcker, who is viewed as a criminal, and the
drug user, who is seen more as a sick person in need of
treatment. However, Member States differ considerably
in how they have chosen to deﬁne these categories in the
new laws that they have adopted in recent years.
One of the issues on which Member States have shown
the greatest degree of divergence is whether or not to set
threshold quantities for personal possession. In the period
2004–06, Bulgaria removed the concept of personal
possession, Italy re-enacted it after 12 years without, and
the United Kingdom enacted the concept but then chose
not to apply it. Belgium and Cyprus introduced deﬁned
limit quantities in 2003, for all drugs and for cannabis
respectively; while in Germany, the Länder are working to
implement more consistently a constitutional court ruling
whose reference to ‘insigniﬁcant quantities’ was undeﬁned,
resulting in interpretations of between 3 and 30 grams.
In 2005, in Slovakia, the legal deﬁnitions of personal
use were widened from a maximum of one dose to a
maximum of three and, for a larger amount, 10 doses. At
the same time, however, the sentence for possession of
any more than this was raised to a clear minimum of four
years in prison, as for a trafﬁcking offence.
Drug use within small groups presents another challenge
to attempts to distinguish between users and suppliers. In
Belgium, the speciﬁc criminal offence of use in a group was
repealed in 2003; in the same year, an amendment to the
Hungarian criminal code permitted diversion to treatment
for the supplier of a small quantity to be consumed ‘jointly’
(since appealed as being legally unclear). In 2006, Malta
found that the minimum six-month sentence for suppliers
was not always appropriate in situations of sharing, and
changed the law to permit exceptions.
Regarding punishment, maximum or probable penalties
for use or possession for personal use, in the absence of
aggravating circumstances, have been reduced in various
European countries since 2001 — either for all drugs
(Estonia, Greece, Hungary, Portugal, Finland) or limited
to cannabis (Belgium, Luxembourg, United Kingdom)
or drugs of lesser risk (Romania). However, during this
period, not all countries have been reducing penalties:
France and Poland decided not to change their laws after
consultations; and Denmark raised the ‘normal’ penalties
from cautions to ﬁnes (which were then increased). A
new law in Italy saw drug consumption reinstated as an
administrative offence, and cannabis reclassiﬁed to be
eligible for the same penalties as other illicit substances,
such as heroin and cocaine. In the United Kingdom, it
has been announced that cannabis is to be reclassiﬁed
upwards.
Alternatives to punishment
The changes in drug users’ access to treatment via the
criminal justice system typically share two common
features. First, they all widen the scope for directing
drug users into treatment. However, some differences
exist between countries regarding the stage at which the
offer of treatment is made, with most countries offering
treatment at the court stage, rather than at the earlier
stages of contact with the police or prosecutors. Secondly,
they are conditional; breach of the treatment order will
restart the procedure of criminal charge, prosecution or
punishment.
Countries have introduced or widened options or systems
for offenders to be referred to treatment or counselling,
as an alternative to punishment or imprisonment, in line
with Ungass and EU action plan objectives. In Ireland and
Malta, following arrest, drug users can now be referred
to treatment; this is also the case in the United Kingdom,
where drug testing on arrest is authorised in certain
circumstances. Special drug courts have been established
Towards a better understanding of drug-related
public expenditure in Europe — EMCDDA 2008
selected issue
In response to the EU drugs action plan 2005–08, the
EMCDDA has developed a project aimed at identifying,
developing and testing methods for quantifying drug-related
public expenditures. A selected issue on this topic gives
an overview on the overall ﬁgures on drug-related public
expenditure in 2005 in the EU Member States and Norway.
Most of the expenditures identiﬁed were originally ‘labelled’
as drug related, and were generally traced back by
exhaustively reviewing ofﬁcial accountancy documents, thus
possibly reﬂecting the voluntary engagement of the States
in the ﬁeld of drugs. When feasible, hidden or ‘unlabelled’
expenditures embedded in programmes with broader goals
were estimated through modelling techniques. This new
twofold approach provides standardised estimates that
maximise the validity and cross-country comparability of
public disbursements in tackling drugs and drug addiction.
This selected issue is available in print and on the Internet in
English only (http://www.emcdda.europa.eu/publications/selected-
issues).
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in Ireland, the United Kingdom (England and Scotland)
and Norway, and are under discussion in Malta; Portugal
set up a system of ‘commissions for the dissuasion of drug
use’ composed of a lawyer, a doctor and a social worker.
New laws in other countries have introduced some form
of treatment as an alternative to punishment: in France,
non-dependent drug law offenders may take, and pay
for, awareness courses; in Spain, Hungary and Latvia,
custodial sentences may be suspended for drug users
undertaking treatment; and in Bulgaria, Hungary, Romania
and Turkey, probation may be combined with treatment.
The Netherlands aims to increase the use of treatment as
a condition of early release from prison. When deemed
appropriate, in Finland, sentenced offenders can now
be directed towards an open prison if they stay drug-
free; in Greece, they may be sent to a special treatment
unit. Eligibility for drug-treatment programmes has been
extended to those convicted of more serious offences in
Italy (if the offence is punishable by up to six years in
prison, raised from four years) and Spain (raised from
three to ﬁve years). In Belgium, at all levels of the criminal
justice process, alternatives exist to divert drug-using
offenders into treatment.
Further descriptions of the various treatment alternatives to
punishment and the extent of their use can be found in the
ELDD’s ‘Topic overview’ and ‘Legal reports’ sections (8).
Focus on protecting the public
In the past decade, criminal law has increasingly been
used to protect the public from the drug user and, in
parallel with the distinction made between the ‘sick’ user
and the ‘criminal’ trafﬁcker, the category of ‘user’ is also
being legally subdivided into those who do and those
who do not trouble or harm other members of society. The
measures that reduce criminal penalties for personal use or
offer alternatives to punishment, described above, are part
of this development. These treatment options or reduced
penalties are, for example, granted on condition that the
user does not cause some form of public disturbance.
Criteria have also been widened and penalties increased
for those offenders who risk harming other members of
society. Most legislative activity has concentrated on those
taking drugs and then driving (Belgium, Czech Republic,
Denmark, Spain, France, Latvia, Lithuania, Portugal,
Finland). New laws regulating testing for drugs in the
workplace in Ireland, Finland and Norway emphasise
that testing is permitted mainly in situations where
considerable danger or risk would arise from being under
the inﬂuence. Drug taking in various forms of transport is
controlled by new laws: trains and ships in Ireland; boats
in Latvia; aviation in Finland. The last few years have also
seen: laws and strategies to prevent or punish drug-related
public nuisance (see the 2005 selected issue); new powers
to close bars or other premises or exclude people from
them (Belgium, Ireland, Netherlands); and powers to close
private dwellings where commercial drug distribution or
systematic drug use takes place (respectively, Netherlands,
United Kingdom). In parallel, new laws to protect non-
users from the use of tobacco have also been introduced
across Europe during this time: since 2004, 24 European
Member States (all except Greece, Hungary and Poland)
have prohibited or severely restricted smoking in enclosed
public places, often with sizeable ﬁnes for transgressors.
To summarise the legal changes reviewed here: it
appears that criminal sanctions have often been reduced
for the individual user who avoids any aggravating
circumstances, but, almost as a counterbalance, increased
for those whose actions may affect other members of
society. The latter reﬂects an increased focus on using
criminal law to protect the public.
Drug-related crime
Drug-related crime is a broad concept which may include all
crimes committed that are, in some way, linked to drugs (9).
In practice, routine data are only available in Europe on
initial reports of drug law offences, mainly from the police.
Though these data are usually taken as indirect indicators of
drug use or drug trafﬁcking, it is important to note that they
reﬂect differences in national legislation and the different
ways in which the laws are applied and enforced. The
data also reﬂect differences in priorities set and resources
allocated by criminal justice agencies to speciﬁc offences. In
addition, there are variations between national information
systems on drug law offences, specially in relation to
reporting and recording practices. Because these differences
make comparisons between countries difﬁcult, it is more
appropriate to compare trends rather than absolute numbers.
Overall, the number of reported drug law offences in EU
Member States increased by an average of 36% between
2001 and 2006 (Figure 2). The data reveal increasing
trends in all reporting countries except Bulgaria, Greece,
Latvia and Slovenia, which reported an overall decline
over the ﬁve-year period (10).
Use- and supply-related offences
The balance between drug law offences related to use and
those related to supply (dealing, trafﬁcking, production) is
(8) http://eldd.emcdda.europa.eu
(9) For a discussion of the relationships between drugs and crime see EMCDDA (2007b).
(10) See Table DLO-1 in the 2008 statistical bulletin.
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similar to that reported in previous years. Most European
countries reported that the majority of the offences were
related to drug use or possession for use, with ﬁgures in
2006 ranging up to 93% in Spain (11). However, in the
Czech Republic, the Netherlands, Turkey and Norway,
supply-related offences were predominant, with these
accounting for between 52% (Turkey) and 88% (Czech
Republic) of all drug law offences reported in 2006.
The number of drug law offences related to use increased
by an average of 51% between 2001 and 2006 in the
European Union, with two thirds of the reporting countries
showing an upward trend, and only Slovenia and Norway
showing a downward trend over the ﬁve-year period (12). In
addition, it is worth noting that, as a proportion of all drug
law offences, use-related offences increased over the same
period in half of the reporting countries.
Offences related to the supply of drugs also increased
during the period 2001–06, but at a much lower pace,
with an average increase of 12 % in the European Union.
Over this period, the number of supply-related offences
increased in more than half of the reporting countries,
and decreased in four countries (Germany, Cyprus,
Netherlands, Slovenia) (13).
Trends by drug
In most European countries, in 2006, cannabis continued
to be the illicit drug most often involved in reported drug
law offences (14). In countries where this is the case,
cannabis-related offences accounted for 36–86% of all
drug law offences. In a few countries, drugs other than
cannabis were predominant in drug offences: in the
Czech Republic, methamphetamine accounted for 60%
of all drug law offences; in Malta, the figure for heroin
was 41%. In Luxembourg, drug law offences were almost
equally distributed between cannabis, heroin and cocaine.
In the ﬁve-year period 2001–06, the number of drug law
offences involving cannabis increased or remained stable
in most reporting countries, resulting in an overall average
increase of 34% in the European Union (Figure 2).
Downward trends were, however, reported by Bulgaria,
the Czech Republic (2002–06), Italy and Slovenia (15).
Cocaine-related offences increased over the period
2001–06 in all European countries except Bulgaria,
Germany and Slovakia. The EU average increased by
61% over the same period.
Over the period 2001–06, drug law offences related
to heroin show a different picture to those related to
cannabis or cocaine, dropping by an average of 14% in
the European Union, mainly between 2001 and 2003.
However, national trends in heroin offences have been
diverging over the period, with a third of the countries
reporting upward trends (16).
The EU average trends in offences for both amphetamine
and ecstasy peaked in 2004. While the trend for
amphetamine-related offences remained upward (average
(11) See Table DLO-2 in the 2008 statistical bulletin.
(12) See Figure DLO-2 and Table DLO-4 in the 2008 statistical bulletin.
(13) See Table DLO-5 in the 2008 statistical bulletin.
(14) See Table DLO-3 in the 2008 statistical bulletin.
(15) See Table DLO-6 in the 2008 statistical bulletin. For a complementary analysis of cannabis-related offences, see Chapter 3.
(16) See Table DLO-7 in the 2008 statistical bulletin.
NB: The trends represent the available information on national number
of reports for drug law offences (criminal and non-criminal)
reported by all law enforcement agencies in the EU Member
States; all series are indexed to a base of 100 in 2001 and
weighted by country population sizes to form an overall EU trend;
the total number of offences reported in 2006 in countries included
in the trends (before weighting) were: amphetamine, 41069;
cannabis, 550878; cocaine, 100117; ecstasy, 17 598; heroin,
77 242; all reports, 936 866. Countries missing data for two or
more consecutive years are not included in the trend calculations:
the overall trend is based on all EU countries except the United
Kingdom; the trend for cannabis is based on 18 countries, heroin
on 18, cocaine on 17, amphetamine on 12 and ecstasy on 13.
For additional information on the methodology, see Figure DLO-3
in the 2008 statistical bulletin.
Sources: Reitox national focal points and, for population data, Eurostat
(http://epp.eurostat.ec.europa.eu/).
Figure 2: Indexed trends in reports for drug law offences in EU
Member States, 2001–06
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increase of 41% over 2001–06), the EU average for
offences related to ecstasy ﬂuctuated over the period with
no overall change between 2001 and 2006.
National drug-related research
Research into the drugs problem is carried out in all
European countries, where it provides the information
essential to describing and understanding the impact of
illicit drugs on a national scale. Based on reports from 25
Member States, Croatia and Norway, it is possible to give
an overview of the organisation of drug-related research
in European countries. At a time when the importance of
evidence-based interventions is increasingly acknowledged,
it is notable that 21 countries reported that research results
inform drug policy, at least to some degree.
Coordinating and funding
Drug-related research is mentioned in the national drug
strategy or action plan of 20 of the 27 reporting countries,
either as a speciﬁc topic or referred to as an essential
component of evidence-based policy. In 15 of the 27
reporting countries, structures to coordinate drug-related
research exist at national level. Only ﬁve countries report
that drug-related research is not mentioned in their
national strategies or that they do not have a national
coordination structure in this ﬁeld.
The State is the main source of funding for drug-related
research reported by the Member States, either through
programmes for general research or through research
programmes in the drugs ﬁeld. Health and social sciences
are two of the main areas of general research in which
funding may be found for drug-related research. Funding
speciﬁcally designated for drug-related research can be
available through national drug coordination bodies (Czech
Republic, Spain, France, Luxembourg, Hungary, Poland,
Portugal, Norway). Both types of funding programmes often
couple research on illicit drugs with other areas within the
addiction ﬁeld, such as alcohol, tobacco and gambling.
The funds are mostly available through contracts for
commissioned research or through framework programmes
to which researchers apply. Other types of funding sources
reported include foundations, scientiﬁc academies, private
institutions, special funds for the ﬁght against drugs, the
European Commission and the United Nations.
Structures and projects
The majority of countries reported that research takes
place mostly in universities and in specialised centres,
some of them hosting national focal points, followed by
public and private research centres. National research
networks were reported by some countries (Germany,
Spain, Portugal). These can play an important role in
the organisation and funding of research, and may also
promote more direct links between research and practice.
Among the major studies carried out since 2000
reported by the Member States, more than half were in
epidemiology and about one third in applied research
(mainly evaluations of interventions in prevention and
treatment). Also cited were studies in determinants, risk
and protective factors for drug use, consequences of drug
use, and drug mechanisms and affects.
Constraints to drug-related research were reported by
several countries. Among the problems identiﬁed were:
organisational aspects, such as a lack of coordination
and scattered resources (Germany, France, Austria); the
More to come on drug-related research
Detailed information on research in the drugs ﬁeld carried out in
European countries has been collected by the EMCDDA through
its network of Reitox national focal points. The information
provided by the Member States includes a description of
national research organisations and funding arrangements.
Member States have also provided lists of main studies carried
out since 2000 and identiﬁed scientiﬁc papers, scientiﬁc
journals and websites through which the ﬁndings of drug-related
research carried out in their country have been disseminated.
The EMCDDA is making this and more information available
through different dissemination products and channels (see
http://www.emcdda.europa.eu/themes/research).
For a more in-depth review of this topic, see the 2008
selected issue on drug-related research (http://www.emcdda.
europa.eu/publications/selected-issues).
The European Commission has commissioned an in-depth
comparative analysis of research into illicit drugs in the
European Union. The study should provide an overview
of the funding available for drug-related research from
the European Union and Member States, building on the
results of the selected issue on research, and widening
the scope to include research in the ﬁeld of drug supply
reduction and security. The study will review the existing
research infrastructure within Member States and at
European level, and make a comparison with other regions,
such as North America and Australia. It will conclude
with recommendations for policy options to address the
knowledge gaps and improve cooperation at European
level. It will also assess existing European networks,
including those of the EMCDDA and its Reitox national
focal points. Results from this study will be available in
early 2009.
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lack of qualiﬁed research staff (Latvia, Hungary); and
methodological aspects (data protection issues, problems
in reaching hidden populations, lack of continuity in
research projects). Several countries identiﬁed the limited
funding available for drug-related research as a major
constraint (Belgium, Greece, Poland, Romania, Finland).
Dissemination
A total of 25 European peer-reviewed journals
specialising in the drugs ﬁeld and publishing in 11
languages other than English were identiﬁed. The
majority of these national journals publish English
abstracts and welcome international contributions. In
addition to publications specialising in illicit drugs and
addiction, articles on illicit drug use are also published in
peer-reviewed journals from a wide array of disciplines
and in professional magazines. In 2006, research
ﬁndings in the drugs ﬁeld were published in more than
100 such European journals. Other types of publication,
including those by national focal points, also play an
important role in dissemination.
Reitox national focal points also play an important role in
disseminating research results in all the reporting countries,
mainly by means of their national reports.
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Introduction
This chapter presents an overview of the responses to
drug problems in Europe, where possible highlighting
trends, developments and quality issues. The set of
measures reviewed here includes prevention, treatment,
harm reduction and social reintegration, which taken
together form a comprehensive demand-reduction system.
The chapter also includes a review of the available data
on the needs of drug users in prisons and the existing
responses in this particular setting. In addition, future
monitoring challenges in another ﬁeld of drug policy, drug
supply reduction, are brieﬂy discussed.
Prevention
Drug prevention can be divided into different levels or
strategies, from environmental to indicated prevention,
which ideally do not compete but complement each
other. The following description of the current situation
and trends in Europe is based on qualitative data on the
provision of universal and selective prevention reported
to the EMCDDA in 2007 (17) and on a literature review on
indicated prevention (EMCDDA, 2008f).
Universal prevention
The objectives of universal school-based drug prevention
in Europe appear to have shifted in recent years. In 2007,
developing life skills was the most frequently reported
objective of prevention activities (12 out of 28 reporting
countries), whereas in 2004, half of the countries (13/26)
reported raising awareness and providing information
as their main objective. Creating protective school
environments, a form of structural intervention, was
also more often mentioned as a main objective in 2007
(six countries) than it was in 2004 (four countries). The
changes in reported objectives may reﬂect the adoption
of a more rational and evidence-based approach, but the
extent to which this change in objectives reﬂects actual
provision is unclear.
Events for parents and strategies solely providing
information (information days, visits of experts or of police
agents at schools) are among the types of school-based
intervention reported by the largest number of countries
(Figure 3). The effectiveness of these interventions is
unclear. In contrast, some of the more strongly evidence-
based interventions are reported in only a few countries.
These include standardised programmes, peer approaches
or interventions speciﬁcally for boys; all of which aim
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(17) Data were provided by national experts in the Member States.
Improving the monitoring of drug supply
reduction
Drug supply reduction can be deﬁned as encompassing
all activities aimed at preventing illicit drugs from reaching
users. These may include instruments such as international
conventions, and EU and national legislation and policies,
as well as actions addressing the various processes
and actors involved in the production and trafﬁcking
of illicit drugs but also involved in the diversion or illicit
manufacture of licit substances (medicines, precursor
chemicals) for illicit ends and in the laundering of drug
money. Law enforcement activities, alternative development
initiatives and projects aimed at preventing drug-related
crime all contribute to reducing the supply of illicit drugs.
Monitoring and analysis constitute, as is the case with drug
demand reduction, an important support for these activities
and their evaluation.
Recent data collection exercises in the framework of the
annual progress reviews of the EU action plan on drugs
and the Ungass review (see Chapter 1) have revealed a
mixed picture regarding the availability of response data in
the supply reduction ﬁeld. Activities related to international
projects are usually well documented, while data on
activities at national level are often difﬁcult to access and
compare. The European Commission, Eurostat, Europol and
the EMCDDA are working to improve this situation in the
framework of the next EU action plan on drugs (2009–12).
Existing conceptual frameworks and information systems,
as well as potential information sources for monitoring
and analysing supply reduction activities in the Member
States, are to be reviewed. There is also a need to
better understand drug markets, in particular supply and
distribution arrangements, both in their economic and
social dimensions. Two studies funded by the European
Commission will explore both the information systems and
sources on drug supply reduction and the international
drug markets.
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to improve communication skills, increase abilities in
handling conﬂicts, stress and frustration, or correct
normative misperceptions about drug use. The overall
predominance of interventions that lack or have only a
weak evidence base might be due to the fact that they
require fewer resources and less staff training.
In addition to activities targeting drug use speciﬁcally,
structural interventions also exist in schools. By aiming
to create protective and normative social environments,
structural interventions seek to inﬂuence young people’s
choices about drug use (Toumbourou et al., 2007).
This approach matches overall prevention policies that
increasingly embrace stricter regulations on tobacco and
alcohol in schools. As such, 20 countries report total
smoking bans in all schools, and 18 countries report full
or extensive provision (18) of drug policies in schools. In
central and western Europe in particular, Member States
report having implemented structural interventions aimed
to reduce tobacco and alcohol use in schools. These
prevention measures may also be complemented by other
structural measures, such as improving the design of
school buildings and school life.
Family-based prevention is another widely utilised
prevention approach. Eleven countries reported full or
extensive provision of family meetings and evenings. In
common with school-based prevention, family-based
prevention seems to be mainly focused on providing
information. Intensive coaching and training for families,
an approach that has shown consistent efﬁcacy across
studies (Petrie et al., 2007), is offered on a limited basis,
with only seven countries reporting the highest provision
levels.
Selective prevention
Selective prevention is guided by social and demographic
indicators, such as unemployment, delinquency or truancy
rates. It intervenes with speciﬁc groups, families or entire
communities, where people, due to their scarce social ties
and resources, may be more likely to develop drug use or
progress into dependency.
Thirteen countries report that most of their family-based
prevention is selective. However, important risk conditions
of families are rarely addressed in Europe. Across 30
reporting countries, only seven report full or extensive
provision of interventions for substance use in families,
NB: Mustap = multisession, standardised programmes with printed material.
Sources: Reitox national focal points.
Figure 3: Most frequent intervention types in universal school-based prevention
(18) Extensive provision: the intervention is provided in a majority of locations where the size of the target population is sufﬁcient for its implementation.
Full provision: the intervention is available in almost all locations where the size of the target population is sufﬁcient for its implementation.
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and ﬁve report providing interventions for family conﬂict
and neglect. In addition, the following categories of
interventions were each reported by four countries:
addressing social disadvantage (e.g. unemployment),
helping with criminal justice problems, or assisting
marginalised families from ethnic minorities. Furthermore,
only three countries address the needs of families coping
with mental health problems.
Risk conditions of young vulnerable groups, for example,
young offenders, homeless, truant, disadvantaged
and minority youth, are also rarely addressed despite
increasing political importance. Since 2004, an increasing
number of drug policies have indicated them as primary
targets for prevention interventions, but the reported level
of intervention provision has not increased during this
period. More detailed data are presented in the 2008
selected issue on vulnerable groups of young people.
Indicated prevention
Indicated prevention aims to identify individuals with
behavioural or psychological problems that may be
predictive for developing problem substance use later
in life, and to target them individually with special
interventions. Such individuals include school dropouts,
and those with psychiatric disorders, antisocial behaviour
or early signs of drug use. A report recently published
by the EMCDDA (2008f) presents longitudinal studies
deﬁning problem trajectories, neurobehavioural studies
and the increasing knowledge about brain plasticity and
the role of neurotransmitters, and highlights ﬁndings from
interventions reported by Member States.
Children with behavioural disorders, such as coexisting
attention deﬁcit (hyperactivity) disorder and conduct
disorder, are at high risk of developing substance use
problems. Intervening early with children with behavioural
disorders requires close cooperation between medical,
social and youth services. The German ‘multi-module
treatment concept’, for example, offers a combination of
counselling for parents and carers; concurrent medical,
psychotherapeutic and psychosocial support; and
educational support in the kindergarten or school. The
Irish approach of targeted education and psychological
counselling for young people, especially for preventing
developmental problems in schools, education facilities
and the family, yielded overall positive evaluation results.
In the Netherlands, a study on the long-term preventive
effects of treating disruptive behaviours in young people
in middle childhood (aged 8–13) found that manualised
behavioural therapy showed signiﬁcantly better follow-up
outcomes on smoking and cannabis use compared to
treatment as usual (Zonnevylle-Bender et al., 2007).
Efﬁcacy and risks of interventions
Drug use among children and in families remains the
main focus of targeted prevention in Europe. A large
number of studies on the social and neurobehavioural
predictors for progression into substance use show
that non-drug-focused prevention efforts may also
have an effect on drug use. Both selective and
indicated prevention may moderate the effect of an
early developmental disadvantage, its translation into
social marginalisation and subsequent progression into
substance abuse. Several research studies have shown
that interventions delivered during the early school years,
aimed to improve educational environments and reduce
social exclusion, also have a moderating effect on later
substance use (Toumbourou et al., 2007).
The overall effectiveness of school-based prevention has
been questioned (Coggans, 2006; Gorman et al., 2007).
Recent literature reviews (19), however, show that certain
components of school-based prevention, such as the focus
on normative beliefs and life skills, seem to be effective.
For example, the EU-Dap study, a European randomised
controlled trial, co-funded by the European Commission,
to develop and evaluate a school-based prevention
programme, reported positive outcomes (20). A follow-up
(19) See the ‘Best practice’ portal (http://www.emcdda.europa.eu/themes/best-practice).
(20) http://www.eudap.net
Drugs and vulnerable groups of young people —
EMCDDA 2008 selected issue
Young people from certain groups are at risk of becoming
socially excluded, and this may be associated with an
increased likelihood of using drugs and of developing
drug use problems. By focusing interventions designed to
reduce drug use and drug-related harm on speciﬁc groups,
the chance of meeting the needs of these groups can be
increased, as can the likelihood of the intervention being
successful.
This selected issue provides in-depth information on the
risk factors and vulnerability proﬁles of speciﬁc groups
and explores drug use and drug-related problems among
them. It also investigates the consequences of vulnerability
resulting from truancy, academic failure, social
disadvantage, family problems and delinquency. Also
discussed are speciﬁc responses to drug use and drug
problems among vulnerable groups, including legislation,
prevention and treatment.
This selected issue is available in print and on the Internet
in English only (http://emcdda.europa.eu/publications/
selected-issues).
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study found that 15 months after the intervention, the
effect of the programme remained stable, with reduced
frequencies of drunkenness and of cannabis use observed
among participants. The ‘Unplugged’ programme used
in the trial challenged norms about the acceptance and
beliefs about the prevalence of substance use among
youth.
Prevention should not only be effective but must also be
safe — unwanted effects must be kept to a minimum.
Thus, the risks of negative effects should be considered
carefully when designing and evaluating interventions.
This is particularly important for universal school-based
prevention, which is delivered to a large and diverse
target population. For instance, providing information
about drug effects alone, a widespread approach in
Europe, is not only ineffective but may carry risks of
unwanted effects (Werch and Owen, 2002). The same
applies to mass-media campaigns, which can carry risks
of increasing the propensity for substance use (21).
One way to ensure that prevention programmes are
evidence based and that risks of unwanted effects are
reduced is to develop standards for the delivery and
content of prevention projects. The number of Member
States reporting standards for project design and
evaluation has increased from three in 2004 to nine
in 2007. Several Member States report that they are
developing certiﬁcation processes to guarantee the
quality of programmes and the efﬁcient use of resources
from public budgets (Czech Republic, Hungary, Poland,
Portugal). In the Czech Republic, for instance, certiﬁcation
of preventive activities is a condition for receiving
subsidies from the State budget.
Treatment
This section aims to provide an overview of drug treatment
in Europe, describing the organisation and provision of
services.
Organisation
In general, drug-treatment services are mainly provided
through the public sector in EU Member States, though
non-governmental organisations (NGOs) may play an
equal role (seven Member States), or even be the main
provider of treatment services (ﬁve Member States).
General practitioners also play an important role, and in
some countries are key providers of substitution treatment.
The private sector can also be involved in some countries,
mainly in residential care. Nevertheless, funding for drug
treatment is mostly provided by the public purse or is
linked to social or health insurances.
Provision
Drug treatment takes place in a variety of settings,
including outpatient and inpatient treatment centres,
general practice, low-threshold agencies and prison.
Outpatient settings, including general practice, account
for most of the treatment for drug use in Europe, mainly
because substitution treatment is usually delivered
in these settings. Drug users entering treatment in
outpatient settings are, according to the latest ﬁgures
from the treatment demand indicator, on average around
30 years old and predominantly male (22). Around one
third refer themselves to treatment, 22% are referred to
treatment by the criminal justice system, with this ﬁgure
growing in recent years, and the remaining are referred
through social and health services or through informal
networks (23).
Half of the clients entering treatment in outpatient settings
reported primary opioid use, while 21% cited cannabis
and 16% cocaine as their primary drug. Increases in the
(21) See Chapter 3 in this report and the 2007 annual report.
(22) See Tables TDI-10 (part iii) and TDI-21 (part ii) in the 2008 statistical bulletin.
(23) See Table TDI-16 in the 2008 statistical bulletin.
The EMCDDA ‘Best practice’ portal
The EMCDDA has this year launched the ﬁrst module
of its Internet portal on best practice for drug-related
interventions (prevention, treatment, harm reduction and
social reintegration). The portal provides an overview
on the latest evidence on the efﬁcacy and effectiveness
of different interventions, presenting tools and standards
aimed at improving the quality of interventions, as well as
highlighting examples of evaluated practice from across
Europe. It is aimed at practitioners, policymakers and
researchers in the drugs ﬁeld and has a strong Europe-
wide focus.
The ﬁrst module of the portal focuses on universal
prevention, in particular on evidence of efﬁcacy which
is based on several reviews published since 2000. For
details of the ﬁndings, see the portal
(http://www.emcdda.europa.eu/themes/best-practice).
The portal provides information on the efﬁcacy of various
interventions, but it should be noted that the evidence
base remains sometimes limited and that making
choices between different interventions requires caution.
Furthermore, as controlled trials measure the efﬁcacy of
programmes, how certain interventions will perform in
different settings remains subject to question. The new
edition of the EDDRA databank, available on the portal,
features examples of evaluated interventions in different
countries and settings, and may provide additional
guidance.
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proportion of clients, and especially new clients, referred
to treatment for problems with non-opioid drugs may
reﬂect improvements in treatment availability for users of
cannabis and cocaine in several Member States as well as
an increase in the numbers of users seeking treatment for
these drugs (see Chapters 3 and 5). However, the overall
availability of services speciﬁcally targeted to the needs of
non-opioid drug users remains limited.
Treatment in inpatient settings takes place mostly in
therapeutic communities, psychiatric hospitals and
specialised departments in general hospitals. The
services provided range from short-term detoxiﬁcation to
prolonged psychiatric and abstinence-based treatment
programmes. Residential services can be particularly
suited for drug users with complex treatment needs,
due to co-morbid physical and mental health problems.
Inpatient clients are, on average, similar to outpatient
clients: around 30 years old, mainly males and entering
drug treatment for primary opioid use (24). The proportion
of drug clients with no employment and unstable
accommodation is, however, higher among inpatient
clients than among outpatient clients, in most countries
where comparison is possible (25).
Historically, drug-treatment services have been organised
around the needs of opioid users, who still represent the
main group of users in treatment. In the majority of Member
States, substitution treatment combined with psychosocial
care has become the predominant option for opioid users.
With the introduction of high-dosage buprenorphine
treatment in Cyprus in 2007, substitution treatment is
now available in all Member States and in Croatia and
Norway (26). In Turkey, substitution treatment has yet to be
introduced, though it is permitted under a 2004 regulation
on treatment centres. After methadone, buprenorphine is
the second most commonly prescribed opioid substitute,
and its use in the treatment of opioid dependence has
increased in recent years (see Chapter 6). It is now
available as a treatment option in all Member States except
Bulgaria, Hungary and Poland. In 2006, it is estimated
that 600 000 opioid users received substitution treatment
in Europe, with an increase since the previous year being
reported in 16 of the 22 countries providing data.
Harm reduction
The prevention and reduction of drug-related harm is a
public health objective in all Member States and in the
EU drug strategy and action plan (European Commission,
2007a). The main interventions in this ﬁeld are opioid
substitution treatment and needle and syringe exchange
programmes (NSPs), which target overdose deaths and
the spread of infectious diseases. These measures are
reported to be available in all countries except Turkey
(see also Chapters 6 and 8) and, while considerable
differences exist in the range and levels of service
provision, the general European trend is one of growth
and consolidation of harm-reduction measures.
In addition, most countries provide a range of healthcare
and social services at low-threshold agencies. However,
some countries report that the implementation of harm-
reduction measures has been delayed due to the lack of
political support. In Greece, expansion of low-threshold
services and substitution treatment has been stalled;
needle and syringe programmes in Romania and Poland
were scaled down in 2006, after external funding ceased;
Cyprus’s only needle and syringe exchange programme
is not ofﬁcially endorsed. In Hungary, where NSPs and
outreach work have been increasing, a study among the
out-of-treatment population suggests that provision is still
insufﬁcient and access barriers are high.
Due to the speciﬁc proﬁle of the Baltic States and Romania
with regard to HIV/AIDS, international donors continue to
play an important role in these countries. Financial support
for harm-reduction activities is provided by the Global Fund
‘Programme to ﬁght against AIDS, malaria and tuberculosis’,
while in Estonia, Lithuania and Latvia, UNODC has recently
launched the project ‘HIV/AIDS prevention and care among
injecting drug users and in prison settings’.
Finally, some Member States have recently looked at
the consequences of the introduction of harm-reduction
interventions. In France, the observed decrease in mortality
rates among drug users coincided with the introduction
of triple antiviral therapies, the development of a harm-
reduction policy and the availability of opioid substitution
treatments; in Spain, the decreasing number of injectors
combined with easy access to methadone maintenance
treatment was associated with a decline of infectious
diseases and drug-related deaths among drug users (De la
Fuente et al., 2006); and in Portugal, available data show
a levelling off of infectious diseases, which probably can
be attributed, in part, to an increase in the availability of
harm-reduction and treatment responses.
Social reintegration
Drug users in treatment often report high levels of
unemployment and homelessness. Such disadvantage
tends also to be more widespread among speciﬁc groups
(24) See Tables TDI-10 (part vii) and TDI-21 (part iv) in the 2008 statistical bulletin.
(25) See Tables TDI-13 and TDI-15 in the 2008 statistical bulletin.
(26) See Tables HSR-1 and HSR-2 in the 2008 statistical bulletin.
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of users, particularly women, heroin and crack users, those
who belong to ethnic minorities and those with co-morbid
psychiatric problems.
Social reintegration is recognised as an essential
component of comprehensive drug strategies, and it can
be implemented at any stage of drug use and in different
settings. The aims of social reintegration interventions
may be achieved through capacity building, improvement
of social abilities, measures to facilitate and promote
employment and to obtain or improve housing. In practice,
reintegration services may offer vocational counselling,
work placements and housing support, while prison-based
interventions may link inmates to community-based housing
and social support services in preparation for their release.
Homelessness, together with living in unstable
accommodation, is one of the most serious forms of social
exclusion facing drug users, affecting about 10% of drug
users entering treatment in 2006 (27). While housing
support is provided to drug treatment clients in many
countries, shortages have also been documented, and two
countries report that it is difﬁcult for drug users to gain
access to the general services for the homeless that are
traditionally used by problem alcohol users (Ireland, Italy).
New measures that can help meet the accommodation
needs of drug users are being undertaken in three
countries (Belgium, Denmark, Netherlands), which report
that facilities for homeless long-term addicts are being
centralised and specialised care homes are being opened
for drug users with problem behaviour or co-morbidity.
Helping drug treatment clients ﬁnd employment is a key
element in social reintegration, as one in every two clients
entering treatment is unemployed (28). New approaches
to helping clients to ﬁnd and hold down employment are
reported to have shown success, these include: ‘mentoring
schemes’, subsidised workplaces (since 2006 also possible
in Lithuania), and special coaching of employers and
employees, as carried out under the ‘Ready for work’
project in Ireland, or various ‘work and social agencies’ in
the Czech Republic.
Health and social responses in prison
Prisons represent an important setting for the delivery
of health and social interventions to drug users. In this
section, data on drug use and drug users in European
prisons is reviewed along with recent information on the
provision of services to imprisoned drug users and new
laws on drug treatment in prison.
Drug use
Data available from a variety of studies continue to point
to an over-representation of drug users in European
prisons, compared to the general population. Surveys
carried out between 2001 and 2006 show that the
proportion of prisoners (29) who report having ever used
an illicit drug varies greatly between prison populations,
detention centres and countries, from a third or less
(Bulgaria, Hungary, Romania) to above 50% in most
studies, and up to 84% in a women’s prison in England
and Wales. Cannabis remains the illicit drug most
frequently reported by prisoners, with lifetime prevalence
levels of up to 78%. Although estimates of lifetime use of
other substances can be very low in some prisons (down
to 1%), some studies report lifetime prevalence levels of
50–60% for heroin, amphetamines or cocaine among
prisoners (30). The most damaging forms of drug use may
also be concentrated among prisoners, with some studies
reporting that more than a third of those surveyed have
ever injected drugs (31).
The fact that drugs ﬁnd their way into most prisons, despite
all measures being taken to reduce the supply of drugs,
is recognised by both prison experts and policymakers.
Studies carried out between 2001 and 2006 in Europe
show that between 1% and 56% of inmates report having
used drugs within prison, and up to a third of inmates
have injected drugs while in custody (32). This raises
concerns around the potential spread of infectious diseases,
especially in relation to the sharing of injection equipment.
The prison population in the European Union is over
607 000 (33), with an estimated annual turnover of
more than 860 000 prisoners. In most countries, the
proportion of prisoners sentenced for drug law offences
is in the range of 10–30%. From the data available,
it can be estimated that more than 400 000 people
with past or current experience of illicit drug use pass
through EU prisons every year. And among these, there
will be a considerable number of problem drug users.
The healthcare needs of this large population of former
or current drug users in European prisons will, to some
extent, be determined by health problems related to drug
use, notably infectious diseases such as hepatitis B and C
viruses and HIV/AIDS (see Chapter 7).
(27) See Table TDI-15 in the 2008 statistical bulletin.
(28) See Table TDI-20 in the 2008 statistical bulletin.
(29) The term ‘prisoners’ is used in a broad sense here, and includes both on-remand and convicted incarcerated persons.
(30) See Table DUP-1 in the 2008 statistical bulletin.
(31) See Table DUP-2 in the 2008 statistical bulletin.
(32) See Tables DUP-3 and DUP-4 in the 2008 statistical bulletin.
(33) Council of Europe Annual Penal Statistics (SPACE), based on a prison population survey with reference to 1 September 2006.
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Healthcare
The responsibility for healthcare in prison lies, in most
countries, with the Ministry of Justice. However, this
is changing, and in a growing number of European
countries, the responsibility has been transferred to the
health system (France, Italy, England and Wales in the
United Kingdom, Norway). In Spain, comprehensive
services for drug users are developed in all prisons
according to the action plan of the national strategy on
drugs (2000–08) and based on a cooperation protocol
between the Ministry of Health and the Ministry of the
Interior, signed in 2005. In other countries, in order to
meet the needs of increasing numbers of incarcerated
drug users, prisons have established cooperation with
public health services and specialist non-governmental
drugs agencies in the community.
Interventions targeting drug-using prisoners have
expanded in the European Union. Compared to ﬁve years
ago, more countries now report activities in the following
areas: drug-related information and prevention; screening
for infectious diseases and vaccinations; and drug
dependence treatment, including substitution treatment. In
addition, these interventions have become more widely
available within countries. Prison-based substitution
treatment is ofﬁcially available in all countries except
Bulgaria, Estonia, Latvia, Lithuania, Cyprus, Slovakia and
Turkey, though, in many countries, the overall accessibility
of this treatment option is limited. Spain is currently the
only European country that provides a wide range of
harm-reduction measures in prisons.
In 2006, only four Member States reported socio-
demographic data and information on drug use patterns of
prisoners in drug treatment through their national treatment
monitoring systems. In France, Cyprus and Slovakia,
an opioid, usually heroin, is most often reported as the
primary drug by those entering drug treatment; while in
Sweden, primary amphetamine use is the main reason for
entering treatment in prison, reﬂecting broadly the patterns
of problem drug use within these countries.
Recent legislation on drug treatment in prison
In 2006 and early 2007, six countries revised their legal
frameworks and guidelines affecting prisoners’ rights to drug
treatment.
In Belgium, a 2006 directive from the Ministry for Justice
states that inmates have the right to the same range of
treatment options as are available outside prison. Meanwhile,
in Ireland new Prison Service guidelines emphasise the
healthcare standard for treatment services, which should be
comparable to those available in the community, while being
appropriate to the prison setting.
In Denmark, a change in the law from January 2007 entitles
imprisoned drug users to free treatment for their drug use. The
law stipulates that the treatment should normally start within
14 days of the prisoner requesting it from the Danish Prison
and Probation Service. However, there is no such entitlement if
the offender is expected to be released within three months or
is considered unﬁt or not motivated for treatment.
In Romania, a new legal basis for establishing substitution
treatment in prisons was created in May 2006 by the
Common Order of the Ministries for Justice, Public Health, and
Administration and Internal Affairs regarding the continuation
of integrated medical, psychological and social assistance
programmes for inmates.
In Norway, a circular in 2006 from the Ministry of Justice
and the Ministry of Health and Social Affairs strengthened
cooperation between the two sectors and aimed at
providing better follow-up during and after the serving
of sentences. More specifically, in Slovakia, a 2006
law permitted the provision of psychological services to
drug users on remand who are suffering from withdrawal
symptoms. The aim of this law is to provide drug users with
such services at the time when they are most needed, at
the time of enforced withdrawal immediately upon entering
custody. It also created a legislative framework to support
the existing special treatment units for convicted drug
users.

36
Introduction
The European picture in respect to cannabis has evolved
considerably over the last decade, as has the debate
on how to respond appropriately to the widespread use
of this drug. In the early and mid-1990s a few countries
stood out as having a high prevalence, whereas the
European norm was levels of use which, by today’s
standards, were low. In almost all countries, cannabis use
increased during the 1990s and early 2000s, and this has
resulted today in a far less varied European picture, even
if differences between countries still exist. Moreover, the
last few years have seen a growing understanding of the
public health implications of the long-term and widespread
use of this drug, and rising reported levels of treatment
demand for cannabis-related problems. Europe may
now be moving into a new phase, as data are pointing
to a stabilising or even decreasing situation. Levels of
use remain high by historical standards, however; what
constitutes an effective response to cannabis use remains a
key question in the European debate on drugs.
Supply and availability
Production and trafﬁcking
Cannabis can be cultivated in a wide range of
environments and grows wild in many parts of the world,
and it is currently believed that the plant is cultivated in
172 countries and territories (UNODC, 2008) (34). These
facts taken together mean that producing estimates of the
worldwide production of cannabis with any precision is
likely to be very difﬁcult. The latest UNODC ﬁgure for the
global production of herbal cannabis stands at 41 600
tonnes (2006), of which more than half is accounted for
by the Americas (North America and South America) and
close to a quarter by Africa (UNODC, 2008).
The widespread cultivation of cannabis also means that
a signiﬁcant proportion of trafﬁcking is likely to be intra-
regional. This is the case for some herbal cannabis in
Europe, where in addition to home production (35), Albania
and the Netherlands have been noted as source countries
(Reitox national reports). Herbal cannabis in Europe is also
reported to come from other parts of the world, including:
west and southern Africa (Nigeria, Angola), south-east Asia
(Thailand), south-west Asia (Pakistan) and the Americas
(Colombia, Jamaica) (CND, 2008; Europol, 2008).
Global production of cannabis resin was estimated at
6 000 tonnes in 2006, down from 7 500 tonnes in 2004
(UNODC, 2007a), with Morocco remaining the main
international producer. The area under cannabis resin
production declined from 134 000 hectares in 2003 to
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(34) For information on the sources of data for drug supply and availability, see the box on this page.
(35) See ‘Cannabis production in Europe’, p. 37.
Drug supply and availability — data and sources
Systematic and routine information to describe illicit drug
markets and trafﬁcking is still limited. Production estimates of
heroin, cocaine and cannabis are obtained from cultivation
estimates based on ﬁeldwork (sampling on the ground)
and aerial or satellite surveys. These estimates have some
important limitations linked, for instance, with variations in
yield ﬁgures or with the difﬁculty of monitoring crops which
are not grown in restricted geographical areas, like cannabis.
Drug seizures are often considered as an indirect indicator
of the supply, trafﬁcking routes and availability of drugs;
however, they also reﬂect law enforcement priorities,
resources and strategies, the vulnerability of trafﬁckers and
reporting practices. Data on purity or potency and retail
prices of illicit drugs may also be analysed in order to
understand retail drug markets. However, the availability of
this type of data may be limited and there may be questions
of reliability and comparability. Intelligence information from
law enforcement agencies may help complete the picture.
The EMCDDA collects national data on drug seizures,
purity and retail prices in Europe. Other data on drug
supply comes largely from UNODC’s information systems
and analyses, complemented by additional information
from Europol. Information on drug precursors is obtained
from the INCB, which is involved in international initiatives
to prevent the diversion of precursor chemicals used in the
manufacture of illicit drugs.
As many parts of the world lack sophisticated information
systems related to drug supply, some of the estimates
and other data reported, though representing the best
approximations available, must be interpreted with caution.
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76 400 hectares producing 1 066 tonnes in 2005
(UNODC and Government of Morocco, 2007). Resin
production is also reported in Afghanistan, where it is
rising rapidly, Pakistan, India, Nepal, and Central Asian
and other CIS countries (UNODC, 2008). Cannabis resin
produced in Morocco is typically smuggled into Europe
via the Iberian peninsula (Europol, 2008), with some of it
being further distributed from the Netherlands.
Seizures
In 2006, 5 230 tonnes of herbal cannabis and 1 025
tonnes of cannabis resin were seized worldwide, down
from peak levels in 2004. North America continued to
account for the bulk of herbal cannabis seized (58%),
while quantities of resin seized remained concentrated in
western and central Europe (62%) (UNODC, 2008).
In Europe, an estimated 177 000 seizures of herbal
cannabis, amounting to 86 tonnes, were made in
2006 (36). The United Kingdom is the EU Member State
reporting the most seizures of herbal cannabis, though
data are not yet available for 2006. Turkey reported
seizures of record amounts of herbal cannabis in 2006.
The number of herbal cannabis seizures in Europe has
increased steadily since 2001, while there has been an
overall decrease in the quantity seized, until 2005, with
an increase noted in the most recent data.
Seizures of cannabis resin in Europe exceed herbal seizures
both in terms of number and quantity: with twice as many
seizures (325 000) and the amount intercepted (713 tonnes)
eight times higher. Most seizures of resin continue to be
reported by Spain (which accounted for about half of all
seizures and for about two thirds of the quantity seized in
2006), followed, at a distance, by France and the United
Kingdom. After a period of stabilisation in 2001–03, the
number of cannabis resin seizures is increasing in Europe,
while the quantities intercepted increased until 2003–04,
but thereafter have been declining.
In 2006, an estimated 10 500 seizures in Europe resulted
in the recovery of about 2.3 million cannabis plants (37)
and 22 tonnes of cannabis plants (64% accounted
by Spain). Following a steady increase since 2001,
the number of seizures of cannabis plants stabilised in
2006 (38). After a sharp decline in 2002 from a record
amount seized in 2001, the number of plants seized in
Europe has been on the increase, although it levelled off in
2006 at half the number reported in 2001. Over the same
ﬁve-year period, the amount of cannabis plants seized in
Europe and reported in kilograms shows a steady increase,
accelerating in 2006 due to record seizures in Lithuania.
Potency and price
The potency of cannabis products is determined by their
content of delta-9-tetrahydrocannabinol (THC), the primary
active constituent. Cannabis potency varies widely between
and within countries, and between different cannabis
samples and products. For a number of methodological
(36) The data on European drug seizures mentioned in this chapter can be found in Tables SZR-1, SZR-2, SZR-3, SZR-4, SZR-5 and SZR-6 in the 2008
statistical bulletin.
(37) Since Turkey reported having seized no cannabis plants in 2005 and 2006, after reporting high levels of seizures of this material over 2001–04, it
was excluded from the European analysis.
(38) This picture is preliminary as data for the United Kingdom, the country reporting the most cannabis plants seized in 2005, are not yet available for 2006.
Cannabis production in Europe
The issue of domestic production of cannabis has become
more important in recent years across Europe, reﬂecting
the fact that a majority of European countries now
report local cultivation of cannabis and some substantial
seizures of cannabis plants. Cannabis grown in Europe is
reported to come from both indoor facilities, where it is
often cultivated intensively, and from outdoor plantations.
The size of plantations varies widely, depending on the
motivation and resources of the grower, from a few plants
for personal use to several thousand in large sites intended
for commercial purposes.
Available information is patchy and does not allow an
accurate assessment of the extent of cannabis cultivation in
Europe. Nevertheless, reports from a number of countries
suggest that it may no longer be viewed as marginal. For
example, French population surveys in 2005 estimated that
about 200 000 people had grown cannabis at least once
in their lifetime. In the United Kingdom, more than
1 500 ‘cannabis farms’, with 400 plants per site on
average, were reportedly closed down by police in London
in 2005–06 (Daly, 2007) and most herbal cannabis now
available is thought to be produced either locally or in
other European countries. In the Netherlands, cannabis
cultivation is widespread in some parts of the country, with
an estimated total of 6 000 cultivation sites dismantled in
2005 and 2006.
Cannabis production seems to have experienced a sharp
increase from the early to mid-1990s in some western
European countries, partly as a response of cannabis
consumers to the perceived poor quality and high price
of imported resin, then the most widely used cannabis
product. In some countries, it seems that a majority of users
are now consuming locally produced herbal cannabis.
This partial substitution of domestically produced herbal
cannabis for imported resin was made possible by
advances in horticultural knowledge and technology (to
maximise yields and avoid detection), which then spread
through the Internet (Hough et al., 2003; Jansen, 2002;
Szendrei, 1997/98). Cannabis that is produced locally
also has the advantage for the producer that it does not
need to be transported across national borders.
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reasons, data are difﬁcult to interpret in this area and the
extent to which seizures analysed reﬂects the overall market
questionable. Research suggests that in general cannabis
produced domestically under intensive conditions tends to be
of higher potency. In 2006, the reported THC content of resin
samples ranged from 2.3% to 18.4%, while that of herbal
cannabis ranged from under 1% to 13%. Over the period
2001–06, the potency of resin and herbal cannabis remained
stable or decreased in many of the 16 European countries
providing sufﬁcient data; however, upward trends were noted
for imported cannabis resin in the Netherlands and for herbal
cannabis in seven other countries. Estimates of the potency of
locally produced herbal cannabis over a number of years are
available only for the Netherlands, which reported a decline
to 16.0% in 2006, from a peak of 20.3% in 2004 (39).
Typical retail prices of both herbal cannabis and cannabis
resin varied from EUR 2 to EUR 14 per gram, with a
majority of European countries reporting prices in the range
EUR 4–10 for both products. During the period 2001–06,
with the exception of Belgium and Germany, retail prices
of cannabis resin (corrected for inﬂation) were reported to
have decreased. The available data from most countries
point to a more stable situation for herbal cannabis prices
during this period, with the exception of Germany and
Austria, where signs of increasing prices were noted.
Prevalence and patterns of use
Among the general population
It is conservatively estimated that cannabis has been used
at least once (lifetime prevalence) by more than 70 million
Europeans, that is over one in ﬁve of all 15- to 64-year-
olds (see Table 2 for a summary of the data). Although
considerable differences exist between countries, with
national ﬁgures varying from 2% to 37%, half of the
countries report estimates in the range 11–22%.
Many countries report comparatively high prevalence levels
of last year and last month use of cannabis. It is estimated
that around 23 million Europeans have used cannabis in the
last year, or on average, about 7% of all 15- to 64-year-olds.
Estimates of last month prevalence will include those using the
drug more regularly, though not necessarily in an intensive
way (see below). It is estimated that about 12.5 million
Europeans used the drug in the previous month, on average
about 4% of all 15- to 64-year-olds.
Cannabis use among young adults
Cannabis use is largely concentrated among young
people (15–34 years), with the highest levels of use
generally being reported among the 15- to 24-year-olds.
This is the case in almost all European countries, the
exceptions being Belgium, Cyprus and Portugal (40).
Population survey data suggest that, on average, 31%
of young European adults (15–34 years) have ever used
cannabis, while 13% have used the drug in the last year
and 7% have used it in the last month. It is estimated that
even higher proportions of Europeans in the 15–24 age
(39) See Tables PPP-1 and PPP-5 in the 2008 statistical bulletin for potency and price data.
(40) See Figure GPS-1 in the 2008 statistical bulletin.
Population surveys: an important tool for
understanding patterns and trends of
drug use in Europe
Drug use in the general or school population can be
measured through representative surveys, which provide
estimates of the proportion of individuals that report having
used speciﬁc drugs over deﬁned periods of time. Surveys
also provide useful contextual information on patterns of use,
sociodemographic characteristics of users and perceptions of
risks and availability (1).
The EMCDDA, in close collaboration with national experts,
has developed a set of common core items for use in adult
surveys (the ‘European Model Questionnaire’, EMQ). This
protocol has now been implemented in most EU Member
States (2). However, there are still differences between
countries in the methodology used and year of data
collection, and this means that small differences, in particular
between countries, should be interpreted with caution (3).
As surveys are expensive to conduct, few European countries
collect information each year, although many collect it
at intervals of two to four years. In this report, data are
presented based on the most recent survey available in each
country, which in most cases is between 2004 and 2007.
Of the three standard time frames used for reporting survey
data, lifetime prevalence is the broadest. This measure does
not reﬂect the current drug use situation among adults, but is
useful for reporting on school students and to provide insight
into patterns of use and incidence. For adults, the focus is on
last year and last month use (4). Identifying those who are using
regularly or having problems with their use of drugs is important,
and progress is being made in this respect with the development
of short scales to assess more intensive forms of use in the
general population, adults and school students (see the box on
developing psychometric scales in the 2007 annual report).
(1) More information on survey methodology is available in the
2008 statistical bulletin
(http://www.emcdda.europa.eu/stats08/gps/methods).
(2) Available at http://www.emcdda.europa.eu/themes/monitoring/
general-population
(3) For more information on national surveys, see Table GPS-121 in
the 2008 statistical bulletin.
(4) The EMCDDA standard age ranges are: all adults (15–64 years)
and young adults (15–34 years). This report uses the terms ‘lifetime
useor prevalence’, ‘last year prevalence’ and ‘lastmonth prevalence’
and, sometimes, the more colloquial terms ‘lifetime experience’,
‘recent use’ and ‘current use’, respectively.
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group have used cannabis in the last year (17%) or last
month (9%), though on average slightly fewer among this
age group have tried the drug (30%). National prevalence
estimates of cannabis use vary widely between countries
in all measures of prevalence, with countries at the upper
end of the scale reporting values up to 10 times those of
the lowest-prevalence countries.
Cannabis use is higher among males than among females
(see the 2006 selected issue on gender), although marked
differences between countries are observed. For example,
the ratio of males to females among those reporting use of
cannabis in the last year ranged from 6.4 males for each
female in Portugal to 1.3 in Italy.
Cannabis use among school students
After tobacco and alcohol, cannabis also continues to be
the psychoactive substance most commonly used by school
students.
Ever in lifetime use of cannabis by 15- to 16-year-old
school students may be taken to reﬂect recent or current
use as ﬁrst experimenting with this substance often
occurs at or around this age. Data from the 2005/06
HBSC survey of 15-year-olds showed large variation in
lifetime prevalence of cannabis use across 27 countries.
Prevalence estimates of under 10% for ever in lifetime use
of cannabis were reported by ﬁve countries; 11 countries
reported values between 10% and 20% and 11 countries
between 21% and 31% (Currie et al., 2008) (41). In this
age group, boys usually report a higher prevalence of
cannabis use than girls, but the difference in reported
prevalence between the sexes is small or even absent
in some of the countries with the highest prevalence
estimates.
As with lifetime experience, there is a wide variation
between countries in estimates of use in the last 30 days
among school students. In some countries it is virtually
unreported, whereas in others around 15% of those
questioned report use during the last 30 days, with
sometimes even higher ﬁgures found among males. On
the basis of data collected in earlier ESPAD surveys, it is
estimated that in 2003 around 3.5 million (22.1%) 15- to
16-year-old school students had used cannabis at least
once in their lifetime in the EU Member States together
with Croatia and Turkey, and, around 1.7 million (11%)
had used the drug in the month prior to the survey.
International comparisons
European ﬁgures can be compared with those from other
parts of the world. For instance, in the United States, the
national survey on drug use and health (Samhsa, 2005)
estimated a lifetime prevalence of cannabis use of 49%
among young adults (15–34 years, recalculated by the
EMCDDA) and a last year prevalence of 21%. For the
same age group, lifetime prevalence of cannabis use was
58% and last year prevalence 28% in Canada (2004),
while in Australia (2004) the ﬁgures were 48% and 20%.
All these ﬁgures are above the corresponding European
averages, which are respectively 31% and 13%.
Patterns of cannabis use
Available data point to a variety of patterns of cannabis
use. Of those aged 15–64 who have ever used cannabis,
only 30% have done so during the last year (42). But,
among those who have used the drug in the last year, on
average 56% have done so in the last month.
Estimating intensive and long-term patterns of use is an
important public health issue. Daily or almost daily use
(use on 20 days or more in the last 30 days) may be an
indicator of intensive use. Data on this form of cannabis
use in Europe was collected in 2007/08 as part of a
‘ﬁeld trial’ coordinated by the EMCDDA in collaboration
with national experts and the Reitox focal points of 13
countries. On the basis of this data, albeit limited, it is
estimated that over 1% of all European adults, about
4 million, are using cannabis daily or almost daily. Most
of these cannabis users, about 3 million, are aged 15–34,
(41) See Figure EYE-5 in the 2008 statistical bulletin.
(42) See Figure GPS-2 in the 2008 statistical bulletin.
Recent school surveys
The ‘Health behaviour in school-aged children’ (HBSC)
survey is a WHO collaborative study which investigates
children’s health and health behaviour and has included
questions about cannabis use among 15-year-old students
since 2001. The second round of this survey with questions
about cannabis use was conducted between October
2005 and May 2006, with the participation of 26 EU
Member States and Croatia.
The fourth round of the ‘European school survey project
on alcohol and other drugs’ (ESPAD) was conducted in
2007 with the participation of 25 EU Member States,
Croatia and Norway. This survey speciﬁcally investigates
substance use among school students who turn 16 during
the calendar year. Results from the latest surveys will be
published in December 2008.
Participation in both of these international school surveys,
each conducted every four years, has grown in each round
and now includes most European countries.
Spain, Italy, Portugal, Slovakia, Sweden and the United
Kingdom also reported data on cannabis use from their
own national school surveys in 2006.
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Table 2: Prevalence of cannabis use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year Last month
15–64 years
Estimated number of users
in Europe
71.5 million 23 million 12.5 million
European average 21.8% 6.8% 3.8%
Range 1.7–36.5% 0.8–11.2% 0.5–8.7%
Lowest -prevalence countries Romania (1.7%)
Malta (3.5%)
Bulgaria (4.4%)
Cyprus (6.6%)
Malta (0.8%)
Bulgaria (1.5%)
Greece (1.7%)
Sweden (2.0%)
Malta (0.5%)
Sweden (0.6%)
Lithuania (0.7%)
Bulgaria (0.8%)
Highest -prevalence countries Denmark (36.5%)
France (30.6%)
United Kingdom (30.1%)
Italy (29.3%)
Italy, Spain (11.2%)
Czech Republic (9.3%)
France (8.6%)
Spain (8.7%)
Italy (5.8%)
United Kingdom
France, Czech Republic (4.8%)
15–34 years
Estimated number of users
in Europe
42 million 17.5 million 10 million
European average 31.2% 13% 7.3%
Range 2.9–49.5% 1.9–20.3% 1.5–15.5%
Lowest -prevalence countries Romania (2.9%)
Malta (4.8%)
Bulgaria (8.7%)
Cyprus (9.9%)
Malta (1.9%)
Greece (3.2%)
Cyprus (3.4%)
Bulgaria (3.5%)
Greece, Lithuania,
Sweden (1.5%)
Bulgaria (1.7%)
Highest -prevalence countries Denmark (49.5%)
France (43.6%)
United Kingdom (41.4%)
Spain (38.6%)
Spain (20.3%)
Czech Republic (19.3%)
France (16.7%)
Italy (16.5%)
Spain (15.5%)
France, Czech Republic (9.8%)
United Kingdom (9.2%)
15–24 years
Estimated number of users
in Europe
20 million 11 million 6 million
European average 30.7% 16.7% 9.1%
Range 2.7–44.2% 3.6–28.2% 1.2–18.6%
Lowest -prevalence countries Romania (2.7%)
Malta (4.9%)
Cyprus (6.9%)
Greece (9.0%)
Greece, Cyprus (3.6%)
Sweden (6.0%)
Bulgaria, Portugal (6.6%)
Greece (1.2%)
Sweden (1.6%)
Cyprus, Lithuania (2.0%)
Highest -prevalence countries Denmark (44.2%)
Czech Republic (43.9%)
France (42.0%)
United Kingdom (39.5%)
Czech Republic (28.2%)
Spain (24.3%)
France (21.7%)
United Kingdom (20.9%)
Spain (18.6%)
Czech Republic (15.4%)
France (12.7%)
United Kingdom (12.0%)
Information based on the last survey available for each country. The study year ranges from 2001 to 2007. The average prevalence for Europe was computed
by a weighted average according to the population of the relevant age group in each country. In countries for which no information was available, the
average EU prevalence was imputed. Populations used as basis: 15–64 (328 million), 15–34 (134 million) and 15–24 (64 million). The data summarised here
are available under ‘General population surveys’ in the 2008 statistical bulletin.
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representing approximately 2–2.5% of all Europeans in
this age group (43).
Trends in intensive cannabis use in Europe are difﬁcult to
assess, but among the countries participating in both ﬁeld
trials in 2004 and 2007 (Ireland, Greece, Spain, France,
Italy, Netherlands, Portugal), the average increase was
about 20%, although this estimation is largely inﬂuenced
by the ﬁgures of Spain, France and Italy.
Repeated use of cannabis can be fairly stable over long
periods of time, even among younger users. A recently
published German study, which followed up for 10 years
a cohort of 14- to 24-year-olds, showed that among those
who had used cannabis repeatedly (ﬁve times or more
in their life) at the beginning of the study period, a large
proportion continued to use the drug, with 56% reporting
use after four years and 46% still using the drug after
10 years. Conversely, occasional use of the drug at the
beginning of the period (one to four times) did not appear
to be associated with subsequent development of long-term
and more problematic forms of use (Perkonigg, 2008).
Cannabis dependence has been increasingly recognised
as a possible consequence of regular use of the drug,
even if the severity and consequences may appear
less serious than those commonly found with some
other psychoactive substances. Nevertheless, due to
the relatively larger proportion of the population using
cannabis regularly, the overall impact of intensive forms of
cannabis use on public health may be signiﬁcant. Analysis
of national population survey data for the United States
reveals that around 20–30% of daily users scored positive
for dependence between 2000 and 2006 (44). In an
Australian study, 92% of long-term cannabis users were
classiﬁed as having been dependent at some point in their
life, with more than half of them judged to be dependent
at the time of the study. A follow-up study carried out
one year later suggested that, among long-term users,
measures of cannabis use and dependence may be stable
for this length of time (Swift et al., 2000).
The EMCDDA is developing, in collaboration with several
countries, methods for monitoring the more intensive and
signiﬁcant long-term forms of cannabis use, including
dependence. Psychometric scales are being tested in
several EU countries and the available evidence will be
analysed this year. This information may assist EU Member
States in assessing the implications of more problematic
forms of cannabis use on public health and in planning
appropriate interventions (45).
Patterns of cannabis use among school students
HBSC data show that frequent cannabis use remains rare
among 15-year-old schoolchildren. Only six countries
report a prevalence of frequent cannabis use (deﬁned here
as 40 times or more during the previous 12 months) above
2%. However, frequent use is generally more prevalent
among males, with estimates up to 5% in seven countries.
Reports indicate that correlations exist between the more
problematic patterns of cannabis use and belonging to
a vulnerable group (e.g. young offenders, truants, low
educational achievers), suggesting that speciﬁc strategies
are needed to provide a safety net for these particularly
vulnerable young people. This issue is highlighted in the
2008 selected issue on vulnerable groups.
An investigation of polydrug use has been made in
cooperation with ESPAD by comparing school students
aged 15–16 years in 2003 who have used cannabis
during the previous 30 days with the other students.
The comparison shows that, on average, students who
have used cannabis are more likely to have used other
substances. Although among cannabis users the last
month prevalence of other drug use remained low (below
10%), levels of cigarette smoking and binge drinking
among cannabis users was about double that (80%)
found among the general student population. These
comparisons indicate that cannabis use is associated with
considerably higher than average rates of both licit and
illicit drug use (46).
Trends in cannabis use
Only Sweden and Norway report a series of surveys of
young people or conscripts dating back to the 1970s. A
ﬁrst wave of use was observed in the 1970s, followed by
a decline in the 1980s and a new substantial increase
during the 1990s. Analysis of year of initiation in recent
surveys also identiﬁed substantial cannabis use expansion
in Spain (mid-1970s) and Germany (early 1990s) (see the
2004 and 2007 annual reports).
National survey data reported to the EMCDDA show
that in almost all EU countries cannabis use increased
(43) The European averages presented are a rough estimation based on a weighted average (for the population) for countries with information. The
average result is imputed for countries without information. The ﬁgures obtained are 1.2% for all adults (15–64 years) and 2.3% for young adults
(15–34 years). See Table GPS-7 in the 2008 statistical bulletin.
(44) NSDUH online analysis facility (http://webapp.icpsr.umich.edu/cocoon/SAMHDA/SERIES/00064.xml), accessed on 25 February 2008 and
analysed using variables MJDAY30A and DEPNDMRJ.
(45) Interventions, e.g. forms of treatment, are presented in ‘Treatment provision’, p. 44.
(46) The analysis is based on data from the database produced within the European school survey project on alcohol and other drugs (ESPAD), and is in
line with the rules for the use of the ESPAD database. The national principal investigators providing data for each of the countries included can be
found on the project’s website (www.espad.org).
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markedly during the 1990s, in particular among young
people (Figure 4) and school students. Around the year
2000, lifetime prevalence of cannabis use among the
15–34 age group increased to levels in excess of 30%
in nine countries and around 40% in two cases, while
last year prevalence reached 15–20% in seven countries
and last month prevalence 8–15% in six countries. Of
particular interest is the trend in cannabis use in the
United Kingdom (England and Wales), the country that
reported the highest prevalence estimates in Europe in the
early and mid-1990s, but where more recently a steady
downward trend has been observed, particularly among
the 16–24 age group (47).
Information from recent national surveys suggests that
cannabis use is stabilising in many countries. Of the 16
countries for which it is possible to analyse the trend from
2001 and 2006, last year prevalence among young adults
increased by 15% or more in six countries, decreased in
three by a similar amount and was stable in seven (48).
Stable or decreasing trends are also evident from the
most recently published data on cannabis use among
school students. A comparison of HBSC data of
2001/02 and 2005/06 shows a stable or decreasing
trend in both lifetime and other more frequent cannabis
use among 15-year-old school students in most EU
countries (49). Other recent national school surveys
conducted in Spain, Portugal, Slovakia, Sweden and the
United Kingdom also report stable or decreasing trends.
As cannabis availability in Europe as a whole does
not seem to have changed and prices seem to be
decreasing in most countries providing information, an
explanation for the current stabilisation or decrease has
to be found elsewhere. The 2005 French population
survey Baromètre sante noted that among those who had
stopped using cannabis, 80% cited a lack of interest
as the reason for quitting. Part of the explanation may
also be found in the observed reduction in tobacco
smoking, which shares the same route of administration
as cannabis and the behaviour may, therefore, be
associated at some level (Reitox national reports and
Currie et al., 2008).
(47) See Figure GPS-10 in the 2008 statistical bulletin.
(48) Where information on the exact years was not available, information from the previous or following year was used; where this information was
unavailable, analysis was not conducted.
(49) See Figures EYE-4 and EYE-5 in the 2008 statistical bulletin.
(1) England and Wales.
NB: See Figure GPS-4 in the 2008 statistical bulletin for further information.
Sources: Reitox national reports (2007), taken from population surveys, reports or scientiﬁc articles.
Figure 4: Trends in last year prevalence of cannabis use among young adults (aged 15–34)
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Decreases in experimental or occasional use of cannabis
are not necessarily directly related to trends in the regular
use of the drug. This can be seen in data from two
consecutive surveys among adolescents in Germany, which
have shown decreases in lifetime and last year prevalence,
while ‘regular use’ of cannabis (more than 10 times in the
last year) remained unchanged (2.3%) (BZgA, 2004 and
BZgA, 2007, cited in the German national report).
Cannabis treatment
Treatment demand patterns
In 2006, among 390 000 reported treatment demands
(data available from 24 countries), cannabis was the
primary reason for entering treatment in about 21% of all
cases, making it the second most reported drug after
heroin (50). However, inter-country differences were
considerable, with cannabis cited as the primary reason for
entering treatment by less than 5% of all clients in Bulgaria,
Lithuania, Luxembourg and Romania, whereas it is reported
as the principal drug by more than 30% of treatment clients
in France, Hungary and the Netherlands (51).
There are also considerable variations regarding new
treatment demands, with cannabis being cited as
the primary drug by less than 10% of new clients in
Bulgaria, Lithuania and Romania and by more than 50%
in Denmark, Germany, France and Hungary (52). Those
variations may be explained by differences in prevalence
of intensive cannabis use, drug treatment organisation or
referral practices. For instance, in some countries with high
proportions of cannabis patients (e.g. Germany, Hungary,
Austria, Sweden), drug treatment is offered as an
alternative to punishment and it is sometimes compulsory
in the event of arrest; in France, which reports the highest
proportion of cannabis clients in Europe, specialised
centres for cannabis users have recently been created and
this will have a direct impact on reporting.
Cannabis users are mainly treated in outpatient centres,
but in some countries (Ireland, Slovakia, Finland, Sweden)
around one third are reported to seek treatment in
inpatient settings (53). Most cannabis clients are reported
to be self-referred, but this referral route is less common
among cannabis clients than among those seeking help
for problems with other drugs.
Those seeking treatment in outpatient settings for
primary cannabis use also report using other drugs:
21% report using alcohol as a secondary substance,
12% amphetamines and ecstasy, and 10 % cocaine.
Among those receiving treatment for other primary drugs,
cannabis is reported as the second most frequently cited
secondary substance (21%) after alcohol (32%) (54).
Trends in new demands for drug treatment
Among the approximately 160 000 new demands for
drug treatment (data available from 24 countries) reported
in 2006, cannabis clients represent the second largest
group (28%), after heroin clients (34%). Compared to the
proportion of all clients reporting cannabis as their primary
drug, the proportion among new clients is higher. Half
of the countries report that the proportion of new clients
requesting treatment for cannabis as their primary drug
is increasing. The absolute number of new demands for
cannabis treatment increased over the period 2002–06,
while the proportion of new clients entering treatment for
primary cannabis use increased between 2002 and 2005
and remained at the same level in 2006 (55).
The increasing trend observed in cannabis treatment
demands may be linked to a number of factors:
increases in cannabis use or intensive and long-term
use; improvements in data coverage; recent expansion
and diversiﬁcation of the treatment system, which was
previously focused on heroin users but is now targeting
users of other drugs; and changes in legislation and
policies, sometimes resulting in an increase of cannabis
treatment referrals by the criminal justice system
(EMCDDA, 2008a). The recent stabilisation of new
treatment demands linked to cannabis use could also be
explained by more recent trends regarding cannabis use,
changes in the treatment system or modiﬁcations of the
routes of referral to treatment.
Client proﬁles
Cannabis users entering treatment in outpatient settings
are predominantly young males, with a gender ratio of
5.2 males for every female and a mean age of 24 years.
Cannabis is the most frequently reported primary drug
among the younger age groups. Among those entering
treatment for the ﬁrst time, primary use of cannabis is
reported by 67% of those aged 15–19 years and 80% of
those younger than 15 years (56).
(50) See Figure TDI-2 (part ii) in the 2008 statistical bulletin.
(51) See Table TDI-5 (part ii) in the 2008 statistical bulletin.
(52) See Table TDI-4 (part ii) in the 2008 statistical bulletin.
(53) See Table TDI-24 in the 2008 statistical bulletin.
(54) See Tables TDI-22 and TDI-23 (part i) and (part iv) in the 2008 statistical bulletin.
(55) See Figures TDI-1 and TDI-2 and Tables TDI-3 (part iv) and TDI-5 (part ii) in the 2008 statistical bulletin.
(56) See Tables TDI-10 and TDI-21 (part ii) in the 2008 statistical bulletin.
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Most cannabis clients appear to be relatively well socially
integrated in comparison to those seeking help for
problems with some other types of drug. Many are still
in education and living in stable accommodation, often
with their parents; however, recent research also reports
a social proﬁle of cannabis patients differing from the
general population of the same age group and reporting
a more disadvantaged background (EMCDDA, 2008a).
Overall, primary cannabis users entering treatment can
be divided into three groups, in terms of frequency of
use: those who use it occasionally (30%), those using it
once to several times a week (30%) and those using it
daily (40%) (57). However, considerable differences are
observed between countries, particularly in the proportion
of regular cannabis users entering treatment. In those
countries where cannabis clients are more numerous, the
proportion of daily users varies from over 70% in the
Netherlands and Denmark, to 40–60% in Spain, France
and Italy, and 20–30% in Germany and Hungary.
Treatment provision
A survey commissioned by the EMCDDA on the provision of
cannabis treatment in a sample of drug treatment services
in 19 Member States found that half of the surveyed
services did not have programmes speciﬁcally dedicated
to cannabis problems (EMCDDA, 2008a). This ﬁnding
suggests that many cannabis users are treated within
the same settings as the users of other drugs, which may
present difﬁculties, both to treatment staff and to clients.
Of the specialist services surveyed, most offered short
courses of treatment for cannabis use of usually less
than 20 sessions. Treatment generally took the form
of individual counselling and therapy or counselling
about the possible implications of cannabis use. Some
agencies reported cannabis detoxiﬁcation, family therapy,
therapeutic community and mutual help groups as possible
components of treatment. Use of residential care for
cannabis treatment when provided was generally in the
context of socio-behavioural problems respite.
The scientiﬁc literature in this area suggests that a number
of psychotherapies have been shown to be effective
for cannabis treatment, including motivational therapy
and cognitive-behavioural therapy, but no form of
psychotherapy has been found to be more effective than
any other (Nordstrom and Levin, 2007). Although most
studies on the efﬁcacy of cannabis treatment have been
carried out in the United States and Australia, European
studies are now beginning to be launched or reported. A
German randomised controlled trial examining a treatment
programme for adolescents with cannabis disorder
‘Candis’ started in 2004. The programme is based on
motivational enhancement, cognitive behavioural therapy
and psychosocial problem solving. Initial results show that
half of the patients had stopped using cannabis by the end
of the treatment. Another 30% reduced their cannabis use.
Furthermore, a noticeable decrease in associated mental and
social problems was reported. A follow-up study is planned.
Initiatives to provide treatment for young cannabis users
have been reported by several countries. In France, about
250 cannabis consultation centres, providing counselling
and support to users and their families, have been set up
throughout the country since 2005. In Denmark, special
funds have recently been allocated for the development
of targeted programmes for young cannabis users. In
addition, Belgium, Germany, France, the Netherlands and
Switzerland are collaborating in an international study
of the effectiveness of a comprehensive family-based
treatment for problematic cannabis use (Incant) (58).
In Germany, there are attempts to transfer the Internet-
based cannabis cessation programme ‘Quit the shit’ (59),
which provides interactive counselling in collaboration
with outpatient treatment facilities, to municipal structures
of youth welfare and drug care or facilities of drug
dependence prevention.
The use of information and communications technology in
drug demand reduction interventions continues to grow
in Europe. In 2006/07, the availability of counselling
and advice on drug use was mentioned by nine Member
States, with eight reporting the use of the Internet (Czech
Republic, Germany, Estonia, Netherlands, Portugal,
Austria, Slovakia, United Kingdom), while Denmark
reported the use of SMS. These Internet-based services are
targeted at young people and focus on problems related
to alcohol and cannabis.
Cannabis users in contact with the criminal justice system
Cannabis is the illicit drug most often mentioned in police
reports for drug law offences (60) in Europe, and offences
related to this drug in the European Union have increased
by an average of 34% between 2001 and 2006 (Figure 2).
The available data show that the majority of reported
cannabis offences are related to use and possession for
use rather than to trafﬁcking and supply; with use-related
offences in the majority of reporting countries accounting for
62–95% of all reported cannabis offences.
(57) See Table TDI-18 in the 2008 statistical bulletin.
(58) http://www.incant.eu
(59) http://www.drugcom.de
(60) See Table DLO-6 in the 2008 statistical bulletin.
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With many drug law offenders being young cannabis
users, who might otherwise not come into contact with
drug services, there have been reports of increasing
cooperation between judicial authorities and prevention
and counselling services in schools and youth welfare
facilities. Germany, Spain (Catalonia), Luxembourg and
Austria have implemented protocols and programmes
for young people breaking drug laws or who have
been convicted for the use or possession of drugs,
mostly cannabis. The offender may be given the choice
of completing a course, instead of paying a ﬁne. The
programmes offered in the various countries aim to prevent
further development of drug use and re-offending, and
may include family, school or psychological counselling.
A follow-up evaluation of the German FReD programmes
for young offenders (100 respondents) found that 44%
of the ex-participants reduced their use of alcohol and
tobacco, 79% reduced or stopped the consumption of
illicit drugs and 69% reported no re-offending since
concluding the course. An evaluation of the similar youth
offending teams (YOT) in the United Kingdom found that
this approach had considerable potential beneﬁts (Matrix
Research, 2007).
Smoking bans and cannabis
The possible links between tobacco policies and cannabis
smoking is an issue meriting attention. Smoking bans are
becoming more widespread in Europe, and nine Member
States now have full smoking bans (public and workplaces
including restaurants and bars) in place, and Belgium,
Denmark, Germany, the Netherlands and Portugal have
recently introduced at least partial smoking bans.
The link between tobacco use and later illicit drug use tends
to fall away when adjusting for underlying risk factors, as has
been shown by a review of prospective studies (Mathers et al.,
2006). However, in Europe, cannabis use is more prevalent
among tobacco smokers than among non-smokers and strong
regulatory tobacco policies could favourably inﬂuence
perceived norms, which are predictors for both tobacco and
cannabis use.
There is also some evidence that cannabis is an economic
complement (i.e. responding in the same direction to price
and availability) to cigarettes (Cameron and Williams, 2001).
Isolated studies found that higher cigarette taxes appear
to decrease the intensity of marijuana use and may have a
modest negative effect on the probability of use among males
(Farrelly et al., 2001).
Finally, it is worth noting that the Dutch ban on smoking
tobacco in restaurants and bars applies also to coffee shops,
and that the city of Amsterdam has decided to ban cannabis
smoking in public.
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Introduction
Globally, after cannabis, amphetamines (a generic term
that includes both amphetamine and methamphetamine)
and ecstasy are among the most commonly consumed
illicit drugs. In Europe today, in terms of the absolute
numbers, cocaine use may be higher, but the geographic
concentration of cocaine in a few countries means that for
most of the European Union, some form of synthetically
produced drug remains the second most commonly used
illicit substance. Moreover, in parts of Europe, use of
amphetamines constitutes an important part of the drug
problem, accounting for a substantial proportion of those
in need of treatment.
Amphetamine and methamphetamine are central
nervous system stimulants. Of the two drugs,
amphetamine is by far the more commonly available
in Europe, whereas signiﬁcant methamphetamine use
appears to be restricted to the Czech Republic and
Slovakia.
Ecstasy refers to synthetic substances that are chemically
related to amphetamines, but which differ to some extent
in their effects. The best-known member of the ecstasy
group of drugs is 3,4-methylenedioxy-methamphetamine
(MDMA), but other analogues are also sometimes
found in ecstasy tablets (MDA, MDEA). Ecstasy use was
virtually unknown in Europe before the late 1980s, but
increased dramatically during the 1990s. Its popularity
has historically been linked with the dance-music scene
and, in general, synthetic drug use at high prevalence is
associated with particular cultural sub-groups or social
settings.
Consumption estimates of lysergic acid diethylamide (LSD),
by far the most widely known hallucinogenic drug, have
been low and somewhat stable for a considerable time in
Europe. However, there appears to be a growing interest
among young people in naturally occurring hallucinogenic
substances.
Supply and availability
Amphetamine
Global amphetamine production, estimated at 126
tonnes in 2006, remains concentrated in Europe, which
accounted for 79% of all amphetamine laboratories
reported in 2006 (UNODC, 2008), though it is spreading
to other parts of the world, notably North America
and south-east Asia (61). Globally, over 19 tonnes of
amphetamines was seized in 2006, most of which was
intercepted in the Near and Middle East (67%), linked to
‘Captagon’ tablets (62) produced in south-eastern Europe,
followed by amphetamine seizures made in western and
central Europe (27%), reﬂecting Europe’s role as both a
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(61) For information on the sources of data for drug supply and availability, see p.36.
(62) Captagon is one of the registered trade names for fenetylline, a synthetic central nervous system stimulant, although tablets sold with this logo on the
illicit market are commonly found to contain amphetamine mixed with caffeine.
Amphetamine and methamphetamine:
differences and similarities
On the illicit drugs market, the main representatives
of the amphetamines group are amphetamine and
methamphetamine (and their salts) — two closely related
synthetic substances, members of the phenethylamine
family. Both substances are central nervous system
stimulants, sharing the same mechanism of action, and
having similar behavioural effects, tolerance, withdrawal
and prolonged (chronic) use effects. Amphetamine is
less potent than methamphetamine, but in uncontrolled
situations the effects are almost indistinguishable.
Amphetamine and methamphetamine products mostly
consist of powders, but ‘ice’, the pure crystalline
hydrochloride salt of methamphetamine is also
used. Tablets containing either amphetamine or
methamphetamine may carry logos similar to those seen on
MDMA and other ecstasy tablets.
Given the physical forms in which they are available,
amphetamine and methamphetamine may be ingested,
snorted, inhaled and, less commonly, injected. Unlike
the sulphate salt of amphetamine, methamphetamine
hydrochloride, particularly the crystalline form (‘ice’), is
sufﬁciently volatile to be smoked.
Source: EMCDDA drug proﬁles (http://www.emcdda.europa.eu/
publications/drug-proﬁles/methamphetamine).
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major producer and consumer of this drug (CND, 2008;
UNODC, 2008).
Most amphetamine seized in Europe is produced, in order
of importance, in the Netherlands, Poland and Belgium,
and to a lesser extent in Estonia and Lithuania. In 2006,
40 sites involved in the production, packaging or storage
of amphetamines were discovered in the European Union
(Europol, 2007a); and the UNODC (2008) reports that
123 laboratories were dismantled in European countries.
Turkey reported seizures of about 20 million
amphetamine tablets with the logo ‘Captagon’.
Production of amphetamine in this form is reported in
both Bulgaria and Turkey, and is thought to be largely
intended for exportation to consumer countries in the
Near and Middle East.
In Europe, an estimated 38 000 seizures amounting to
6.2 tonnes of amphetamine powder were made in 2006.
While the provisional ﬁgures for 2006 suggest a decline
from the higher levels reported in 2004 and 2005, both
seizures and the amount of amphetamines intercepted
have increased over the ﬁve-year period 2001–06 (63).
However, this conclusion is provisional as the most recent
data from the United Kingdom, the country in Europe
which typically reports the most seizures, are not yet
available. Seizures of amphetamine tablets, as opposed
to powder, are increasingly being reported by a few
countries, with a total of 390 000 tablets seized in the
European Union (mostly in Spain) in 2006.
The purity of amphetamine samples intercepted in
Europe in 2006 varied considerably and to such an
extent that any comment on typical values must be made
with caution. Nevertheless, countries reporting data for
2006 can be divided into two groups, with 10 countries
reporting values of between 2% and 10% and the others
reporting higher purity levels (25–47%). This latter group
typically included those countries known for having
greater involvement with the production, trafﬁcking or
consumption of amphetamine (Netherlands, Poland, Baltic
and Nordic countries). Over the past ﬁve years, the purity
of amphetamine has been stable or falling in most of those
19 countries where sufﬁcient data are available to allow
an analysis.
In 2006, the typical retail price of amphetamine varied
between EUR 10 and EUR 15 a gram in half of the
reporting countries. Over the period 2001–06, with the
exception of the Czech Republic, Spain and Romania,
the retail price of amphetamine was reported to have
fallen in all 16 countries reporting sufﬁcient data for
analysis.
Methamphetamine
Production of methamphetamine is concentrated in North
America and east and south-east Asia. In 2006, global
production of methamphetamine was estimated at 266 tonnes,
exceeding that of any of other illicit synthetic drug. About
15.8 tonnes of methamphetamine was recovered worldwide in
2006, most of which was seized in east and south-east Asia,
followed by North America, and less than 1% of seizures
originating from Europe (UNODC, 2007a, 2008).
(63) The data on European drug seizures mentioned in this chapter can be found in Tables SZR-11 to SZR-18 in the 2008 statistical bulletin. Note that
where data for 2006 are absent, the corresponding data for 2005 are used to estimate European totals.
International action against the manufacture
and diversion of synthetic drug precursors
Law enforcement efforts increasingly target the precursor
chemicals necessary for illicit drug production as an
additional counter-measure, and this area is one in
which international cooperation is particularly valuable.
Project Prism is an international initiative set up to prevent
the diversion of precursor chemicals used in the illicit
manufacture of synthetic drugs, through a system of pre-
export notiﬁcations for licit trade and the reporting of
shipments stopped and seizures made when suspicious
transactions occur. Information on activities in this area
are reported to the International Narcotics Control Board
(INCB, 2008b).
Globally, reports suggest that over 11 tonnes of
ephedrine and pseudo-ephedrine, key precursors of
methamphetamine, were seized in 2006. China accounted
for around half of this total followed by Canada and
Myanmar. EU Member States (mainly Belgium and
Hungary) together with the Russian Federation and Ukraine
accounted for only 0.3 tonnes, although Europol (2008)
reports a recent increase in the exportation, transhipment
and diversion of these chemicals in the European Union.
Global seizures of 1-phenyl-2-propanone (P-2-P), which can
be used for the illicit manufacture of both amphetamine
and methamphetamine, declined in 2006. An exception
to this trend was the EU Member States (mainly Denmark,
Netherlands, Poland) along with Turkey and the Russian
Federation, which together accounted for most of the
global seizures of 2 600 litres of P-2-P. This precursor is
predominantly used for amphetamine production in Europe
with manufacturers typically sourcing P-2-P from Asian
countries (China), although since 2004 it has also reported
to have been sourced and trafﬁcked from the Russian
Federation (Europol, 2007a).
Global seizures of 3,4-methylenedioxyphenyl-2-propanone
(3,4-MDP-2-P), used to manufacture MDMA, decreased in
2006 to 7 500 litres, of which Canada accounted for all
except 105 litres seized by the Netherlands. Seizures of
safrole, which may replace 3,4-MDP-2-P in the synthesis of
MDMA, remained marginal in 2006, with 62 litres seized
worldwide, mostly in Australia; in Europe, only France
reported a seizure of safrole (7 litres).
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Illicit production of methamphetamine does occur in
Europe, though it is largely limited to the Czech Republic,
where over 400 small-scale ‘kitchen laboratories’ were
detected in 2006. The drug is also reported to be
produced in Slovakia and, to a lesser extent, Lithuania
(INCB, 2008a).
About 3 000 seizures of methamphetamine amounting
to 154 kg of the drug were reported in 17 European
countries in 2006. Norway accounts for most seizures
and amounts recovered, followed by Sweden, the Czech
Republic and Slovakia. In the latter two countries,
seizures tended to be small, usually of a few grams or
less. Between 2001 and 2006, both the number and the
quantity of methamphetamine seized in Europe have been
increasing; though still remaining low in comparison to
other drugs. In 2006, the limited data available suggest
that the typical purity of methamphetamine fell somewhere
between 20% and 55%.
Ecstasy
Global ecstasy production is reported by the UNODC
(2007a) to have fallen to around 102 tonnes in 2006.
Production appears to have become more geographically
diffuse, with manufacture for local consumption now
more common in North America and east and south-east
Asia. Despite this, Europe remains the main location for
ecstasy production, with manufacture concentrated in
the Netherlands (where, after a few years of decline,
production may have increased again in 2006), Belgium
and, to a lesser extent, Poland and the United Kingdom.
The relative importance of Europe as both a consumer and
producer of ecstasy can be seen from the data on drug
seizures. Europe reported over 20 000 seizures resulting
in the interception of nearly 14 million ecstasy tablets
in 2006. The Netherlands accounted for the largest
quantity of ecstasy seized (4.1 million tablets), followed
by the United Kingdom, Turkey, France and Germany.
Overall, the number of ecstasy seizures has decreased
over the period 2001–06, and the quantity seized has
also declined, after a peak year in 2002 (64). Of the 4.5
tonnes of ecstasy seized worldwide in 2006, western
and central Europe accounted for 43%; as a point of
comparison, North America accounted for 34% (UNODC,
2008).
In Europe, most ecstasy tablets analysed in 2006 contained
MDMA or another ecstasy-like substance (MDEA, MDA)
as the only psychoactive substance present, with 17
countries reporting that this was the case in over 70% of
the total number of tablets analysed. Spain and Poland
were exceptions, reporting that the analysis of tablets
marketed as ecstasy frequently found amphetamine or
methamphetamine to be present, often in combination with
MDMA or one of its analogues. In Latvia and Malta, most
tablets analysed did not contain any controlled substance.
Most countries reported that the typical MDMA content of
ecstasy tablets was somewhere between 25 and 65 mg —
although there was considerable variation in the samples
analysed (9–90 mg). In addition, high-dose ecstasy tablets
containing over 130 mg of MDMA were reported by
some countries (Belgium, Denmark, Germany, France,
Netherlands, Norway) and high-quality MDMA powder
has now become available in some markets. No clear
medium-term trend is observable in the MDMA content
of ecstasy tablets. It is clear, however, that in comparison
to when the drug ﬁrst became widely available in Europe
in the early 1990s, ecstasy has become considerably
cheaper. Although there are some reports of tablets being
sold for as little as EUR 1, most countries now report
typical retail prices in the range of EUR 3–9 per tablet,
and the data available for 2001–06 suggest that the retail
price (adjusted for inﬂation) has continued to fall.
LSD
LSD use and trafﬁcking is still considered marginal,
although seizures in Europe are possibly suggestive of a
revival in interest in the drug in the last few years. After
a long-term downward trend dating back to the 1990s,
both the number and the quantity of seizures have been
increasing since 2003. The current situation is unclear,
as although the data provisionally available indicates a
slight decline in both measures, the United Kingdom, the
country that usually reports the greatest quantities of LSD
seized, has not yet reported. LSD retail prices (adjusted
for inﬂation) have been slightly declining since 2001, and
ranged in 2006 between EUR 5 and EUR 11 per unit in
most European countries.
Prevalence and patterns of use
Among EU Member States, use of amphetamines or
ecstasy is relatively high in: the Czech Republic, Estonia
and the United Kingdom; and relatively high, in respect
to the overall national drug situation, in some central
and northern European countries. In contrast, overall,
consumption levels of synthetic hallucinogenic drugs such
as lysergic acid diethylamide (LSD) are lower and have
been largely stable for a considerable period.
Higher prevalence levels in some countries need to be
understood in the context of, in simple terms at least,
two distinct consumption patterns. In a limited number of
(64) This picture is preliminary as data for the United Kingdom, the country reporting the most seizures in 2005, are not yet available for 2006.
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Stimulant markets in Europe: the relative prevalence of cocaine or amphetamines in seizures and population surveys, and the
proportion of drug users in treatment reporting these substances as primary drugs
A synthesis of information from a variety of sources suggests
that different stimulant drugs may play a similar role in different
countries and, therefore, it may be wise when developing
policy in this area to consider not only the individual
substances but also the stimulant market as a whole. In some
countries, cocaine appears to be the dominant stimulant drug,
while in others, amphetamine or methamphetamine appear
more commonly used. The picture that emerges from combining
data from general population surveys and reports of seizures
suggests that northern and central European countries generally
tend to belong to an ‘amphetamines group’, while in the
countries in the west and south of Europe, cocaine use largely
predominates.
The relative importance of stimulants in the overall drug
problem also varies greatly between countries. This can
be seen in treatment data where, for a restricted group of
The European stimulant market: ‘cocaine countries’ and ‘amphetamines countries’?
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countries, the use, often by injection, of amphetamine or
methamphetamine accounts for a substantial proportion
of the overall number of problem drug users and those
seeking help for drug problems. In contrast to these
chronic populations, a more general association exists
between synthetic drugs, ecstasy in particular, and
nightclubs, dance music and some sub-cultures; this results
in signiﬁcantly higher levels of use being reported among
young people, compared with the general population,
and exceedingly high levels of use being found in some
settings or speciﬁc sub-populations.
Amphetamines
Recent population surveys indicate that lifetime prevalence
of the use of amphetamines (65) in Europe varies between
countries, from 0.1% to 11.9% of all adults (15–64 years).
On average, 3.3% of all European adults report having
used amphetamines at least once. Use of the drug in the
last year is much lower, with a European average of 0.6%
(range 0.0–1.3%). The estimates suggest that around
11 million Europeans have tried amphetamines, and about
2 million have used the drug in the last year (see Table 3
for a summary of the data).
Among young adults (15–34 years), lifetime prevalence of
amphetamine use varies considerably between countries,
from 0.2% to 16.5%, with a European average of about
5%. Last year use of amphetamines in this age group
ranges from 0.1% to 2.9%, with the majority of countries
reporting prevalence estimates of between 0.7% and
1.9%. It is estimated that, on average, 1.3% of young
Europeans have used amphetamines in the last year.
Problem amphetamine use
The EMCDDA indicator on problem drug use (PDU)
can be used in a restricted sense for amphetamines,
where it deﬁnes as such the injecting or long duration/
regular use of the substance. Only one Member State
(Finland) has provided a recent national estimate of
problem amphetamine use, which in 2005 was estimated
to amount to between 12000 and 22000 problem
amphetamine users (4.3 to 7.9 cases per 1000, aged
15–54 years), about four times the estimated number of
problem opioid users in the country.
The number of reported treatment demands relating
to the use of amphetamine is relatively small in most
European countries. Treatment for the use of amphetamine
accounts for a sizeable proportion of the overall reported
(65) Survey data on ‘amphetamine use’ often do not distinguish between
amphetamine and methamphetamine, though, typically this will be
related to the use of amphetamine (sulphate or dexamphetamine), as
use of methamphetamine is uncommon in Europe, with less than 1%
of world methamphetamine seizures reported from this continent.
countries, stimulant drugs are responsible for a relatively
high proportion of all demands for drug treatment
(methamphetamine in the Czech Republic and Slovakia;
amphetamine in Latvia, Sweden and Finland; and cocaine
in Spain, Italy and the Netherlands); while elsewhere,
the proportion of treatment clients reporting any of these
substances as their main reason for seeking help is very low,
and sometimes even negligible.
Data from treatment clients also suggests that those being
treated for problems caused by stimulant drugs tend to be
experiencing problems with only one class of stimulants.
For example, among those receiving treatment for cocaine in
outpatient settings (all demands), only around 8% reported
amphetamines as their secondary drug; while among
amphetamine clients, less than 9% reported cocaine as
a secondary problem drug. Moreover, reports from some
countries suggest that one stimulant can sometimes displace
another on the drugs market. For example, data exists to
suggest that: cocaine may be replacing amphetamines and
ecstasy among some drug-using populations; and, in the
Netherlands, amphetamines may be used as a cheaper
substitute for cocaine outside of urban areas.
While stimulant drugs may differ in their effects and
consequences, in respect to drug treatment the options, rates
of retention and outcomes are broadly similar (Rawson et
al., 2000; Copeland and Sorensen, 2001).
To some extent, similarities can also be seen in patterns
by which these drugs are used and in the overall typology
of users. For example, recreational and less intensive
and damaging patterns of use among socially well-
integrated users can coexist with intensive use among
more marginalised groups, with greater association
with dependence problems and more risky modes of
administration, such as injection and smoking.
NB: The background colour indicates the relative dominance of
cocaine or amphetamines according to general population
surveys (prevalence of use in the last year among the
population aged 15–34) and data on seizures; pie charts
represent the proportions of all drug treatment requests
accounted for by these two drugs — only segments
representing cocaine and amphetamines are displayed. For
Italy, the Netherlands and Poland, where data on seizures
were unavailable, only data from population surveys
were used. For Croatia, only seizures data were used. For
Norway and Belgium treatment data were unavailable. The
data available for Romania did not permit inferences to be
made for the country as a whole. In the Czech Republic
and Slovakia, methamphetamine is the amphetamine most
commonly used.
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treatment demand in Latvia, Sweden and Finland, where
between 25% and 35% of drug clients entering treatment
reported amphetamine as their primary drug problem.
Other than in these countries, treatment for amphetamine
accounts for more than 5% of reported drug treatment
only in Denmark, Germany, the Netherlands and Poland,
where between 6% and 9% of users in treatment report
amphetamine as their primary drug (66).
In most countries, though not in Sweden and Finland, the
proportion of new clients entering treatment for primary
amphetamine use is greater than the proportion of all
clients receiving treatment for this drug. From 2002 to
2006, the proportion of new clients entering treatment for
primary amphetamine use has been relatively stable in
Europe as a whole, though over this period an increase has
been reported by Latvia and Denmark, while in Sweden
and Finland the percentage of new amphetamine clients
declined, possibly suggesting an ageing population (67).
Amphetamine users entering treatment are, on average,
around 29 years old and male. Although the male to
female ratio is around 2:1, the overall proportion of
females among amphetamine clients is higher than that
found for other drugs (68).
Problem methamphetamine use
In contrast to other parts of the world, where the use
of methamphetamine has increased in recent years,
levels of its use in Europe appear limited (Grifﬁths et al.,
2008). Historically, use of this drug in Europe has been
concentrated in the Czech Republic and, to some extent,
(66) See Table TDI-5 (part ii) in the 2008 statistical bulletin.
(67) See Figure TDI-1 and Tables TDI-4 (part ii), TDI-5 (part ii) and TDI-36 in the 2008 statistical bulletin.
(68) See Table TDI-37 in the 2008 statistical bulletin.
Table 3: Prevalence of amphetamines use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year
15–64 years
Estimated number of users in Europe 11 million 2 million
European average 3.3% 0.6%
Range 0.1–11.9% 0.0–1.3%
Lowest -prevalence countries Greece (0.1%)
Romania (0.2%)
Malta (0.4%)
Cyprus (0.8%)
Greece, Malta (0.0%)
France (0.1%)
Portugal (0.2%)
Highest -prevalence countries United Kingdom (11.9%)
Denmark (6.9%)
Norway (3.6%)
Ireland (3.5%)
United Kingdom, Estonia (1.3%)
Norway, Latvia (1.1%)
15–34 years
Estimated number of users in Europe 7 million 2 million
European average 5.1% 1.3%
Range 0.2–16.5% 0.1–2.9%
Lowest -prevalence countries Greece (0.2%)
Romania (0.5%)
Malta (0.7%)
Cyprus (0.8%)
Greece (0.1%)
France (0.2%)
Cyprus (0.3%)
Portugal (0.4%)
Highest -prevalence countries United Kingdom (16.5%)
Denmark (12.7%)
Norway (5.9%)
Spain, Latvia (5.3%)
Estonia (2.9%)
United Kingdom (2.7%)
Latvia (2.4%)
Denmark (2.2%)
Information based on the last survey available for each country. The study year ranges from 2001 to 2007. The average prevalence for Europe was computed
by a weighted average according to the population of the relevant age group in each country. In countries for which no information was available, the
average EU prevalence was imputed. Populations used as basis: 15–64 (328 million), 15–34 (134 million) and 15–24 (64 million). The data summarised here
are available under ‘General population surveys’ in the 2008 statistical bulletin.
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Slovakia. Only these two countries report recent estimates
of problem use. In 2006, in the Czech Republic there
were estimated to be approximately 17 500–22 500
methamphetamine users (2.4 to 3.1 cases per 1 000
aged 15–64 years), almost twice the estimated number
of problem opioid users; and in Slovakia, approximately
6 200–15 500 methamphetamine users (1.6 to 4.0 cases
per 1 000 aged 15–64 years), around 20% fewer than
the estimated number of problem opioid users.
In the last ﬁve years, the reported demand for treatment
related to methamphetamine use has been increasing
in both countries. Methamphetamine has become the
primary drug most often reported by those requesting
treatment for the ﬁrst time in Slovakia, where it accounts
for 25% of all drug treatment requests. In the Czech
Republic, 59% of all drug treatment clients report
methamphetamine as their primary drug (69). Clients
in treatment for methamphetamine report high rates of
injecting drug use: around 50% in Slovakia and 80% in
the Czech Republic.
Ecstasy
It is estimated that about 9.5 million European adults have
tried ecstasy (3% on average) and that about 3 million
(0.8%) have used it in the last year (see Table 4 for
a summary of the data). Considerable variation exists
between countries, with recent surveys suggesting that
between 0.3% and 7.3% of all adults (15–64 years) have
ever tried the drug, and with most countries reporting
lifetime prevalence estimates in the range 1.3–3.1%.
Use of the drug in the last year varied across Europe, from
0.2% to 3.5%. On all measures, and as with most other
illicit drugs, reported use was far higher among males
than among females.
Ecstasy consumption was more common among young
adults (15–34 years), where lifetime prevalence estimates
ranged at national level from 0.5% to 14.6%, with
between 0.4% and 7.7% of this age group reporting
using the drug in the last year. It is estimated that 7.5
million young Europeans (5.6%) have ever tried ecstasy,
with around 2.5 million (1.8%) reporting use in the last
year. Estimates of prevalence are higher still if attention is
restricted to a younger age band: among the 15–24 age
group, lifetime prevalence ranges from 0.4% to 18.7%,
though most countries reported estimates in the 2.5–8%
range (70). Although most countries reported estimates of
1.3–4.6% for use in the last year by this age group, there
was a considerable difference between the lowest national
estimate at 0.3% and the highest at 12%, reﬂecting the
different experiences of some Member States.
Among school students, large increases in prevalence
levels may occur with small increases in age, for example
data available from 16 countries show that, compared
to younger students, lifetime prevalence of ecstasy use
among 17- to 18-year-old school students is generally
considerably higher, suggesting that ﬁrst use of the drug
commonly takes place after the age of 16 (71).
Despite the number of ecstasy users in Europe being
similar to that of amphetamine, very few are seen by
treatment services. In 2006, in most countries, less than
1% of drug users entering treatment mentioned ecstasy
as their primary problem drug and in most countries only
a trivial number of clients are being treated for ecstasy-
related problems. Only ﬁve countries report having more
than 100 ecstasy clients entering treatment (France,
Italy, Hungary, United Kingdom, Turkey), representing
between 0.5% and 4% of all drug clients in these
countries. With an average age of 24–25 years, users
of ecstasy are among the youngest groups entering drug
treatment and regularly report the concomitant use of
other substances, including cannabis, cocaine, alcohol
and amphetamines (72).
LSD
Lifetime prevalence of LSD use among the adult population
(15–64 years) ranges from almost zero to 5.4%. Among
young adults (15–34 years), lifetime prevalence estimates
are a little higher (0.3% to 7.1%), although lower prevalence
levels are reported among the 15- to 24-year-olds. In contrast,
in the few countries providing comparable data, the use of
LSD is often exceeded by that of hallucinogenic mushrooms,
where lifetime prevalence estimates for young adults range
from 1% to 9%, and last year prevalence estimates between
0.3% and 3% (EMCDDA, 2006).
Trends in the use of amphetamines and ecstasy
Reports of stabilising or even decreasing trends in
amphetamine and ecstasy consumption in Europe are
supported by the most recent data. After general increases
in the 1990s, population surveys now point to an overall
stabilisation, or even moderate decrease, in the popularity of
both drugs, although this pattern is not seen in all countries.
Amphetamine use (last 12 months) among young adults (15–
34) in the United Kingdom declined substantially between
1996 (6.5%) and 2002 (3.1%), with the ﬁgures remaining
(69) See Table TDI-5 (part ii) in the 2008 statistical bulletin.
(70) See Table GPS-17 in the 2008 statistical bulletin.
(71) See Tables EYE-1 and EYE-2 in the 2008 statistical bulletin.
(72) See Tables TDI-5 and TDI-37 (part i), (part ii) and (part iii) in the 2008 statistical bulletin.
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stable thereafter. A marked increase in amphetamine use
is reported in Denmark between 1994 and 2000, but the
results of the 2005 survey indicate a decrease in the use
of this substance since the beginning of this decade (73).
Among the other countries reporting repeated surveys over
a similar time span (Germany, Greece, Spain, France,
Netherlands, Slovakia, Finland), the trends are largely
stable (74). During the ﬁve-year period 2001–06, of the 14
countries with sufﬁcient data on last year prevalence of
amphetamine use among the 15–34 age group, three report
a decrease of 15% or more, four report stabilisation and
seven report an increase of 15% or more.
For ecstasy use among young adults (15–34), the picture
is more mixed, with levels of use still high among young
males (75) and in studies of some speciﬁc recreational
settings. After general increases in use in some European
countries in the late 1980s and early 1990s, leading to
similar levels of ecstasy use in Germany, Spain and the
United Kingdom in the mid-1990s, last year prevalence
of use has remained consistently higher in the United
Kingdom compared to the other countries (76). Over
the ﬁve-year period, 2001–06, last year prevalence of
ecstasy use among young adults decreased in three of
the 14 countries providing sufﬁcient information, while it
remained stable in ﬁve countries and increased in six.
Data from a few countries suggest that cocaine could
be replacing amphetamines and ecstasy among some
sectors of the drug-using population. This may be the
(73) In Denmark in 1994 the information refers to ‘hard drugs’, which was considered mainly amphetamines.
(74) See Figure GPS-8 in the 2008 statistical bulletin.
(75) See Figure GPS-9 (part ii) in the 2008 statistical bulletin.
(76) See Figure GPS-21 in the 2008 statistical bulletin.
Table 4: Prevalence of ecstasy use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year
15–64 years
Estimated number of users
in Europe
9.5 million 2.6 million
European average 2.8% 0.8%
Range 0.3–7.3% 0.2–3.5%
Lowest -prevalence countries Romania (0.3%)
Greece (0.4%)
Malta (0.7%)
Lithuania (1.0%)
Greece, Malta (0.2%)
Denmark, Poland (0.3%)
Highest -prevalence countries United Kingdom (7.3%)
Czech Republic (7.1%)
Ireland (5.4%)
Spain (4.4%)
Czech Republic (3.5%)
United Kingdom (1.8%)
Estonia (1.7%)
Slovakia (1.6%)
15–34 years
Estimated number of users
in Europe
7.5 million 2.5 million
European average 5.6% 1.8%
Range 0.5–14.6% 0.4–7.7%
Lowest -prevalence countries Romania (0.5%)
Greece (0.6%)
Malta (1.4%)
Lithuania, Poland (2.1%)
Greece (0.4%)
Italy, Poland (0.7%)
Denmark, Lithuania, Portugal (0.9%)
Highest -prevalence countries Czech Republic (14.6%)
United Kingdom (13.0%)
Ireland (9.0%)
Slovakia (8.4%)
Czech Republic (7.7%)
United Kingdom (3.9%)
Estonia (3.7%)
Netherlands, Slovakia (2.7%)
Information based on the last survey available for each country. The study year ranges from 2001 to 2007. The average prevalence for Europe was computed
by a weighted average according to the population of the relevant age group in each country. In countries for which no information was available, the
average EU prevalence was imputed. Populations used as basis: 15–64 (328 million), 15–34 (134 million) and 15–24 (64 million). The data summarised here
are available under ‘General population surveys’ in the 2008 statistical bulletin.
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case in the United Kingdom and Denmark, and to
some extent in Spain. Both the United Kingdom and
Denmark report relatively high lifetime prevalence
estimates for the use of amphetamines at 11.9% and
6.9% respectively, but levels of reported use in the last
year and last month are more in line with those found
in other countries. Increases in cocaine consumption
in these countries have been matched to some extent
by a decrease in the use of amphetamines, raising the
possibility that one stimulant drug is replacing another
in these markets (77). Possible changes in the patterns
of drug use in other countries (Germany, France, Italy,
Netherlands) are less clear. Overall, the interplay
between different drugs that may have similar appeal to
users remains poorly understood.
An analysis of data from those national school surveys
newly available in 2007 (Czech Republic, Spain,
Portugal, Slovakia, Sweden, United Kingdom) supports
the suggestion of an overall stabilisation in the situation
with no change or even some decrease noted in reported
lifetime use of both amphetamine and ecstasy.
Recreational settings
Use of amphetamines and ecstasy in recreational settings
Studies of drug use in selected recreational settings where
young people congregate and which are known to be
sometimes associated with drug use, such as dance events
or music festivals, can provide a useful window on the
behaviour of those using amphetamines and ecstasy on a
regular and intensive basis. Estimates of drug use in these
settings are typically high, but are not generalisable to the
wider population.
A study of young people aged 15–30, who regularly
go out in nightlife settings, carried out in 2006 in nine
European cities (Athens, Berlin, Brno, Lisbon, Liverpool,
Ljubljana, Palma, Venice, Vienna) reported lifetime
prevalence estimates of 27% for ecstasy use and 17%
for amphetamine. Frequent use of these drugs was much
lower, with only 1.4% of the respondents reporting that
they used ecstasy once a week or more often and less
than 1% that this was the case for amphetamine. The
mean age at ﬁrst use for both drugs among the study
group was 18 years (78). Concomitant alcohol use was
common, with 34% of those interviewed reporting having
been ‘drunk’ more than twice during the four weeks before
interview. This level of drunkenness was more commonly
reported by males than females: 42% and 27%,
respectively (European Commission, 2007b).
A French survey carried out in 2004 and 2005 at ﬁve
electronic music venues reported last month prevalence
of 32% for ecstasy and 13% for amphetamine among
a sample of 1496 respondents. However, it should be
noted that prevalence was higher among speciﬁc sub-
populations that were characterised by their counter-
cultural elements and labelled as ‘alternative’. Among
these sub-populations, prevalence estimates for ecstasy
and amphetamine were 54% and 29% respectively.
Interventions in recreational settings
An increasingly common trend reported in Europe is for
authorities to address aspects of licit and illicit drugs
collectively when considering local public order or
health issues. This approach is particularly relevant to
interventions targeting settings where both synthetic and
stimulant drugs and alcohol are consumed, such as night
bars and clubs. One of the problems in this area is that
the relative roles of illicit and licit substances may be
difﬁcult to distinguish. The use of alcohol among young
people is a growing area of concern in Europe, and in
2006 the European Commission adopted an EU alcohol
strategy to support Member States in reducing alcohol-
related harm among young people. Indeed, harmful use of
alcohol is associated with one in every four deaths among
young men (aged 15–29) and one in 10 among young
women (79).
Concerns about the combined use of drugs and alcohol
by young people in public settings have led to the
development of strategies that aim to alter the social,
economic and physical environments associated with
alcohol and drug consumption, with the goals of:
modifying consumption behaviours and norms; creating
conditions less favourable to intoxication; and reducing
opportunities for alcohol and drug-related problems to
occur (80). A number of measures are reported by Member
States to take place in, or around, nightlife settings with
the speciﬁc aim of reducing harm or positively modifying
the social environment. These include: training for bar and
security staff; increased enforcement of existing legislation;
raising awareness of substance-related harms; provision of
late-night transport services; and improvements intended
to provide a safer nightlife environment. Measures in this
area are diverse, including such things as: improvements
to street lighting; the availability of drinking water; proper
ventilation; or even measures to provide a rapid response
(77) See ‘The European stimulant market: “cocaine countries” and “amphetamine countries”?’, p. 50.
(78) See Table EYE-2 in the 2008 statistical bulletin.
(79) http://ec.europa.eu/health/ph_determinants/life_style/alcohol/documents/alcohol_factsheet_en.pdf
(80) http://www.emcdda.europa.eu/themes/prevention/environmental-strategies
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to medical emergencies. Often, a common feature of this
approach is that it is based upon a dialogue between
different stakeholders, such as the police, licensing
authorities, club owners and healthcare providers, who
are required to work together in partnership to identify
both local needs and possible solutions.
An example of work in this area can be found in Denmark
where, in cooperation with municipal authorities and
the police, restaurant owners and people working in
the nightlife environment are offered courses to promote
shared attitudes on limiting the use and sale of drugs and
alcohol. Some approaches in this area developed by
individual Member States are also beginning to attract
wider attention, as illustrated by the fact that the safe-dance
guidelines developed in the United Kingdom have now
been implemented in clubs in both Paris and Brussels. Club
owners, with the participation of outreach workers and
local authorities, help promote moderate drinking, raising
awareness of the harms of drugs and alcohol, while raising
the safety characteristics of settings (e.g. providing free
water, staff trained in ﬁrst aid, chill-out areas).
The relationship between driving and drug and alcohol
consumption has been an issue included in some
environmental strategies. Examples here include the
provision of alternative transportation for intoxicated
drivers, which is available in some Parisian nightclubs,
and the promotion of public transport options by clubs in
Brussels. In Spain, prevention campaigns that focus on
‘designated drivers’ and on raising awareness of the risks
of driving under the inﬂuence of psychoactive substances
have been conducted, particularly during weekends. These
campaigns may have contributed to the 16% decrease
observed in Spain in the number of trafﬁc accidents
involving young people aged 18–20, in 2006 (81).
Strategies that address the environment in which young
people consume both drugs and alcohol appear to have
considerable potential for safeguarding public health and
improving public safety, with beneﬁts that can extend
beyond those using drugs and into the wider community.
However, today in Europe, such approaches tend to be
limited to particular known problem areas, often in major
city centres, and are rarely comprehensively implemented,
strongly suggesting that there is considerable potential
for further investment and development in this area. More
generally, the focus of work in this area has tended to be
restricted to interventions targeting speciﬁc problematic
behaviours, or aspects of the environment, rather than
the broader task of addressing the normative beliefs and
attitudes that young people have towards the use of drugs
and alcohol in speciﬁc settings.
Treatment provision
In most Member States, limited demand is reﬂected in
the limited availability of treatment services speciﬁcally
targeting users of amphetamine, methamphetamine
or ecstasy. This situation is somewhat different in a
few Member States with long-established chronic
amphetamine- or methamphetamine-using populations.
In these countries (principally the Czech Republic,
Slovakia, Finland, Sweden), users of amphetamine or
methamphetamine are treated within specialist services.
Treatment options appear to consist of detoxiﬁcation,
followed by individual therapy in an outpatient setting or
group therapy in either outpatient or residential settings.
Therapeutic options with robust evidence of effectiveness
are generally lacking to guide the treatment of
dependence on psychostimulants, such as amphetamines
and cocaine. As noted in Chapter 5, no pharmacological
agents are currently available to help users to manage
abstinence or reduce the cravings associated with
psychostimulant dependence. Furthermore, the literature
would suggest that no particular psychosocial intervention
has shown strong evidence of effectiveness in helping
psychostimulant users to maintain abstinence.
(81) For more information on prevention campaigns across Europe, see the 2007 selected issue on drugs and driving.
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Introduction
The most recent data continues to point to an overall
increase in the use of cocaine in Europe. Population
surveys carried out in a number of countries have
recorded a marked increase in use among young people
since the mid-1990s. These ﬁndings are supported by
the results of targeted studies, which have observed very
high levels of cocaine use in some recreational settings
(nightlife and dance-music venues). In parallel, indicators
of cocaine availability in Europe, including the number
of seizures of the drug and the amount seized, have
increased dramatically.
In some EU Member States, the demand for treatment for
cocaine use has increased substantially in recent years,
and now even exceeds that for opioid treatment in some
countries, cities and regions. Moreover, a substantial
proportion of opioid users in treatment report cocaine
as their secondary drug, which may be contributing to
their problems and can complicate their care. In many
countries, cocaine is also reported in the toxicological
analysis of a high proportion of drug-related deaths,
generally in combination with opioids and other
substances.
The existence of considerable differences between
countries, with many countries still reporting very low
levels of use, is an important caveat to the observation
that, overall, cocaine use is increasing in Europe. National
experiences of cocaine problems are also very mixed;
with, for example, a relatively small number of countries
accounting for the majority of all cocaine treatment
demands reported in Europe.
Supply and availability
Production and trafﬁcking
Cultivation of coca bush, the source of cocaine, continues
to be concentrated in a few countries in the Andean
region (82). The United Nations Ofﬁce on Drugs and
Crime (2008) estimated potential cocaine production at
994 tonnes of pure cocaine hydrochloride for the year
2007, of which Colombia accounted for 61%, Peru 29%
and Bolivia 10%. Analysis of the number of laboratories
dismantled suggests that most production remains located
in these three countries, although it may also occur in
other South American countries, before exportation to the
main consumer markets in North America and Europe.
Information on illicit trafﬁcking in potassium permanganate
(a chemical reagent used in the synthesis of cocaine
hydrochloride) supports this ﬁnding, with Colombia
reporting 99 of the 101 tonnes of permanganate
potassium seized globally in 2006 (INCB, 2008b).
Cocaine produced in the Andean region is then smuggled
to Europe from South American countries (via Brazil,
Ecuador, Venezuela). While the Caribbean continues to be
an important transit zone for cocaine heading to Europe,
transhipment via countries in west Africa, in particular
in the Gulf of Guinea and off the coasts of Cape Verde,
Guinea and Guinea-Bissau, has been increasing markedly
during the past few years (CND, 2008; INCB, 2008a) (83).
Spain and Portugal remain the major entry points of
cocaine into Europe, the latter’s role having substantially
increased since 2005. Cocaine continues, however, also
to enter Europe more directly either by shipment across
the Atlantic or by air; in particular to the Netherlands,
Belgium, Italy, France, the United Kingdom and Germany.
Both the Netherlands and France are reported to be major
transit countries for further cocaine distribution in Europe
(Europol, 2007b). Recent reports of cocaine importation
via east European countries (Bulgaria, Estonia, Latvia,
Lithuania, Romania, Russia) may point to the development
of new trafﬁcking routes in this part of Europe.
Seizures
Cocaine is the most trafﬁcked drug in the world after
herbal cannabis and cannabis resin. In 2006, global
seizures of cocaine decreased slightly to 706 tonnes.
South America continued to report the largest amount
seized, accounting for 45% of the global ﬁgure, followed
by North America with 24%, and west and central Europe
with 17% (UNODC, 2008).
Chapter 5
Cocaine and crack cocaine
(82) For information on the sources of data for drug supply and availability, see p.36.
(83) See also ‘West Africa: now a regional transit hub for trafﬁcking to Europe’, p. 59.
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The number of cocaine seizures has been on the increase for
the last 20 years in Europe, and continued to rise during the
period 2001–06, with the exception of a decrease in 2003.
The quantity of cocaine seized has also been increasing
over the last decade, but with regular ﬂuctuations. In 2006,
cocaine seizures in Europe increased to 72 700 cases and
the quantity recovered to 121 tonnes (84). Spain continued to
be the country reporting the highest seizures, accounting
for 58% of all seizures and 41% of the quantity
intercepted in Europe that year. The huge increase in the
amount seized in Portugal since 2005, accounting for 28%
of the European total in 2006, points to the growing use
of the Iberian peninsula by cocaine trafﬁckers as an entry
point to the European market.
Purity and price
The typical purity of cocaine in Europe ranged between
1% and 90% in 2006, although most countries reported
values between 25% and 55% (85). Of the 23 countries
providing sufﬁcient data, most reported a declining
trend in the purity of cocaine over the period 2001–06;
increases were noted, however, in Greece and France
over the period 2003–06.
In 2006, the typical retail price of cocaine varied between
EUR 50 and EUR 75 per gram in most European countries,
although Cyprus, Romania, Sweden and Turkey reported
much higher values. Over the period 2001–06, cocaine
sold on the streets has become cheaper in the 18 countries
reporting sufﬁcient data, with the exception of Romania,
where an increase in price (adjusted for inﬂation) was noted.
Prevalence and patterns of use
Diversity is not only found in the overall levels of cocaine
use reported by Member States, it is also reﬂected in the
characteristics of cocaine users themselves, who fall across
a broad social continuum ranging from some of the most
privileged to the most marginalised members of society.
Patterns of cocaine use can be correspondingly diverse,
ranging from the occasional and recreational to the highly
compulsive and dependent. The form that cocaine is used
in (cocaine hydrochloride or crack cocaine), and the
route of administration by which it is used, are additional
complicating factors. This diversity is an important
consideration, both for understanding the range of problems
that are likely to be associated with different patterns of
cocaine use, and also for informing the targeting and
development of services for a disparate group of drug users.
Among the general population
Overall, cocaine remains the second most used illicit drug
in Europe, after cannabis, although use varies greatly
between countries. It is estimated that around 12 million
Europeans have used it at least once in their lifetime;
on average 3.6% of adults aged 15–64 years (see
Table 5 for a summary of the data). National ﬁgures vary
from 0.4% to 7.7%, with 12 countries, mostly Member
States that have joined the European Union since 2004,
(84) The data on European cocaine seizures mentioned in this chapter can be found in Tables SZR-9 and SZR-10 in the 2008 statistical bulletin. Note that
across the chapter, where national data for 2006 are absent, the corresponding data for 2005 are used to estimate European totals.
(85) See Tables PPP-3 and PPP-7 in the 2008 statistical bulletin for purity and price data.
West Africa: now a regional transit hub for
trafﬁcking to Europe
In the last ﬁve years, west Africa has emerged as an
important region in cocaine trafﬁcking to Europe (1),
acting as a site of transit, storage and repackaging (Europol,
2007b; UNODC 2007b; USDS, 2008). It is estimated that
almost a quarter of the cocaine trafﬁcked to Europe in 2007
was transited via this region (UNODC, 2008). Against a
background of increasing cocaine use in Europe, the growth
in trafﬁcking via the west African route is thought to have
contributed to the decline in the price of the drug, while
reinforcing the role of the Iberian peninsula as an entry
point for cocaine distribution in Europe (Europol, 2007b).
Cocaine is trafﬁcked from west Africa to Europe mainly by
sea, with large shipments transported by ﬁshing vessels to
unloading sites mainly on the coast of northern Portugal
and Galicia in Spain. Smaller shipments of cocaine are
trafﬁcked by air or overland, increasingly associated with
smuggling cannabis resin from north Africa.
The growth of the west African cocaine trafﬁcking route
has been attributed to several factors. These include
more effective controls on alternative trafﬁcking routes
(Europol, 2007b); the geographical position of west
Africa; and the economic vulnerabilities of countries
in this area, often resulting in weak judicial and law
enforcement systems.
The international community has launched several
initiatives to address the problem. Among other initiatives
taken by the European Union, the Council, through the
horizontal working party on drugs, has placed west Africa
at the top of the agenda and presented a resolution on the
strengthening of international support to west Africa to the
2008 UN Commission on Narcotic Drugs. Furthermore,
seven Member States, with EU support, have acted
together to establish the Maritime Analysis and Operations
Centre–Narcotics (MAOC-N), a law enforcement centre,
located in Lisbon, with military support, that aims to
suppress cocaine trafﬁcking, with special focus on the
eastern part of the Atlantic.
(1) UNODC (2007b) reports that Senegal, Ghana, Mauritania,
Guinea-Bissau, Cape Verde, Nigeria, Benin and Sierra Leone
registered the largest seizures in 2006/07.
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reporting very low levels of lifetime prevalence among all
adults (0.4–1.2%).
It is estimated that around 4 million Europeans have used
the drug in the last year (1.2% on average), although
again national variation between countries is considerable.
This can be seen in results from recent national surveys,
which report last year prevalence estimates of between
0.1% and 3%; though only in four countries do levels of
use exceed 1%. At 2 million, the prevalence estimate for
last month use is around half that for last year prevalence,
and represents about 0.5% of the adult population. These
estimates are likely to be conservative.
Overall, cocaine use appears to be concentrated in a
few countries, notably Spain and the United Kingdom,
and to a lesser extent Italy, Denmark and Ireland, while
use of the drug is relatively low in most other European
countries. In countries where amphetamines dominate the
market in illicit stimulant drugs, estimates of use of cocaine
are low in almost all cases; conversely, in most countries
where cocaine is the main illicit stimulant, low levels of
amphetamine use are reported (86).
Cocaine use among young adults
Cocaine use is mainly concentrated among young adults
(15–34 years). For instance, of the 4 million Europeans
that have used the drug in the last year, around seven out
of eight are likely to be young adults.
In Europe, it is estimated that 7.5 million young adults
(15–34 years), or an average of 5.4%, have used cocaine
at least once in their life. National ﬁgures vary from
0.7% to 12.7%. The European average for last year use
of cocaine among this age group is estimated at 2.3%
(3.5 million) and for last month use at 1% (1.5 million).
Use is particularly high among young males (15–34
years), with last year prevalence of cocaine use between
4% and 7% in Spain, Denmark, Ireland, Italy and the
United Kingdom (87). The female to male prevalence ratio
for last year use ranged between 1:1 and 1:13 for young
adults in different countries. Weighted averages for the
European Union as a whole suggest that, among cocaine
users aged 15–34, the male to female ratio was nearly
4:1 (3.8 males for each female).
Measures of more recent cocaine use (last year and last
month) are highest among the 15–24 age group, although
this phenomenon is less marked than in the case of
cannabis or ecstasy (88). Last year prevalence of cocaine
use for this age group is estimated at 2.6%, which
translates into 2 million 15- to 24-year-olds using the drug
in the last year.
Cocaine use is also associated with certain lifestyles. An
analysis of data from the British Crime Survey 2003/04
estimated that around 13% of 16- to 29-year-olds who
frequently visit pubs or wine bars report last year use
of cocaine, compared with 3.7% among less frequent
visitors. Among 30- to 59-year-olds, the ﬁgures were 3.1%
and 1% respectively. Reported use of crack cocaine in
the same survey was very low, even among the group
reporting the highest cocaine prevalence levels. This
supports the ﬁndings of more focused studies, which
report a different proﬁle for the user of powder cocaine
compared to that found for crack cocaine. It is likely that
in other countries cocaine use is also associated with
similar lifestyle factors.
(86) See ‘The European stimulant market: “cocaine countries” and “amphetamines countries”?’, p. 50.
(87) See Figure GPS-13 in the 2008 statistical bulletin.
(88) See Figure GPS-15 and Tables GPS-14 to GSP-16 for all years and Tables GPS-17 to GPS-19 for latest data in the 2008 statistical bulletin.
Estimating cocaine use by analysing communal
wastewater
The application of recent developments in analytical
chemistry to the detection of cocaine in wastewater has
introduced a new approach to the monitoring of illicit drug
use in the community, known as ‘sewage epidemiology’.
The method involves measuring the levels of breakdown
products of illicit drugs excreted in the urine of consumers.
The levels of breakdown products measured in wastewater
are then scaled up to calculate consumption of illicit drugs
among the population. In the case of cocaine, the main
metabolite excreted in the urine is benzoylecgonine. As
breakdown in the human body of cocaine is the only likely
source of benzoylecgonine in wastewater systems, with
certain assumptions, it is possible to back-calculate from
the amount of the metabolite in the wastewater to the
amount of cocaine consumed in the community (although
not to the number of consumers).
Sewage epidemiology is still in an early stage of
development and, as well as important technical and ethical
questions, the information it offers must be integrated into
current research thinking. These issues are addressed in
the new EMCDDA publication on wastewater analysis
(EMCDDA, 2008b). Bringing together experts from a wide
range of disciplines, the report concludes that, although
further developments are required, sewage epidemiology
has potential for drug surveillance at the community
level. The approach could also have potential as a drug
surveillance tool to assist public health and law enforcement
ofﬁcials in identifying patterns of drug use across
municipalities of varying sizes. And, because wastewater
sampling and analysis can be conducted on a daily, weekly
or monthly basis, the data could potentially be used to
give a more real-time measure that provides communities
with more possibilities for monitoring the impact and
effectiveness of prevention and intervention activities.
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Table 5: Prevalence of cocaine use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year Last month
15–64 years
Estimated number of users
in Europe
12 million 4 million 2 million
European average 3.6% 1.2% 0.5%
Range 0.4–7.7% 0.1–3.0% 0–1.6%
Lowest-prevalence countries Romania, Malta
Lithuania (0.4%)
Greece (0.7%)
Greece (0.1%)
Poland, Latvia
Czech Republic (0.2%)
Greece, Estonia,
Czech Republic (0.0%)
Malta, Lithuania, Poland,
Finland, Latvia (0.1%)
Highest-prevalence countries United Kingdom (7.7%)
Spain (7.0%)
Italy (6.6%)
Ireland (5.3%)
Spain (3.0%)
United Kingdom (2.6%)
Italy (2.2%)
Ireland (1.7%)
Spain (1.6%)
United Kingdom (1.3%)
Italy (0.8%)
Ireland (0.5%)
15–34 years
Estimated number of users
in Europe
7.5 million 3.5 million 1.5 million
European average 5.4% 2.3% 1%
Range 0.7–12.7% 0.2–5.4% 0.0–2.8%
Lowest-prevalence countries Romania, Lithuania (0.7%)
Malta (0.9%)
Greece (1.0%)
Greece (0.2%)
Poland (0.3%)
Latvia, Czech Republic (0.4%)
Estonia (0.0%)
Greece, Poland, Latvia,
Czech Republic (0.1%)
Highest-prevalence countries United Kingdom (12.7%)
Spain (9.6%)
Denmark (9.1%)
Ireland (8.2%)
United Kingdom (5.4%)
Spain (5.2%)
Italy (3.2%)
Ireland (3.1%)
Spain (2.8%)
United Kingdom (2.7%)
Italy (1.2%)
Denmark, Ireland (1.0%)
15–24 years
Estimated number of users
in Europe
3 million 2 million 800 000
European average 4.5% 2.6% 1.2%
Range 0.4–11.2% 0.2–6.1% 0.0–3.2%
Lowest-prevalence countries Romania (0.4%)
Greece (0.6%)
Lithuania (0.7%)
Malta, Poland (1.1%)
Greece (0.2%)
Poland (0.3%)
Czech Republic (0.4%)
Latvia (0.6%)
Estonia (0.0%)
Greece Latvia (0.1%)
Czech Republic, Poland,
Portugal (0.2%)
Highest-prevalence countries United Kingdom (11.2%)
Spain (8.7%)
Denmark (8.0%)
Ireland (7.0%)
United Kingdom (6.1%)
Spain (5.8%)
Ireland (3.8%)
Denmark, Italy (3.3%)
United Kingdom (3.2%)
Spain (3.1%)
Italy (1.3%)
Bulgaria, Ireland (1.1%)
Information based on the last survey available for each country. The study year ranges from 2001 to 2007. The average prevalence for Europe was computed
by a weighted average according to the population of the relevant age group in each country. In countries for which no information was available, the
average EU prevalence was imputed. Populations used as basis: 15–64 (328 million), 15–34 (134 million) and 15–24 (64 million). The data summarised here
are available under ‘General population surveys’ in the 2008 statistical bulletin.
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Studies conducted in recreational settings often report
a high prevalence of cocaine use. For example, a 2006
study in nine European cities (Athens, Berlin, Brno, Palma,
Lisbon, Liverpool, Ljubljana, Venice, Vienna), with 1 383
young people aged 15–30 who regularly ‘go out in
nightlife settings’, found that 29% reported using the drug
at least once and nearly 4% that they used cocaine once
a week or more at some point (European Commission,
2007b). Higher prevalence levels were also reported in a
2004–05 French survey of 1496 individuals interviewed
in ﬁve different electronic music settings. Nearly 35%
of the sample had used cocaine and 6% crack or free-
base cocaine during the last month. The study also
reported differences between sub-populations: last month
prevalence was 50% for cocaine use and 13% for crack
use among those labelled ‘alternative’, while around a
quarter of the more mainstream sub-populations had used
cocaine and 2% crack during the last month.
Cocaine use among school students
Among school students, overall prevalence levels for
cocaine use are much lower than those for cannabis use.
Ever in lifetime prevalence of cocaine use among 15- to
16-year-old school students is 2% or lower in most countries,
rising to 4% in Spain and 5% in the United Kingdom (89).
In countries that have reported recent data from national
school surveys (Spain, Portugal, Slovakia, Sweden, United
Kingdom), prevalence of cocaine use is stable or decreasing
slightly, although changes in prevalence levels are usually
too small to be statistically signiﬁcant. In Spain, recent
survey data have shown a signiﬁcant decrease among 17- to
18-year-old school students.
Patterns of cocaine use
Data from general population surveys suggest high
discontinuation rates among cocaine users: in those
countries where last year prevalence is above 2%,
between 80% and 90% of adults who have used cocaine
at least once in their life have not used it during the last
month (90).
Only limited information is available on the frequency of
cocaine use in Europe. An analysis of the British Crime
Survey found that about 20% of those young people
(16–24 years) who had used cocaine in the previous
year consumed the drug more often than once a month.
A multi-city European study with targeted samples of
cocaine users in nine cities (Prinzleve et al., 2004) found
that the reported frequency of use was on average lower
among integrated users (seven days a month) than among
socially excluded users (11 days) or among opioid users in
treatment (14 days).
Problem cocaine use and treatment demand
National estimates of problem cocaine use (injection or
long duration/regular use) are available only for Spain
and Italy, and regional estimates are available for the
United Kingdom. According to the most recent data for
Spain, in 2002 there were between 4.5 and 6 problem
cocaine users per 1 000 adult population (15–64 years).
Similarly, in Italy, in 2006, there were estimated to be
between 3.7 and 4.5 problem cocaine users per 1 000
adults. Information for the United Kingdom is not directly
comparable to that of Spain and Italy, as it is based on
crack cocaine use. In 2004–05, one study estimated the
number of problem crack cocaine users in England at 5.7
to 6.4 per 1 000 adult population.
Cocaine, mainly powder cocaine, was cited as
the principal reason for entering drug treatment in
Europe in 2006 by about 16% of all treatment clients,
corresponding to around 61 000 reported cases in 24
countries (91). Cocaine was also reported as a secondary
drug by around 18% of all drug outpatient clients (92).
There is a wide variation between countries, with cocaine
users making up a high proportion of treatment clients
only in Spain (47%) and the Netherlands (35%); though,
the drug now accounts for 25% of treatment demands in
Italy. Elsewhere in Europe, cocaine accounts for between
5% and 10% of all treatment demands (10 countries) or
less than 5% (12 countries) (93).
The proportion of cocaine users is higher among those
entering drug treatment for the ﬁrst time. Across Europe, in
2006, cocaine was reported as the primary drug by 23%
of new clients (around 37 000 individuals) (94). In Spain,
according to the latest data, in 2005, cocaine was the
primary drug most often cited by those entering treatment,
and new cocaine clients represented 63% of all new
Spanish drug clients.
Trends in cocaine use
Using last year prevalence among young adults (15–34
years) as an indicator of trends in levels of recent use (as
cocaine use concentrates in this age group) shows that
cocaine use increased considerably during the second half
(89) See Table EYE-1 in the 2008 statistical bulletin.
(90) See Figure GPS-16 in the 2008 statistical bulletin.
(91) See Table TDI-115 and Figure TDI-2 in the 2008 statistical bulletin.
(92) See Table TDI-22 (part i) in the 2008 statistical bulletin.
(93) See Table TDI-5 (part ii) in the 2008 statistical bulletin; for Spain data refer to 2005.
(94) See Figure TDI-2 in the 2008 statistical bulletin.
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of the 1990s in Spain, Denmark and the United Kingdom.
New data (2005–07 surveys) conﬁrm the rising trend
reported already last year in France, Ireland, Spain, the
United Kingdom, Italy, Denmark and Portugal; in Germany,
the Netherlands, Slovakia and Finland, a stable prevalence is
observed; and in Poland, a decline was reported (Figure 5).
The increasing trend in demand for cocaine treatment noted
in previous years also appears to be continuing, even if it is
disproportionately inﬂuenced by a few countries. Between
2002 and 2006, the proportion of new clients demanding
treatment for primary cocaine use grew from 13% to 25%,
and the number of reported cases rose from around 13 000
to almost 30 000. An increase was also observed in the
number and proportion of all cocaine clients entering
drug treatment: from 22 000 clients (13% of all treatment
demands) in 2002 to 50 000 (19%) in 2006. The largest
increases were reported by Italy and Spain (95).
The increasing trend in cocaine users entering drug
treatment may be related to increases in the prevalence
of cocaine use and related problems, but also to other
factors (e.g. increase of treatment referrals or interventions
speciﬁcally targeted to cocaine users); and proportions by
drug type are obviously inﬂuenced by changes in demand
for treatment by the users of other substances.
International comparisons
Overall the estimated lifetime prevalence of cocaine
use is lower among young adults in the European Union
than among their counterparts in Australia, Canada
and the USA. However, at the national level Denmark,
Ireland, Spain, Italy and the United Kingdom (England
and Wales) report higher ﬁgures than Australia. Only the
United Kingdom (England and Wales) reports a lifetime
prevalence estimate that is similar to that of the USA (96).
In some respect, this measure can be seen as reﬂecting the
historical development of cocaine problems and the earlier
experience of the USA and, in the European context, the
United Kingdom, with widespread cocaine use.
Treatment and harm reduction
Proﬁle of treatment clients
Outpatient centres account for nearly all (94%) reported
cocaine treatment demands in Europe (97). However, it
(95) See Figures TDI-1 and TDI-3 and Table TDI-3 (part ii) in the 2008 statistical bulletin.
(96) See Figure GPS-20 in the 2008 statistical bulletin.
(97) See Table TDI-24 in the 2008 statistical bulletin.
(1) England and Wales.
NB: In Denmark, the value for 1994 corresponds to ‘hard drugs’. See Figure GPS-14 in the 2008 statistical bulletin for further information.
Sources: Reitox national reports (2007), taken from population surveys, reports or scientiﬁc articles.
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Figure 5: Trends in last year prevalence of cocaine use among young adults (aged 15–34)
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should be noted that cocaine treatment also sometimes
takes place in private clinics, sometimes on a residential
basis, and this form of care is not well represented in the
current monitoring system.
Cocaine clients entering outpatient treatment have the
highest male to female ratio among drug treatment
clients (ﬁve men for every woman). Their mean age is 31
years (98), which makes it the third oldest drug client group,
after opioid users and users of hypnotics and sedatives.
Most cocaine clients report having started using the drug
between the ages of 15 and 24 years (99).
There is considerable inter-country variation reported in
respect to the route of administration for cocaine clients.
Overall, around half (55%) of the cocaine clients are
reported as snorting the drug, with nearly a third (32%)
smoking it, and a much smaller proportion (9%) injecting
the drug (100). Broadly, two main groups of cocaine
users can be identiﬁed among those in treatment. The
ﬁrst of these are typically more socially integrated,
reporting stable housing and employment status, and
generally report snorting the drug. The second is a
more marginalised group of clients who are typically
smoking or injecting cocaine (see EMCDDA, 2006),
and more often report using either crack cocaine or the
combination of cocaine and heroin. Crack clients, in
particular, commonly live in large cities, belong to ethnic
minority groups, and report high levels of unemployment
and poor living conditions (101). This problem is small
in European terms and is geographically limited, with
signiﬁcant crack cocaine problems limited to a relatively
small number of cities. In 2006, around 8 000 crack
cocaine clients (about 2% of all drug clients) were
reported to have entered drug treatment in 20 European
countries, although most of them were reported by the
United Kingdom (102).
Treating the problems associated with the concurrent use
of both cocaine and heroin is becoming an increasingly
important issue in some countries. Users in treatment
may be current or former heroin users, sometimes in
substitution treatment. In some countries, they represent
the largest group of cocaine treatment clients. Some
studies have suggested that concomitant use of cocaine
and heroin can be associated with the presence of
dual diagnosis, or aggravate underlying psychological
problems such as bipolar disorder. Also, concomitant
cocaine use during methadone maintenance treatment
has been shown to contribute to persistent heroin use
(98) See Tables TDI-10 and TDI-21 in the 2008 statistical bulletin.
(99) See Table TDI-11 (part iii) in the 2008 statistical bulletin.
(100) See Tables TDI-17 (part ii) and (part vi) and TDI-111 (part vii) and (part viii) in the 2008 statistical bulletin.
(101) See the 2007 selected issue on cocaine and crack cocaine.
(102) See Table TDI-115 in the 2008 statistical bulletin.
Health problems related to cocaine use
Awareness of the links between cocaine use and illness
is often limited, even among medical professionals.
As a result, some cocaine-related problems will go
unidentified, and those suffering them may not receive
appropriate care. Underreporting of cocaine problems
will impede the understanding of the impact of the drug
on public health.
The risks associated with certain problematic modes
of cocaine use are well known and mostly affect
recognised groups of users (former or current opioid
users, marginalised groups). For example, injecting
cocaine use is associated with the risk of infection and
an elevated risk of overdose, while use in combination
with opioids appears to be linked to a higher risk of
opioid overdose.
Health problems associated with powder cocaine,
however, are more likely to go unrecognised and may
affect users who might not normally consider themselves
at risk. Chronic use of cocaine can cause significant
health problems, most of which are cardiovascular
(atherosclerosis, cardiomyopathy, arrhythmias,
myocardial ischemia) and neurological (cerebrovascular
accidents and seizures). These problems can be
aggravated by existing conditions (e.g. vascular
malformations) and risk factors such as smoking or
alcohol use. Many of the deaths attributed to cocaine
are produced through these pathologies.
Use of cocaine in combination with alcohol increases
blood levels of cocaine by as much as 30%. From a
behavioural perspective, cocaine use may facilitate
excessive alcohol use by enabling users to drink longer,
which in turn may increase the amount of cocaine
consumed (Gossop et al., 2006). The formation of
cocaethylene in the liver may also be linked to further
possible health risks associated with the combined use
of cocaine and alcohol.
There have been few studies to assess the overall public
health impact of cocaine use. A large-scale population
study in the USA (1988–94) found that a quarter of
non-fatal acute myocardial infarctions among those
aged 18–45 years were attributed to ‘frequent lifetime
cocaine use’. Frequent users had a seven times higher
risk of non-fatal myocardial infarctions than non-users
(Qureshi et al., 2001). However, it is not possible to
generalise directly from this study to Europe. Currently,
our understanding of the possible health impact of
increasing cocaine use in Europe remains poorly
developed and an important area for future public
health inquiry.
For further reading on health problems related to
cocaine use, see the 2007 selected issue on cocaine.
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or re-initiation — a risk for HIV and other blood-borne
infections and serious medical, social and criminal
problems.
Cocaine treatment
Following the increase of cocaine use and associated
problems in several Member States, specialised drug
treatment facilities face the difﬁcult task of adapting
their traditionally opioid-oriented services to the varied
cocaine and crack-using populations. However, with the
exception of Spain, in 2006, Member States assessed the
availability and accessibility of cocaine-speciﬁc treatment
programmes as low.
Of the Member States that report high prevalence levels of
cocaine or crack cocaine, several have been particularly
active in responding to this problem. In 2007, Spain
introduced a speciﬁc national action plan on cocaine, while
Ireland implemented and evaluated a number of speciﬁc
programmes aimed at different groups of cocaine users.
These programmes target problematic intranasal cocaine
users, polydrug users with cocaine problems, as well as
women and sex workers using cocaine. In Italy, a large-
scale clinical trial will be carried out in 2008 to investigate
the effectiveness of two pharmaceuticals (aripiprazole and
ropinirole) for the treatment of cocaine dependence.
Information on the nature of the services provided to
problem cocaine users in Europe is scarce. Nonetheless,
national clinical publications or surveys among
professionals provide a good insight into current
practices. According to a recent United Kingdom
report (NICE, 2007), cocaine-related problems in
British specialised treatment centres appear to be only
addressed when the primary drug problem is related
to opioids. Also, a recent Italian survey among experts
involved in the treatment of cocaine users indicated
difﬁculties in applying some of the elements considered
by them as crucial factors for achieving successful
treatment outcomes, such as providing appropriate
services (e.g. short-term residential care, structured
psychosocial interventions), or clinically differentiating
the different types of cocaine users. These difﬁculties
were reported to be due to organisational problems,
lack of resources and lack of effective cocaine-speciﬁc
treatment interventions. It is likely that professionals in
other Member States face similar problems. Adequate
investment, appropriate treatment protocols and
specialised training needs are, therefore, likely to be key
issues for service development in this area.
Recent literature reviews indicate that current psychosocial
interventions do not show strong evidence of effectiveness
in treating cocaine dependence, nor do effective
pharmacological treatment approaches exist. A recent
Cochrane review on psychosocial cocaine and other
psychostimulant interventions concluded that the only
consistent, positive behavioural results (retention in
treatment, reduction in drug consumption) were observed
in psychosocial interventions that included contingency
management as a component (103).
Unlike opioid dependence, no effective pharmacological
treatment options are currently available to help cocaine
users maintain abstinence or reduce use (see the 2007
selected issue on cocaine). Experimental therapeutic
drugs to reduce cocaine consumption and cravings
have shown potential in clinical trials (e.g. baclofen,
tiagabine, topiramate). Modaﬁnil, a central nervous
system stimulant, has shown particularly promising results
as a psychostimulant substitution drug with the advantage
that, compared to other potential substitute drugs (e.g.
d-amphetamine), its abuse liability is low (Myrick et al.,
2004). Furthermore, buprenorphine, topiramate and
tiagabine have shown promising results in reducing
cocaine use in opioid users undergoing substitution
treatment with concomitant cocaine use.
(103) See ‘Contingency management’.
Contingency management
By rewarding abstinence, contingency management (CM)
aims to reduce the reinforcing effects of drugs. Typically,
CM is introduced at the beginning of a course of treatment,
with psychosocial support, and the incentives are
contingent on the production of drug-free urine samples.
For example, the incentive could be vouchers of small
monetary value, which increase with each successive
period of abstinence. In this scenario, failure to stay drug-
free results in the loss of the accumulated gains.
This technique repeatedly reinforces the drug-free
behaviour of the client and provides a regular goal to
be achieved. The strongest evidence for the effectiveness
of CM in maintaining abstinence from drugs comes from
studies on cocaine and heroin treatment, though there
is some evidence for the approach in cannabis and
methamphetamine treatment.
Although most research on CM has been conducted outside
Europe, feasibility studies of CM have recently reported
positive results in Spain for cocaine users (Secades-Villa et
al., 2008) and in addressing cocaine use among opioid
substitution treatment clients in the Netherlands (DeFuentes-
Merillas and De Jong, 2008), where the average incentive
at the end of the trial was goods to the value of EUR 150.
An economic analysis by the National Institute for Clinical
Excellence (NICE, 2007) in the United Kingdom suggested
that CM is a cost-effective option in the context of cocaine
treatment, especially when considering the wider economic
costs of cocaine use.
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Immunotherapy for cocaine dependence through a
cocaine vaccine (TA-CD) is also under investigation.
Once administered, the vaccine induces the production
of antibodies that bind to cocaine molecules in the
bloodstream and, thereby, allow naturally occurring
enzymes to convert them into inactive molecules. The
results of the initial clinical trials are encouraging, though
further studies are required to test the viability of the
vaccine as a pharmacotherapy for cocaine dependence.
The cocaine vaccine is primarily intended to be used
in relapse prevention, but the term ‘vaccine’ also raises
expectations about its potential use to prevent cocaine
dependence when used as a prophylactic treatment (e.g.
in drug-naive children or adolescents). The effectiveness of
such an approach is uncertain and raises ethical concerns,
which are discussed in depth in the forthcoming EMCDDA
publication Addiction neurobiology: ethical and social
implications.
Harm reduction
Problem cocaine use is frequently associated with severe
physical and mental health consequences. For example,
an Irish two-year follow-up survey on cocaine in local
communities revealed a deterioration of the general health
of cocaine-dependent clients, especially among injectors.
Several projects also reported a rise in the number of
clients experiencing abscesses and wounds due to poor
injecting habits; other problems reported among clients
using cocaine include weight loss, sexually transmitted
infections, heart conditions, amputations and risk taking.
Member States usually provide cocaine-injecting users with
the same services and facilities as those provided to opioid
users, such as recommendations for safe use, training
for safe injecting and needle exchange programmes.
Low-threshold drug services play a signiﬁcant role in this
respect as they provide basic care, as well as counselling
and medical help. Users with severe cocaine and crack-
related problems, such as co-morbid physical and mental
health problems or social problems, such as housing, can
be referred to residential rehabilitation programmes and
therapeutic communities. These programmes not only aim to
achieve abstinence, but offer respite and intensive care and
support in order to help the users to change their chaotic
and high-risk lifestyles.
A qualitative study in six Spanish cities showed that the
main substances used among sex workers were alcohol
and cocaine. Drug use was reported as occasional and
instrumental in helping to reduce psychological barriers
or inhibition, and increase tolerance to long hours of
sex work with different clients. Among the consequences
of drug use in prostitutes were unprotected sex and a
higher risk of violence by clients. Severe crack cocaine
consumption patterns are also often observed in this
group.
Sex workers with cocaine and crack cocaine problems
are targeted by outreach and harm-reduction services.
For example, in the Netherlands, municipal health
services have implemented special health programmes
targeting crack cocaine-using sex workers; in France,
the association Espoir Goutte d’Or, which focuses on
risk prevention and harm reduction for crack cocaine
users and sex workers, organises voluntary counselling
on a weekly basis and rapid testing for HIV and
hepatitis.
Recreational use of cocaine in combination with
excessive alcohol consumption frequently occurs in
nightlife settings and can be associated with serious
acute physical problems. As reported in Chapter 4,
Member States are increasingly adopting an integrated
approach towards reducing harm related to the use of
alcohol and illicit drugs in recreational settings. The
programmes offer advice and information to young
people on the risks associated with alcohol and drug
use in general, usually including material on the risks
associated with acute and chronic cocaine consumption.
The members of the European Foundation of Drug
Helplines are also very active in raising awareness and
providing support to drug users by offering advice and
information on the risks of drugs.
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Heroin supply and availability
Two forms of imported heroin have historically been
offered on the illicit drugs market in Europe: the commonly
available brown heroin (its chemical base form), which
comes mainly from Afghanistan; and white heroin (a salt
form), which typically originates from south-east Asia,
though this form is considerably less common (104). In
addition, some opioid drugs are produced within Europe,
principally homemade poppy products (e.g. poppy straw,
poppy concentrate from crushed poppy stalks or heads) in
some east European countries (e.g. Latvia, Lithuania).
Production and trafﬁcking
Heroin consumed in Europe originates predominantly
in Afghanistan, which remains the world leader in illicit
opium supply, followed by Myanmar and Mexico. Global
opium production increased again substantially (34%) in
2007 to an estimated 8 870 tonnes, mainly as a result of
an increase in Afghan production, which was estimated
at 8 200 tonnes. Global potential production of heroin
has consequently reached a record level in 2007, with an
estimated 733 tonnes (UNODC, 2008). The rising number
of laboratories dismantled in Afghanistan over the last few
years suggests that opium is increasingly being transformed
into morphine or heroin in the country itself. However, large
seizures of morphine in neighbouring countries (Pakistan,
Iran) indicate that signiﬁcant processing is also taking place
outside Afghanistan (CND, 2008; UNODC, 2007a).
Heroin enters Europe mainly by two major trafﬁcking routes:
the historically important Balkan route and its several
branches, following transit through Pakistan, Iran and Turkey;
and the increasingly used ‘northern route’ via central Asia
and the Russian Federation (Figure 6). Secondary trafﬁcking
routes were reported for heroin from south-west Asia, for
example directly from Pakistan to Europe (United Kingdom),
but also via Pakistan and countries in the Middle East and
Africa to illicit markets in Europe and North America (INCB,
2008a; Europol, 2008; UNODC, 2007a; WCO, 2007).
Heroin from south-west Asia is also smuggled to Europe
via south Asia (Bangladesh) (INCB, 2008a). Within the
European Union, the Netherlands and, to a lesser extent,
Belgium play an important role as secondary distribution
hubs (Europol, 2008).
Seizures
Worldwide reported seizures of opioids increased in 2006
to 384 tonnes for opium and to 104 tonnes for heroin and
morphine. While Iran accounted for most of the opium
(81%) seized worldwide, heroin and morphine were
intercepted mainly in Pakistan (34%), followed by Iran
(20%), Turkey (10%) and China (6%) (UNODC, 2008).
In Europe, an estimated 48 200 seizures resulted in the
interception of 19.4 tonnes of heroin in 2006. The United
Kingdom continued to report the highest number of
seizures, while Turkey again reported the greatest amount
seized, with 10.3 tonnes recovered in 2006 (105). The
amount of heroin intercepted in an average seizure varied
greatly between these two countries, with the size of the
average seizure in Turkey being 100 times that reported
for the United Kingdom, reﬂecting different positions in
the supply chain (Figure 6). Over the last 10 years, heroin
seizures have been ﬂuctuating downwards in Europe, with
a relative peak in 2001 and a record low in 2003. The
quantity of heroin intercepted in the European Union has
shown an overall decline between 2001 and 2006. In
contrast, the amount seized in Turkey has increased almost
three-fold during this period.
Global seizures of acetic anhydride (used in the illicit
manufacture of heroin) increased to 26 400 litres in
2006, most of it recovered in the Russian Federation
(9 900 litres) and Colombia (8 800 litres), followed by
Turkey (3 800 litres) (INCB, 2008b). The trafﬁcking routes
between Afghanistan and Europe are also being used to
smuggle precursor chemicals (mainly acetic anhydride via
the ‘northern route’) and synthetic drugs (mainly ecstasy)
eastwards (Europol, 2008).
Seizures of 3-methylfentanyl reported in 2006 in Latvia
and Lithuania and reports of increased injecting of
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(104) For information on the sources of data for drug supply and availability, see p. 36.
(105) See Tables SZR-7 and SZR-8 in the 2008 statistical bulletin. Note that, for estimating purposes, 2006 missing data on European seizures were
replaced by 2005 data. This analysis is preliminary as data for the United Kingdom are not yet available for 2006.
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NB: Trafﬁcking ﬂows represented on the map synthesise the analyses of a variety of international and national organisations (Reitox national focal
points, Europol, INCB, UNODC, WCO). Such analyses are based on information related to drug seizures along the trafﬁcking routes, and also
intelligence information from law enforcement agencies in transit and destination countries, and sometimes on reports from complementary
sources. The main trafﬁcking routes represented on the map should be considered as indicative of the main ﬂows, as there may be deviations to
other countries along the routes, and there are numerous secondary sub-regional routes not represented here which may change rapidly.
Figure 6: Main heroin trafﬁcking ﬂows from Afghanistan to Europe
To eastern, southern
and west Africa, and Europe
To Arabian Peninsula,
and Europe
To rest of
Asia and
Europe
To Baltic and Nordic countries
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illegally produced fentanyl in Estonia, points to the need
to monitor more closely the availability of synthetic
opioids such as fentanyl (which is considerably more
potent than heroin).
Purity and price
In 2006, the typical purity of brown heroin ranged
between 15% and 25% in most reporting countries,
although values under 10% were reported in Greece,
France and Austria, and higher ones in Malta (31%),
Turkey (36%) and the United Kingdom (43%). The typical
purity of white heroin was generally higher (45–70%) in
the few European countries reporting data (106).
The retail price of brown heroin varied in 2006 from
EUR 14.5 per gram in Turkey to EUR 110 per gram in
Sweden, with most European countries reporting typical
prices of EUR 30–45 per gram. The price of white
heroin is reported only by a few European countries
and ranged between EUR 27 and EUR 110 per gram.
Over the period 2001–06, the retail price of brown
heroin fell in a majority of the 13 European countries
reporting time trends, although signs of increases have
been noted in Poland.
Prevalence estimates of problem opioid use
Data in this section are derived from the EMCDDA
problem drug use (PDU) indicator, which includes mainly
injecting drug use and the use of opioids, although in
a few countries users of amphetamines or cocaine are
also an important component. Estimates of the number of
problem opioid users are generally uncertain, given the
relatively low prevalence and hidden nature of this type
of drug use, and statistical extrapolations are required
to obtain prevalence estimates from the available data
sources. Moreover, as most studies are based on a
localised geographical area, such as a city or district,
extrapolation to the national level is often difﬁcult.
Patterns of problem drug use in Europe appear to be
becoming more diverse. For example, in some countries
where problem opioid use has historically predominated,
recent reports suggest that other drugs including cocaine
are growing in importance. The need for effective
monitoring of a range of problem drug use patterns has
prompted the EMCDDA to report on problem drug use sub-
populations deﬁned by drug and which may overlap (107).
Estimates of the prevalence of problem opioid use at national
level during the period 2002–06 range roughly between
one and six cases per 1 000 population aged 15–64;
overall prevalence of problem drug use is estimated to range
between one and 10 cases per 1 000. The lowest well-
documented estimates of problem opioid use available are
from Cyprus, Latvia, the Czech Republic and Finland (though
both the Czech Republic and Finland have large numbers of
problem users of amphetamines), while the highest estimates
are from Malta, Austria and Italy (Figure 7).
From the relatively limited data available, an estimated
average prevalence of problem opioid use of between four
and ﬁve cases per 1 000 of the population aged 15–64
can be derived. Assuming this reﬂects the EU as a whole,
it implies some 1.5 million (1.3 million to 1.7 million)
problem opioid users in the EU and Norway in 2006.
(106) See Tables PPP-2 and PPP-6 in the 2008 statistical bulletin for purity and price data.
(107) For an overview of available estimates of the component parts of problem drug use, see the 2008 statistical bulletin.
Figure 7: Estimates of the annual prevalence of problem opioid
use (cases per 1 000 population aged 15–64)
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NB: The symbol indicates a point estimate; a bar indicates an
estimation uncertainty interval: a 95% conﬁdence interval, or one
based on sensitivity analysis. Target groups may vary slightly,
owing to different estimation methods and data sources; therefore,
comparisons should be made with caution. Non-standard age
ranges were used in the studies from Finland (15–54) and Malta
(12–64). For Germany, the interval represents the lowest bound of
all existing estimates and the highest bound of them, and the point
estimate a simple average of the midpoints. Methods of estimation
are abbreviated: CR=capture–recapture; TM= treatment multiplier;
MI=multivariate indicator; TP= truncated Poisson; MM=mortality
multiplier; CM=combined methods; OT=other methods. See Figure
PDU-1 (part ii) in the 2008 statistical bulletin for further details.
Sources: Reitox national focal points.
Chapter 6: Opioid use and drug injection
71
Trends and incidence of problem opioid use
Time trends in the prevalence of problem opioid use are
difﬁcult to estimate because of the limited number of repeated
estimates and the uncertainty around individual estimates.
Data from nine countries with repeated estimates during the
period 2001–06 suggest diverse developments. Prevalence
seems relatively stable in the Czech Republic, Germany,
Greece, Italy, Malta, Slovakia and Finland, whereas an
increase was observed in Austria (most recent data 2004)
and signs of a possible decrease in Cyprus (108).
Incidence of problem opioid use (the number of new
cases occurring in a given year) is a more sensitive
measure for changes over time, and may provide an
early view on future developments in prevalence and in
treatment demand. The estimation models used, though,
make several assumptions. Furthermore, these models
can provide only a partial estimate of incidence, as they
are based on only those cases that come into contact
with treatment. Only two countries report recent data,
showing different trends. In Italy, incidence is estimated
to have declined from around 32 500 new cases in
1990 to about 22 000 new cases in 1997, after which it
has risen again to around 30 000 new cases in 2006.
In Spain, to the contrary, the incidence of problem
opioid use is estimated to have continuously declined
since its peak around 1980, although in recent years
(2002–04) it seems to have stabilised at a relatively low
level (around 3 000 new cases per year). The EMCDDA,
in collaboration with a group of national experts,
has recently developed new guidelines for incidence
estimation, in order to encourage further work in this
area (Scalia Tomba et al., 2008).
Opioid users in treatment
Opioids, mainly heroin, remain the principal drugs for
which clients seek treatment in most reporting countries.
Of the 387 000 treatment requests reported in 2006
(data available from 24 countries), heroin was recorded
as the principal drug in 47% of cases for which the
primary drug is known. In most countries, between 50%
and 80% of all treatment demands are reported to be
related to opioid use; in the remaining countries the
proportion varies between 15% and 40% (109). Opioids
are not only the most frequently reported primary drug
among those entering treatment but even more so among
those who are already in treatment. A recent project
involving nine countries and focusing on all clients in
treatment found that primary opioid users accounted
overall for 59% of clients but only for 40% of clients
entering treatment for the ﬁrst time in their lives (110).
Most drug clients entering outpatient treatment for
primary opioid use also use other drugs, including
cocaine (25%), other opioids (23%) and cannabis
(18%). In addition, of those in treatment for the
primary use of other drugs, 13% of clients in outpatient
treatment and 11% in inpatient treatment report opioids
as a secondary drug (111).
Some countries report a signiﬁcant proportion of
treatment demands relating to opioids other than heroin.
Buprenorphine misuse is reported as the main reason for
entering treatment by 40% of all clients in Finland and
8% of clients in France. In Latvia and Sweden, between
5% and 8% of drug clients report primary use of opioids
other than heroin or methadone: mainly buprenorphine,
painkillers and other opioids (112). Several countries report
(108) See Tables PDU-6 (part ii) and PDU-102 in the 2008 statistical bulletin for full information including conﬁdence intervals.
(109) See Table TDI-5 in the 2007 statistical bulletin.
(110) See Table TDI-39 in the 2008 statistical bulletin.
(111) See Tables TDI-22 and TDI-23 in the 2008 statistical bulletin.
(112) See Table TDI-113 in the 2008 statistical bulletin.
Opioid indicators are no longer decreasing
In contrast to trends described in previous annual reports,
recent data show some increases in drug-induced deaths,
heroin seizures and new treatment demands for heroin in
the European Union.
In 2003, the downward trend in the number of drug-
induced deaths reported in Europe, mostly related to the
use of opioids, ceased and between 2003 and 2005
most Member States have been reporting an upward
trend. Numbers of seizures of heroin increased by over
10% in 16 out of 24 reporting countries between 2003
and 2006. After falling for several years, new demands
for treatment with heroin as the primary drug have
increased in about half of the countries reporting data
between 2005 and 2006. This may reﬂect a change in
incidence of heroin use beginning a few years earlier,
because of the natural time lag between initiation of use
and ﬁrst treatment.
These recent trends occur alongside increased opium
production in Afghanistan, raising a concern that these
events might be linked through increased availability of
heroin on the European market. This is an important issue
for further investigation as available data do not allow a
clear picture to be drawn. Moreover, important confounding
factors exist. For example, the use of pharmaceutical
opioids for non-medical purposes is reported to have
continued at high levels or increased in several countries
(Czech Republic, Estonia, France, Austria, Finland) and may
represent an important factor in explaining trends in drug-
induced deaths.
Annual report 2008: the state of the drugs problem in Europe
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an increase in the proportion of polydrug users among
heroin clients and a rise in the number of clients using
opioids other than heroin.
The absolute number of heroin treatment demands reported
through the treatment demand indicator increased by over
30 000 cases from 108100 to 138 500 between 2002
and 2006. Similarly, among clients entering treatment
for the ﬁrst time in their life, there was an increase in the
number of primary heroin users from around 33 000 in
2002 to over 41000 in 2006. Factors that might explain
this trend include an increase in the numbers of problem
heroin users, an expansion in treatment provision or
improved reporting coverage.
Injecting drug use
Prevalence of injecting drug use
Injecting drug users are among those at highest risk of
experiencing health problems from their drug use, such as
blood-borne infections (e.g. HIV/AIDS, hepatitis) or drug-
induced deaths. Only 11 countries were able to provide
recent estimates of the levels of injecting drug use, despite
their importance for public health (Figure 8). Improving the
level of information available on this special population is,
therefore, an important challenge for the development of
health monitoring systems in Europe.
The available estimates suggest large differences between
countries in the prevalence of injecting drug use. Estimates
range between one and ﬁve cases per 1 000 population
aged 15–64 for most of the countries, with an exceptionally
high level of 15 cases per 1000 reported in Estonia.
The lack of data makes drawing conclusions on time
trends in the prevalence of injecting difﬁcult, although the
available data suggest a decline in Norway (2001–05),
and a stable situation in the Czech Republic, Greece,
Cyprus and the United Kingdom (113).
Injecting among opioid users entering treatment
Overall, 43% of all opioid users entering drug outpatient
treatment in 2006 reported injecting the drug. Changes
in the proportion of injectors among heroin users entering
treatment may indicate trends in the wider group of
problem opioid users. Declines in this proportion between
2002 and 2006 have been observed by nine countries
(Denmark, Germany, Ireland, Greece, France, Italy,
Sweden, United Kingdom, Turkey), whereas two countries
report an increase (Romania, Slovakia). Countries differ
considerably in the levels of injecting among heroin users
entering treatment, with the lowest proportions of injectors
reported in Spain, France and the Netherlands (under
25%) and the highest (over 80%) in Bulgaria, the Czech
Republic, Romania, Slovakia and Finland (114).
Among opioid users entering outpatient treatment for
the ﬁrst time in 2006, a slightly lower proportion report
injecting the drug (around 40%). Looking at time trends,
the proportion of injectors among new opioid clients
decreased from 43% in 2003 to 35% 2006 in the 13
countries where sufﬁcient data are available (115).
An analysis of the treatment demand data for nine
countries taking part in a pilot study revealed that around
63% of all opioid clients (those already in treatment
(113) See Table PDU-6 (part iii) in the 2008 statistical bulletin.
(114) See Tables PDU-104, TDI-4, TDI-5 and TDI-17 (part v) in the 2008 statistical bulletin.
(115) See Figure TDI-7 and Table TDI-17 (part i) in the 2008 statistical bulletin.
NB: The symbol indicates a point estimate; a bar indicates an
estimation uncertainty interval: a 95% conﬁdence interval, or
one based on sensitivity analysis. For Estonia, the upper limit
of the uncertainty interval is off-scale (37.9 per 1 000). Target
groups may vary slightly, owing to different estimation methods
and data sources; therefore, comparisons should be made with
caution. Methods of estimation are abbreviated: CR=capture–
recapture; TM= treatment multiplier; MI=multivariate indicator;
TP= truncated Poisson; MM=mortality multiplier; CM=combined
methods; OT=other methods. See Figure PDU-2 in the 2008
statistical bulletin for further details.
Sources: Reitox national focal points.
Figure 8: Estimates of the prevalence of injecting drug use (cases
per 1 000 population aged 15–64)
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and those entering treatment in the last year) reported
injecting the drug at entry to treatment (116). This suggests
that among clients already in treatment the proportion of
injectors at treatment entrance was relatively high.
Studies among injecting drug users may provide another
window on national differences and changes over time in
injecting drug use within Europe. Many countries conduct
regularly repeated studies on groups of injectors, usually
in the context of infectious disease testing, that are often
recruited from a variety of settings in order to maximise
generalisability. Comparisons between countries should
be made with caution due to potential biases in selective
recruitment to these studies (117).
Some countries show large proportions (above 20%)
of new injecting drug users (injecting for less than two
years) in these studies, whereas in several countries this
proportion is under 10% (Figure 9). Young injecting
drug users (under age 25) account for more than 40%
of the injectors sampled in the Czech Republic, Estonia,
Lithuania, Austria and Romania, whereas less than 20%
of the injectors sampled are under 25 in nine other
countries.
In general, a large proportion of new injectors has to
give cause for alarm, especially if reinforced by a large
proportion of young injectors. While a higher proportion
of new injectors can indicate a new upsurge of injecting,
other factors could also relate to this (e.g. shorter
injecting careers, better treatment availability, higher
death rates among the older population).
Countries with long-established problem opioid user
populations generally have low proportions of both
young and new injectors. In the remaining, often newer,
Member States data show higher levels of young
injectors. The varying levels of new injectors in these
countries, where information is available, may reﬂect
differences in the average age of initiation as well as
increasing injecting incidence among the younger or the
older populations.
(116) See Tables TDI-17 (part v) and TDI-40 in the 2008 statistical bulletin.
(117) It might be expected that the proportion of young or new injecting drug users is lower in samples recruited from drug treatment than in more ‘open’
settings such as low-threshold services, as on average clients entering treatment do so only after some years of using drugs. However, statistical analysis
of the association between recruitment setting and proportions of young or new injecting drug users shows no statistical signiﬁcance, suggesting that
recruitment setting (coded as ‘only drug treatment’, ‘no drug treatment’ and ‘mixed settings’) may not have a strong effect on these proportions.
NB: Samples are of injectors tested for infectious diseases (HIV and HCV). The latest available sample for each country during the period 2002–06
has been used, subject to there being at least 100 injectors. An asterisk indicates that no data are available for new injectors. For further
information, see Figure PDU-3 in the 2008 statistical bulletin.
Sources: Reitox national focal points.
Figure 9: Proportion of young and new injectors in samples of injecting drug users
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Treatment of problem opioid use
Proﬁle of opioid clients entering treatment
Clients entering treatment for primary opioid use tend
to be older (mean age 32 years) than those entering
treatment for cocaine, other stimulants and cannabis
(mean age 31, 27 and 24 years respectively), with
female clients generally being one or two years younger
than their male counterparts. Opioid clients are generally
younger in those countries that have joined the European
Union since 2004 and in Ireland, Greece, Austria and
Finland (118).
On average, men outnumber women opioid clients by
three to one, with higher proportions of men found, in
particular, in south European countries (Bulgaria, Greece,
Spain, France, Italy, Cyprus, Malta, Portugal) (119).
Opioid users report higher rates of unemployment
and lower levels of educational attainment than other
clients (see Chapter 2), and in some countries a higher
frequency of co-morbid psychiatric disorders is noted.
About half of opioid users seeking treatment report
initiation before the age of 20 and around one third
between the age of 20 and 24 years; ﬁrst use of opioids
after the age of 25 is uncommon (120). An average
time lag of between seven and nine years is reported
between ﬁrst use of opioids and ﬁrst contact with drug
treatment, with male clients reporting a longer time lag
than females (121).
Treatment provision and coverage
Treatment for opioid users is mostly conducted in
outpatient settings, which can include specialist centres,
general practitioners and low-threshold facilities. In a
few countries, inpatient centres also play a major role,
notably Bulgaria, Greece, Finland and Sweden (122).
Drug-free and substitution treatments for opioid use
are available in all EU Member States, Croatia and
Norway. In Turkey, the future use of substitution treatment
is currently under study. In most countries substitution
treatment is the most widely available option, though in
2005, Hungary, Poland and Sweden reported that drug-
free approaches were predominant.
Substitution treatment, generally integrated with
psychosocial care, is typically provided at specialised
outpatient centres and in shared-care arrangements with
ofﬁce-based general practitioners. The available data
on the number of clients in substitution treatment suggest
an overall increase in the last year, except for France,
the Netherlands, Malta and Luxembourg, where the
situation was stable. The biggest proportional increase
was reported by the Czech Republic (42%), although
increases in excess of 10% were also reported by Poland
(26%), Finland (25%), Estonia (20%), Sweden (19%),
Norway (15%), Hungary and Austria (11%).
A simple comparison of the estimates of the number
of problem opioid users and the reported number
of treatments delivered suggests that more than one
in three could be receiving substitution treatment. It
should, however, be borne in mind that there is still
lack of precision in both data sets which implies this
calculation should be viewed with caution. Furthermore,
wide confidence intervals in the estimates of problem
opioid use mean that comparisons between countries
are difficult. Nevertheless, the available data indicate
that the proportion of problem opioid users receiving
substitution treatment differs considerably between
(118) See Tables TDI-10, TDI-32 and TDI-103 in the 2008 statistical bulletin.
(119) See Tables TDI-5 and TDI-21 in the 2008 statistical bulletin.
(120) See Tables TDI-11, TDI-107 and TDI-109 in the 2008 statistical bulletin.
(121) See Table TDI-33 in the 2008 statistical bulletin.
(122) See Table TDI-24 in the 2008 statistical bulletin.
Widening pharmaceutical options
New pharmaceutical options for the treatment of opioid
dependency have been developed and made available in
Europe. The aims of these new prescribing options include
improving the effectiveness of treatment, responding to the
needs of different groups of opioid users and reducing the
possibilities for the misuse of substitution drugs.
A buprenorphine/naloxone combination was launched on
the EU market in 2006 as an alternative to buprenorphine
alone, with the aim of reducing the potential and
attractiveness for injecting use. A number of Member
States are currently assessing the value of this substance as
a treatment option for opioid dependence (1).
Prescription of medical heroin (diamorphine), as a
treatment option for chronic treatment-resistant opioid
users, is available to a limited extent in the Netherlands
(815 clients in 2006), the United Kingdom (400 clients)
and Germany, where the participants of the heroin trial
continue to receive diamorphine according to a special
regulation. Additionally, a randomised trial of injectable
opioids (RIOTT) is currently underway in the United
Kingdom which will assess the effectiveness of injectable
diamorphine, injectable methadone and oral methadone.
In February 2008, it was also decided to introduce a
diamorphine prescription scheme in Denmark.
(1) Technical information on the substance is available on the
EMEA website (http://www.emea.europa.eu/humandocs/
Humans/EPAR/suboxone/suboxone.htm).
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countries, with estimated rates of around 5% in
Slovakia, 20–30% in Finland, Greece and Norway,
35–45% in the Czech Republic, Malta and Italy, and
over 50% in the United Kingdom (England), Germany
and Croatia (123).
While oral methadone remains the main drug used
for substitution treatment in Europe, the use of
buprenorphine is becoming increasingly common.
One reason for this is that it may be associated with
lower rates of mortality when misused (Connock et al.,
2007). The Danish National Board of Health, after a
review of substitution guidelines, has now urged general
practitioners to prescribe buprenorphine instead of
methadone.
Treatment effectiveness, quality and standards
Reviews of randomised controlled trials and observational
studies conclude that methadone maintenance treatment
(MMT) and buprenorphine maintenance treatment (BMT)
can both be effective for the management of opioid
dependence. A recent Cochrane review concluded,
however, that buprenorphine is less effective than
methadone delivered at adequate doses (Mattick et
al., 2008). A number of studies have also found that
diamorphine maintenance can be effective for people
failing to respond to MMT (Schulte et al., in press).
Overall, substitution treatment has been linked to a
number of positive outcomes including: retention in
treatment, reductions in illicit opioid use and injecting,
reductions of mortality and criminal behaviour, and
stabilisation and improvement of health and social
conditions of chronic heroin users.
Psychosocial and psychotherapeutic interventions
combined with pharmocotherapy have also shown to
be effective in treatment outcome studies, for example
NTORS in the United Kingdom (Gossop et al., 2002)
and DATOS in the United States (Hubbard et al.,
2003). These approaches may not only increase
treatment motivation, prevent relapse and reduce harm,
but also provide advice and practical support to clients
who have to address their housing, employment and
family-related problems in parallel to treating their
opioid dependence. The available evidence, however,
does not support the use of psychosocial treatments
alone (Mayet et al., 2004).
A number of countries have recently reported making
improvements to their treatment guidelines. In Croatia,
Denmark and Scotland, substitution programmes have
been reviewed and guidelines have been revised to
increase treatment quality and prevent diversion into
the black market. The United Kingdom guidelines on
clinical management of drug dependence have also
been updated, and the National Institute for Clinical
Excellence has issued speciﬁc guidance on methadone
and buprenorphine prescribing, treatment with
naltrexone, detoxiﬁcation and on psychosocial treatment.
Portugal has also drawn up new guidance to ensure
timely access to treatment.
Treatment in prisons
There is wide recognition among EU policymakers for
the need to harmonise practice and quality of services
between community and prisons. However, a report
issued by the European Commission (2007a) highlighted
the lack of services for drug users available in prisons
and drew attention to the importance of intervening in
this setting. Examples of the limitations in the provision
of drugs services in prison include: lack of capacity and
expertise (Latvia, Poland, Malta), fragmented assistance
(Latvia), lack of interventions for speciﬁc groups such as
young drug-using inmates (Austria), and absence of a
public-health based prevention strategy (Greece).
More positively, prison drug programmes have become
more widespread, and new initiatives are reported by
many countries. For example, in Portugal, the legal
framework for a syringe exchange programme in prisons
has been established; in Lithuania, a decree obliging
prisons to provide pre-release counselling was passed; in
Denmark, since January 2007, all inmates with sentences
longer than three months can beneﬁt from a ‘treatment
guarantee’; in the Czech Republic, substitution treatment
has been expanded to 10 prisons; and in Ireland,
treatment services in prison are currently being assessed
with the aim of achieving equivalence with those in the
community.
The level of drug treatment provision in prison remains
low, compared to the community, although the
prevalence of drug use is generally higher. In many
countries, detoxiﬁcation is the preferred and sometimes
the only treatment option available. Substitution treatment
is offered in theory in most countries, but data indicate
that few drug users receive it in practice. Exceptions are
Spain, where 14% of all sentenced prisoners (19 600)
received substitution treatment in 2006, and the United
Kingdom (England and Wales), where it is expected
that the numbers receiving methadone will increase
from 6 000 to 12 000 following the introduction of new
guidance in April 2007.
Practical guidance for substitution treatment in custodial
settings, endorsed by the WHO and UNODC, has
(123) See Figure HSR-1 in the 2008 statistical bulletin.
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recently been published (Kastelic et al., 2008), and some
research points to opioid substitution therapy in prison
showing positive effects on risk behaviour and mortality
(Dolan et al., 2003). A recent review of research studies
on prison-based substitution programmes concluded
that positive effects depended on the provision of
sufﬁcient dosage and treatment lasting for the duration of
imprisonment (Stallwitz and Stöver, 2007). Furthermore,
careful discharge planning and linkage to community
care are other key elements of services in this area
needed to ensure that gains in health status made during
time spent in custody are not subsequently lost (124).
(124) See ‘Elevated risk of drug-induced death on completion of prison sentences or treatment’, p. 88.
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Drug-related infectious diseases
Infectious diseases such as HIV and hepatitis B and C are
among the most serious health consequences of drug use.
Even in countries where HIV prevalence in injecting drug
users (IDUs) is low, other infectious diseases including
hepatitis A, B and C, sexually transmitted diseases,
tuberculosis, tetanus, botulism and human T-lymphotropic
virus may disproportionately affect drug users. The EMCDDA
is systematically monitoring HIV and hepatitis B and C
among injecting drug users (prevalence of antibodies,
or other speciﬁc markers in the case of hepatitis B). The
data have to be interpreted with caution, given several
methodological limitations in the different data systems (125).
HIV and AIDS
By the end of 2006, the incidence of diagnosed HIV
infection among injecting drug users (IDUs) appears to have
been low in most countries of the European Union, and the
overall EU situation appears relatively positive in a global
context. This may, at least partly, follow from the increased
availability of prevention, treatment and harm-reduction
measures, including substitution treatment and needle and
syringe programmes. Other factors, such as the decline in
injecting drug use that has been reported in some countries,
may also have played an important role. Nonetheless, in
some parts of Europe, data suggest that HIV transmission
related to injecting drug use still continued at relatively high
rates in 2006, underlining the need to ensure the coverage
and effectiveness of local prevention practice.
Trends in HIV infection
Data on newly diagnosed cases related to injecting
drug use for 2006 suggest that infection rates are still
falling overall in the European Union, following the peak
in 2001–02, which was due to outbreaks in Estonia,
Latvia and Lithuania (126). In 2006, the overall rate of
newly diagnosed infections among IDUs in the 25 EU
Member States for which national data are available
was 5.0 cases per million population, down from 5.6 in
2005 (127). Of the three countries reporting the highest
rates of newly diagnosed infections (Estonia, Latvia,
Portugal), Portugal continued to report a downward
trend in 2005/06, while in Estonia and Latvia the trends
levelled off at 142.0 and 47.1 newly diagnosed cases
per million population, respectively. Between 2001 and
2006, no strong increases have been observed in any
country in the population rate of HIV infection. Where
some slight increase is observed (e.g. Bulgaria, Ireland),
this remained below one additional case per million
population per year.
Looking at absolute numbers reveals which countries
contribute more strongly to the overall EU total. The
largest numbers of newly diagnosed infections among
IDUs were reported in 2006 by countries with the highest
infection rates (Portugal, 703 new diagnoses; Estonia,
191; Latvia, 108) (128) and those with large populations
(United Kingdom, 187; Germany, 168; France, 167;
Poland, 112) (Figure 10). Against the general background
of declining trends, the largest increases in absolute
numbers since 2001 are observed in the United Kingdom,
with about 13 additional cases per year, and in Germany,
with about 10 additional cases, although these are not
evenly distributed over the years. In Bulgaria, the low rate
of increase has accelerated recently, with 0, 2, 0, 7, 13
and 34 new cases per year between 2001 and 2006,
suggesting the potential for an outbreak.
Trend data from HIV prevalence monitoring in samples
of IDUs are an important complement to data from HIV-
case reporting, as they provide information also on
non-diagnosed infection. Prevalence data are available
from 25 countries over the period 2002–06 (129). In 15
countries, HIV prevalence remained unchanged during
the period. In ﬁve countries (Bulgaria, Germany, Spain,
Chapter 7
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(125) For details on methods and deﬁnitions, see the 2008 statistical bulletin.
(126) See Table INF-104 in the 2008 statistical bulletin.
(127) National data are not available from Spain and Italy. Adjusting for those two countries, the rate would be 5.9 cases per million population, down
from 6.4 in 2005.
(128) In Portugal, 703 cases were reported by EuroHIV for 2006, while 432 were reported by the Portuguese Epidemiological Surveillance Centre of Transmissible
Disease (CVEDT); the discrepancy is due to classiﬁcation by reporting year (EuroHIV) versus by year of diagnosis (CVEDT).
(129) See Table INF-108 in the 2008 statistical bulletin.
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Italy, Latvia) prevalence showed statistically signiﬁcant
decreases, all based on national samples. Although in
two of these, regional increases were also reported: in
Bulgaria, one city, Soﬁa; and in Italy, eight out of 21
regions and one city. Finally, in ﬁve countries, national
trends are either not reported or appear stable, while
there was at least one sub-national sample indicating an
increasing trend, even if prevalence levels remain mostly
at low levels (Belgium, Czech Republic, Lithuania, United
Kingdom, and possibly Slovenia).
The comparison of trends in newly diagnosed infections
related to injecting drug use with trends in HIV prevalence
among IDUs suggests that the incidence of HIV infection
related to injecting drug use is declining in most countries
at national level. Interpretation is more difﬁcult where
these data sources partially conﬂict, as is the case in, for
example, Bulgaria, Germany and the United Kingdom;
although in these countries, both the incidence of new
diagnoses and its rate of increase (except for Bulgaria in
2004–06) are low.
The high annual rate of new HIV diagnoses related
to injecting drug use in Estonia, Latvia and Portugal
suggests that transmission is still occurring in these
countries at high levels. For Estonia, this is supported
by 2005 prevalence data, which suggest that around
a third of new IDUs (those injecting for less than two
years) were HIV positive. Further indications of ongoing
HIV transmission are given by reports of high prevalence
levels (over 5%) among young IDUs (samples of 50 or
more IDUs under age 25) in several countries: Spain
(national data, 2005), Portugal (national data, 2006),
Estonia (two regions, 2005), Latvia (national and in two
cities, 2002/03), Lithuania (one city, 2006) and Poland
(one city, 2005) (130).
AIDS incidence and access to HAART
Information on the incidence of AIDS is important for
showing the new occurrence of symptomatic disease,
though it is not a good indicator of HIV transmission.
AIDS incidence data may also provide information on the
coverage and effectiveness of highly active antiretroviral
treatment (HAART). High incidence rates of AIDS in some
(130) See Tables INF-109 and INF-110 in the 2008 statistical bulletin.
NB: No national data are available for Spain and Italy, data are shown for regions where available. For both countries partial numbers totalled over
100 new cases in 2005 and showed a declining trend. For further information, see Table INF-104 in the 2008 statistical bulletin.
Source: EuroHIV.
Figure 10: Absolute number of newly diagnosed HIV infections among injecting drug users by year of report: countries with peak level
greater than 300 (left) and between 100 and 300 (right)
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European countries may indicate that many IDUs infected
with HIV do not receive HAART at a sufﬁciently early
stage in their infection to obtain maximum beneﬁt from the
treatment.
Portugal remains the country with the highest incidence
of AIDS related to injecting drug use, with an estimated
22.4 new cases per million population in 2006, although
the trend is now clearly downward, from 29.9 cases per
million in 2005. Relatively high levels of AIDS incidence
are also reported for Estonia, Spain and Latvia, at 17.1,
15.1 and 13.5 new cases per million, respectively. Among
these three countries, the trend is downward in Spain
and Latvia, but not in Estonia, where the most recent data
indicate an increase from 11.9 new cases per million in
2005 to 17.1 per million in 2006. An increase has also
been recorded in Lithuania, from 2.0 new cases per
million in 2005 to 5.0 cases per million in 2006 (131).
Hepatitis B and C
While high prevalence levels of HIV infection are found
only in some EU Member States, viral hepatitis and, in
particular, infection caused by hepatitis C virus (HCV),
is more highly prevalent in IDUs across Europe. HCV
antibody levels among national samples of IDUs in
2005–06 vary from around 15% to 90%, with most
countries typically reporting levels in excess of 40%.
Only a few countries (Bulgaria, Czech Republic, Finland)
report a prevalence of under 25% in national samples of
IDUs; though infection rates at this level still constitute a
signiﬁcant public health problem (132).
Within countries, HCV prevalence levels can vary
considerably, reﬂecting both regional differences and
the characteristics of the sampled population. For
example, in the United Kingdom, local studies report
levels between 29% and 59%, while in Italy different
regional estimates range from around 40% to 96%. While
estimates generated from non-probability samples must
always be taken with caution, the variations in prevalence
levels found are likely to have important implications for
the targeting and delivery of prevention and treatment
programmes. Furthermore, understanding the factors
responsible for differential levels of infection is likely to
inform the development of better intervention strategies.
Studies among young (under age 25) and new (injecting
for less than two years) IDUs suggest that the time window
to prevent HCV infection is quite short, as many contract
the virus early in their injecting careers. Recent studies
(2005–06) typically report prevalence levels of between
20% and 50%, although with considerable variation
between samples.
The prevalence of antibodies to hepatitis B virus
(HBV) varies to an even greater extent than that of
HCV antibodies, possibly partly due to differences in
vaccination levels, although other factors may play a
role. The most complete data set available is that for the
antibody to the hepatitis B core antigen (anti-HBc), which
indicates a history of infection. In 2005–06, six of the
11 countries providing data on IDUs reported anti-HBc
prevalence levels of over 40% (133).
Trends over time in notiﬁed cases of hepatitis B and C
show different pictures. The proportion of IDUs among all
notiﬁed cases of hepatitis B may have declined slightly in
some countries, possibly reﬂecting the increasing impact
of vaccination programmes targeted at IDUs. In the case
of hepatitis C, the proportion of IDUs among notiﬁed
cases has declined in ﬁve countries, but has increased in
(131) See Figure INF-1 in the 2008 statistical bulletin.
(132) See Tables INF-111 to INF-113 in the 2008 statistical bulletin.
(133) See Table INF-115 in the 2008 statistical bulletin.
‘Hot spots’ of HIV/AIDS
The most recent data indicate that the incidence of HIV
infection among IDUs is generally low in the European
Union. However, vigilance is needed as some Member
States continue to show high rates of new HIV infections
linked to injecting drug use, and the situation is even more
worrying in some neighbouring countries.
After a recent HIV epidemic in Estonia and Latvia, rates of
newly diagnosed infections in IDUs decreased from 2001
but have now stabilised at still high levels (142.0 and 47.1
new cases per million population, respectively, in 2006),
suggesting that transmission rates remain high. Portugal still
has the largest number of newly diagnosed infections in
the European Union (see p. 78) and, although the trend is
down, the annual rate of newly reported diagnoses is still
high at 66.5 new cases per million population in 2006.
In neighbouring countries to the east of the European
Union, the situation is of particular concern. In the two
largest countries, Russia and Ukraine, the number of
newly diagnosed cases is high and still increasing. In
2006, newly diagnosed infections related to injecting
drug use were estimated at over 11 000 in Russia and
7 000 in Ukraine (78.6 and 152.9 new cases per million,
respectively).
High rates of ongoing transmission among IDUs indicate
the need to review both the availability, level and range
of existing service provision, including speciﬁc measures
aimed at reducing the spread of infectious diseases, such
as needle exchange and substitution treatment. In addition,
targeted studies among IDUs are needed to investigate
why some populations appear particularly vulnerable, the
factors associated with risk behaviour and barriers for
self-protection, and to identify promising approaches to
prevent new outbreaks.
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ﬁve other countries (Czech Republic, Luxembourg, Malta,
Sweden, United Kingdom) (134). For both hepatitis B and
hepatitis C, the proportion of IDUs among the notiﬁed cases
continued to differ markedly between countries in 2006,
suggesting geographic differences in the epidemiology of
these infections, although bias due to different testing and
reporting practices cannot be ruled out.
Preventing infectious diseases
EU Member States employ a combination of some
of the following measures to reduce the spread and
consequences of infectious diseases among drug
users: drug treatment, including substitution treatment
(see Chapter 6), health information and counselling,
distribution of sterile injection materials, and education
towards safer sex and safer use. The availability and
coverage of these measures varies signiﬁcantly between
countries.
Needle and syringe programmes and opioid substitution
treatment are available in all EU Member States, Croatia
and Norway, although with considerable diversity in
both delivery settings and targeted population. Levels of
both substitution treatment and harm-reduction service
provision in Europe have increased considerably over
the past decade. In some countries, however, these
interventions remain limited and, overall, needs still
exceed provision in these areas.
A recent cohort study in Amsterdam pointed to the
beneﬁts of the combined availability of methadone
maintenance and needle exchange, as the involvement
with both services, compared to the involvement with
only one, was associated with a lower incidence of HCV
and HIV infections among injecting drug users (Van den
Berg et al., 2007).
Assessing the coverage of needle and syringe
programmes is difﬁcult, and only some countries provide
relevant ﬁgures. For instance, the Czech Republic reports
a network of 90 low-threshold facilities, which reaches
about 25 000 drug users per year, 70% of whom are
injectors, and provides on average 210 syringes per IDU.
Increases in the numbers of syringes given out by needle
and syringe programmes are reported from some
countries: in Estonia, the estimated number of syringes
given out per IDU has doubled between 2005 and
2006, reaching 112; in the same period, Hungary’s
syringe exchange programmes increased their turnover of
syringes by 56% and their clients by 84%; and Finland
continues to report a rise in the number of clients seen
and syringes distributed at health counselling centres.
Not all countries reported increases, however: in Malta
and Slovakia, syringe provision remained stable in 2006;
Poland reported a decrease in the number of agencies
operating and a reduction of 15% in the number of
syringes exchanged; Romania reported a 70% decline
in the number of syringes exchanged in Bucharest, with
ﬁnancial problems being reported as the main cause.
In a number of countries, stabilisation or decreases in
syringe exchange may reﬂect changes in overall patterns
of drug injecting and in the availability of treatment: in
Luxembourg, the number of syringes distributed by low-
threshold agencies, after increasing for several years,
stabilised in 2005 and decreased in 2006; recent
declines in syringe provision have also been reported in
Portugal and Belgium (the Flemish community), and at the
local level in Germany and the Netherlands.
Needle exchange and low-threshold services may also
provide a conduit to care for those with poor access
to generic services. This includes primary healthcare
delivery as well as measures to promote sexual health,
such as the distribution of condoms and lubricants and
the provision of safer sex education. The delivery of
infectious disease prevention services through outreach
teams or at low-threshold facilities is also established in
(134) See Tables INF-105 and INF-106 in the 2008 statistical bulletin.
Access to HIV testing and treatment
Among people with HIV infection in Europe, as many as
one in every three may be unaware of being infected
(ECDC, 2007), and reports from some EU Member States
suggest that levels of awareness may even be lower among
infected IDUs.
As a result many of those who become infected with the
virus will not have the advantage of early treatment and
care. They may also contribute to the spread of HIV by
unknowingly exposing others to the risk of infection. In
addition, the quality of the data collected by the HIV
surveillance systems is diminished.
Preliminary data suggest that access to antiretroviral
treatment and care by IDUs is disproportionately low
(Donoghoe et al., 2007). Effective antiviral treatment
approaches need to take account of the speciﬁc situation
and needs of IDUs. These can include coexisting health
and social problems (e.g. homelessness and lack of
insurance), but also stigma and discrimination in healthcare
settings or repeated arrests and incarceration.
To improve the access to HIV testing and treatment, the
EMCDDA has developed speciﬁc guidelines for offering
annual voluntary medical examination to IDUs, including
testing for HIV and viral hepatitis (1).
(1) http://www.emcdda.europa.eu/publications/methods/
pdu/2008/medical-examination
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a majority of countries, although services in this area
are still being developed. For example, a transnational
low-threshold prevention network, which will use common
service standards and epidemiological monitoring
protocols, is currently being established in Estonia, Latvia
and Lithuania.
Medical services are provided at low-threshold clinics
and by mobile services, or via referral schemes. For
example, the Czech low-threshold network works closely
with regional public healthcare services to facilitate
access to counselling, testing and treatment for somatic
co-morbidity, in particular, viral hepatitis. In Bulgaria, a
mobile surgery in Bourgas, on the Black Sea, provided
750 consultations in 2006. Some Danish municipalities
received government funds for healthcare programmes
targeted at the most vulnerable drug users. In addition,
the ‘health room’ project in Copenhagen, which
combines healthcare and social counselling measures
with a low-threshold approach, is a three-year pilot
scheme established in 2008.
Prevention of viral hepatitis
In 2006, initiatives to prevent the spread of viral hepatitis
were reported by several countries. For example, in
Luxembourg, following the results of an action-research
project, the provision of safer-use counselling for young
and new drug users was strengthened and free access
to injection paraphernalia for IDUs was improved. In
Denmark, free hepatitis A and B vaccinations have been
available since 2006 for drug users and their partners,
and municipalities must now provide a comprehensive
range of services for infectious diseases to those who
inject drugs. Finally, in Ireland, a working group on HCV
was tasked in 2007 with the development of a national
strategy for surveillance, education and treatment.
Prisons are important settings for interventions targeting
infectious diseases related to drug use and for providing
healthcare to a population that is otherwise hard to
reach (see Chapter 2). Recent research indicates that it
is important to provide viral testing to all those who have
ever engaged in illicit drug use and showed that the
detection of chronic hepatitis C infection on reception into
prison was a cost-effective measure (Sutton et al., 2006).
In addition to those with infections receiving the necessary
treatment and care, drug users in prison could beneﬁt from
a range of interventions such as health education and
hepatitis B immunisation (135).
Drug-related deaths and mortality
Drug use is one of the major causes of health problems
and death among young people in Europe. The
considerable mortality resulting from opioid use,
in particular, is illustrated by an international study
supported by the EMCDDA, which found that in seven
European urban areas, 10% to 23% of mortality among
15- to 49-year-olds could be attributed to opioid use
(Bargagli et al., 2005).
The EMCDDA’s key indicator ‘Drug-related deaths and
mortality among drug users’ principally monitors deaths
directly caused by drug use (drug-induced deaths) and, to
a more limited extent, overall mortality among drug users,
which also includes deaths associated with various other
health and social problems.
Drug-induced deaths
The EMCDDA deﬁnition of drug-induced deaths (136)
refers to those deaths that are directly caused (poisonings
or overdoses) by the consumption of one or more drugs,
where at least one of the substances present is an illicit
(135) See the DUP tables in the 2008 statistical bulletin.
(136) The term ‘drug-induced deaths’ has now been adopted, as it reﬂects more accurately the case deﬁnition used.
Hepatitis B vaccination among drug users
Transmission of hepatitis B virus (HBV) continues among
IDUs in Europe, among whom rates of active HBV infection
(prevalence of HBsAg) remain high in most countries,
compared to the general population (1). Vaccination is
considered the most effective measure to prevent hepatitis B
virus (HBV) infection and its consequences. In line with the
1991 WHO recommendation, most, but not all EU Member
States have adopted universal vaccination against this
virus. Infant vaccination policies, however, will mostly affect
future generations of drug users. To reduce the spread of
the infection sooner, over half the EU Member States have
adopted vaccination programmes speciﬁcally targeting
injecting drug users and/or prisoners. Nevertheless,
coverage of these programmes varies between countries,
and a third of EU Member States still report no vaccination
programme speciﬁcally for drug users.
Vaccination programmes targeting drug users often face
the problem of low compliance resulting in non-completion
of vaccination courses. Given the availability of a safe
and effective vaccine, strategies to achieve higher levels
of immunisation among those at risk may involve a ﬂexible
approach, targeting drug users early in their career and
reaching out to those communities with a higher prevalence
of drug use. Repeated offers of vaccination and extra doses
for those with decreased immune response may also help
to achieve higher immunisation results. This may require
EU Member States to review and possibly ﬁne-tune their
policies in order to decrease the occurrence of chronic HBV
infection and its consequences.
(1) See Tables INF-106 and INF-114 in the 2008 statistical bulletin.
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drug. The number of drug users, their patterns of use
(injection, polydrug use) and the availability of treatment
and emergency services are all factors that can inﬂuence
the overall number of such deaths in a community. In
general, drug-induced deaths occur shortly after the
consumption of the substance(s).
Improvements in the quality and reliability of European
data in recent years have allowed better descriptions
of overall and national trends, and most countries have
now adopted a case deﬁnition in line with that of the
EMCDDA (137). Nevertheless, differences in the quality
of reporting between countries mean that any direct
comparisons should be made with caution.
During the period 1990–2005, between 6 500 and 8 500
drug-induced deaths were reported each year by EU
Member States, adding up to about 130 000 deaths. These
ﬁgures should be considered as a minimum estimate (138).
Population mortality due to drug-induced death varies
widely between countries, ranging from three to ﬁve to
over 70 deaths per million inhabitants aged 15–64 years
(on average, 21 deaths per million). Rates of over 20
deaths per million are found in 16 European countries
and over 40 per million in ﬁve countries. Among males
aged 15–39 years, the mortality rates are, on average
and in most countries, twice as high (averaging 44 deaths
per million in Europe). In 2005–06, drug-induced deaths
accounted for 3.5% of all deaths among Europeans aged
15–39 years, and for more than 7% in eight countries (139)
(Figure 11).
There is still limited research on the morbidity and
other consequences of non-fatal overdoses and limited
investment in prevention efforts, despite evidence that the
numbers may be considerable. Studies have estimated that
there could be between 20 and 25 non-fatal overdoses
for each fatal one. Although it is difﬁcult to know if these
estimations can be applied to the European Union as a
whole, it would produce a rough estimation of about
120 000 to 175 000 non-fatal overdoses per year.
Deaths related to opioids
Heroin
Opioid overdose is one of the leading causes of death
among young people in Europe, particularly among
males in urban areas (140). Opioids, mainly heroin or its
metabolites, are present in the majority of drug-induced
deaths reported in the European Union, accounting for
55% to almost 100% of all cases, with over half of the
countries reporting proportions of over 80% (141). In the
toxicology reports on deaths attributed to heroin, other
substances are often found that may have played a
role. The most frequently reported of these are alcohol,
benzodiazepines, other opioids and, in some countries,
cocaine. Recent work by the EMCDDA, in which nine
countries participated, found that more than one drug was
mentioned in the toxicological results of 60% to 90% of
opioid-induced deaths. This suggests that a substantial
(137) See detailed methodological information on drug-related deaths in the 2008 statistical bulletin.
(138) See Table DRD-2 (part i) in the 2008 statistical bulletin.
(139) See Table DRD-5 and Figure DRD-7 (part ii) in the 2008 statistical bulletin.
(140) As most cases reported to the EMCDDA are opioid overdoses, general characteristics of drug-induced deaths are used for description of opioid cases.
(141) See Figure DRD-1 in the 2008 statistical bulletin.
Drug-related mortality: a complex concept
Both the scientiﬁc and the policy debates on drug-related
mortality are hampered by the range of concepts and
deﬁnitions that have been used in this area. If very broad
and inclusive concepts are used, the data may be of little
value for understanding the underlying factors associated
with drug-related mortality. For example, if all deaths with
a positive toxicological examination are grouped together,
this will include cases where drugs have played a direct
causal role, an indirect role or no role at all.
Another important issue is the substances considered,
which can be limited to illicit drugs or extended to other
psychoactive substances and medicines. In the latter
case, it may be difﬁcult to distinguish deaths that may be
primarily related to mental health issues (e.g. suicide in the
context of depression) from those attributable to substance
use. Moreover, many drug-induced deaths are, in fact,
polydrug deaths, and understanding the respective role of
different drugs can be difﬁcult.
Conceptually, drug-related mortality includes two broad
components. The ﬁrst, and best documented, refers to those
deaths directly caused by the action of one or more drugs.
These deaths are typically called ‘overdoses’, ‘poisonings’
or ‘drug-induced deaths’. The second component is broader
and covers deaths which cannot be directly attributable
to the pharmacological action of the drugs, but are
nevertheless linked with their use: long-term consequences
of infectious diseases, interactions with mental health issues
(e.g. suicide) or with other circumstances (e.g. road trafﬁc
accidents). There are also deaths related to drugs, but due
to circumstantial reasons (e.g. violence related to the drug
trade).
The EMCDDA’s current approach to reporting on overall
drug-related mortality is based on estimating mortality
rates among cohorts of problem drug users. However,
other approaches are being explored whereby data from
various sources can be combined to estimate the total
burden of mortality attributable to drugs in a community
(see ‘Overall drug-related mortality’, p. 86).
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proportion of all drug-induced fatalities may be related to
polydrug use.
The majority of opioid overdose deaths (60–95%) are
male, mostly between 20 and 40 years of age, with a
mean age in most countries in the mid-thirties (142). In many
countries, the mean age of those dying from overdose is
increasing, suggesting a possible stabilisation or decrease
in the number of young heroin users. However, elsewhere
(Bulgaria, Estonia, Romania, Austria) a relatively high
proportion of overdose deaths are among those under 25
years, which may indicate a younger population using
heroin or injecting drugs in these countries (143).
Methadone and buprenorphine
Research shows that substitution treatment reduces the risk
of fatal overdose. Each year, however, a number of deaths
associated with opioid substitution medicines are reported,
mostly due to misuse or, in a small number of cases, to
problems occurring during treatment (144).
The presence of methadone in a substantial proportion
of drug-induced deaths is reported by several countries,
although, in the absence of common reporting standards,
the role played by the substance is often unclear. Countries
reporting a non-trivial number of deaths with the presence
of methadone include Denmark, Germany, the United
Kingdom and Norway; other countries did not report cases,
or only a limited number (145). In the United States, a marked
increase has been reported in deaths related to methadone
since 1999. Most of these deaths are attributable to the
misuse of methadone diverted from hospitals, pharmacies,
practitioners and pain management physicians, while only
a limited number of them are attributed to methadone
obtained from substitution programmes (146).
NB: For the Czech Republic, EMCDDA Selection D was used instead of the national deﬁnition; for the United Kingdom, the drug strategy deﬁnition
was used; for Romania, data refer only to Bucharest and several counties in the competence area of the Toxicology Laboratory of Bucharest.
The calculations of population mortality rates are based on national populations for 2005 as reported by Eurostat. Comparisons of population
rates should be made with caution, as there are some differences in case deﬁnitions and quality of reporting. For conﬁdence intervals and more
information on the data see Figure DRD-7 (part i) in the 2008 statistical bulletin.
Sources: Reitox national reports 2007, taken from national mortality registries or special registries (forensic or police) and Eurostat.
Figure 11: Mortality rates among all adults (15–64 years) due to drug-induced deaths
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(142) See Table DRD-1 (part i) in the 2008 statistical bulletin.
(143) See Figures DRD-2, DRD-3 and DRD-4 in the 2008 statistical bulletin.
(144) See ‘Deaths related to substitution treatment’, p. 85.
(145) See Table DRD-108 in the 2008 statistical bulletin.
(146) National Drug Intelligence Center, ‘Methadone diversion, abuse and misuse: deaths increasing at alarming rate’, November 2007, document 2007-
Q0317-001 (http://www.usdoj.gov/ndic/pubs25/25930/index.htm#Key).
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Deaths due to buprenorphine poisoning appear to be
infrequent, despite the increasing use of this substance
in substitution treatment in many European countries.
In France, very few deaths are reported, although the
number of drug users receiving buprenorphine treatment
is considerable (76 000–90 000). In Finland, however,
buprenorphine is present in most drug-induced deaths,
usually in combination with sedative medicines or alcohol
or taken by injection (147).
Fentanyl
A worrying epidemic of fatal 3-methylfentanyl poisonings in
Estonia has been recently reported based on post-mortem
forensic toxicology ﬁndings, with 46 fatal poisonings
in 2005 and 71 in 2006 (Ojanperä et al., in press).
Furthermore, preliminary ﬁndings from Estonia indicate that
85 deaths in 2004 were related to the same substance.
There have also been sporadic reports of fentanyl deaths
from other European countries and recent, generally short-
lived, epidemics of deaths have been reported in the United
States; for example, 350 deaths were attributed to fentanyl
in Chicago between 2005 and 2007 (Denton et al.,
2008). The very high potency of this substance may elevate
the risk of drug overdose, while it may be overlooked in
toxicological screening. Increased illicit production and
use of fentanyl is therefore likely to challenge both existing
monitoring systems and public health responses.
Deaths related to other drugs (148)
Cocaine-induced deaths are more difﬁcult to deﬁne and
identify than those related to opioids (see the 2007
selected issue on cocaine). Deaths directly caused by
pharmacological overdose seem to be uncommon, and
these are usually linked with very large cocaine doses.
Otherwise, most cocaine deaths seem to be the result of
the chronic toxicity of the drug leading to cardiovascular
and neurological complications. The role of cocaine in
these deaths may not always be identiﬁed, and they
may not be reported as cocaine-related. Interpreting
the data on deaths attributable to cocaine is further
complicated by the presence of other substances in
many cases, making the drawing of causal associations
difﬁcult.
In 2006, more than 450 deaths related to cocaine were
reported in 14 Member States — though it is likely that the
number of cocaine-induced deaths in the European Union
is under-reported.
Deaths in which ecstasy is present continue to be infrequently
reported. Most deaths with ‘presence of ecstasy’ are
reported in the United Kingdom, but in many cases the drug
has not been identiﬁed as the direct cause of death.
While amphetamine deaths are also infrequently reported
in Europe, in the Czech Republic a substantial number
of drug-induced deaths have been attributed to pervitin
(methamphetamine). In Finland, 64 deaths were reported
in which amphetamines were identiﬁed toxicologically,
although this does not necessarily imply that the drug was
the direct cause of death.
(147) See Table DRD-108 in the 2008 statistical bulletin and the 2007 annual report for further information.
(148) See Table DRD-108 in the 2008 statistical bulletin.
Deaths related to substitution treatment
Research has demonstrated that the risk of overdose
decreases substantially while heroin users are in
methadone substitution treatment. For example, a recent
cohort study, involving more than 5 000 heroin users,
reported that the risk of overdose death was reduced by
a factor of 9 while users were in substitution treatment
compared with time outside, including any other type of
treatment or no treatment (Brugal et al., 2005).
Methadone, however, is identiﬁed in the toxicological
reports of some deaths. This does not imply the existence,
in all cases, of a direct causal link, as other drugs or
factors may be present. Nonetheless, overdose death can
occur, and among the factors that may be involved are:
changes in tolerance, excessive dosage, inappropriate
use by the client, and the drug being used for non-
therapeutic purposes.
Measures to prevent diversion of methadone into the
illicit market have been linked to reductions in the number
of reported methadone deaths in the United Kingdom
(Zador et al., 2006) and, overall, good practice in
substitution treatment may be an important component
in reducing the risk of methadone-related deaths. Both
patient and community health is, therefore, likely to be
safeguarded by improving: quality standards of treatment,
including prescription practices; client monitoring during
the ﬁrst phases of treatment; monitoring for possible
cardiac toxicities; information on risks of use of other
medicines or psychoactive substances; and dispensing
practices to decrease the risk of diversion.
The dramatic expansion of methadone treatment in
Europe has not been reﬂected in a parallel rise of
methadone-related deaths. A study carried out in the
United Kingdom found that, between 1993 and 2004,
the total quantity of oral methadone prescribed increased
by a factor of 3.6, while the number of deaths involving
methadone decreased from 226 to 194 (Morgan et al.,
2006). This represents a decrease in the methadone-
related death rate from 13 per 1 000 patient years in
1993 to 3.1 per 1 000 patient years in 2004. While
similar studies in other countries would be very useful,
the available evidence suggests that methadone-related
deaths are more likely to be linked to deﬁciencies in
prescribing practices than to overall levels of substitution
treatment.
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Trends in drug-induced deaths
Drug-induced deaths increased sharply in Europe
during the 1980s and early 1990s, possibly paralleling
the increase in heroin use and drug injection, and
thereafter remained at high levels (149). However,
data from countries with long time series suggest
differentiated trends: in some (e.g. Germany, Spain,
France, Italy), deaths peaked in the early to mid-
1990s, with a later decrease; in other countries (e.g.
Ireland, Greece, Portugal, Finland, Sweden, Norway),
the number of deaths peaked around the year 2000,
before decreasing; and in some others (e.g. Denmark,
Netherlands, Austria, United Kingdom), an upward trend
was observed, but without a clear peak (150).
Trends in drug-induced deaths over the period 2001 to
2005/06 are more difﬁcult to describe. In the ﬁrst years
of the decade (2000–03), many EU countries reported
decreases and, overall, drug-induced deaths fell by 3%
in 2001, 14% in 2002 and 7% in 2003 (151). In 2004
and 2005, however, most European countries reported
small increases. A number of factors could be associated
with this, including: increases in polydrug use, a possible
growth in the availability of heroin or an ageing
population of chronic drug users (152).
In the absence of data from some of the larger countries,
overall estimates of the number of drug-induced deaths
for 2006 remain provisional. However, the available
data from 18 countries are suggestive of a small
decrease compared to 2005.
The number of drug-induced deaths in those younger
than 25 years of age has seen a moderate overall
decrease in Europe, whereas in those Member States
joining the European Union after 2004, until recently
there has been an increase in the number of deaths
among this age group (153). However, an increase in the
proportion of younger cases has been observed in recent
years in Greece, Luxembourg and Austria, and to a
lesser extent in Bulgaria, Latvia and the Netherlands (154).
This observation requires further investigation, as it could
point to increases in the numbers of young people using
opioids in these countries.
Overall drug-related mortality
A recent study found that opioid users recruited in
treatment in eight sites (seven cities and one country) in
Europe had a very high mortality rate compared to peers
of the same age (see EMCDDA, 2006). Other cohort
studies have found mortality rates between six and 54
times higher among drug users than among the general
population. These differences are mainly due to drug
overdose, although other factors are also important, and
in some countries AIDS deaths play a signiﬁcant role.
Darke et al. (2007) formulate four broad categories
of deaths in drug users: overdoses (including alcohol
intoxication), disease, suicide and trauma. Among
diseases, conditions related to blood-borne viruses (HIV,
HCV and HBV, see above), neoplasms, liver diseases
and diseases of the circulatory and respiratory systems
can be associated with drug use. Trauma involves mostly
accidents homicides and other violence.
A recent Norwegian study of a cohort of drug users
admitted to drug treatment found that among 189
recorded deaths, overdoses, accounted for half of all
deaths, where the causes were known. Diseases, mainly
AIDS and liver diseases, accounted for almost a further
quarter, while suicide and trauma each accounted for
about one tenth, and alcohol poisonings for about 2%
(Figure 12). It should be noted that the proportion of
AIDS deaths can be considerably higher in countries with
a high HIV prevalence among drug users.
Cohort studies are a valuable tool for estimating and
understanding the overall mortality related to drug
use, but other approaches can help improve the
understanding of the issue and provide an overview
at national level. Several new methods in this area
are currently being explored by the EMCDDA, in
close collaboration with Member States, with the aim
of implementing them at EU level. In one of these
approaches, mortality rates are extrapolated from
cohort studies to local (Bargagli et al., 2005) or
national estimates of problem drug users (Cruts et al.,
2008). In another approach, drug-attributable fractions,
derived from various studies, are applied to the causes
of death that are most frequently related to drug use
(e.g. AIDS, accidents, suicides and poisonings) and
which are recorded in the general population mortality
registers.
Deaths indirectly related to drug use
AIDS deaths attributed to injecting drug use is another
important cause of death. Based on data from Eurostat
(149) See Figure DRD-8 in the 2008 statistical bulletin. For historical reasons, this trend refers to the EU-15 and Norway.
(150) See Figure DRD-11 in the 2008 statistical bulletin.
(151) Figures reported here differ from those reported in previous years because of changes in case deﬁnition or coverage in Denmark, Spain, France and
the United Kingdom, and updates in several countries.
(152) See ‘Opioid indicators are no longer decreasing’, p. 71, and Table DRD-2 (part i) and Figure DRD-12 in the 2008 statistical bulletin.
(153) See Figure DRD-13 (part i) in the 2008 statistical bulletin.
(154) See Figure DRD-9 in the 2008 statistical bulletin.
Chapter 7: Drug-related infectious diseases and drug-related deaths
87
and EuroHIV (End-year report for 2005, 2006), it can
be estimated that, in 2003, over 2 600 people died of
AIDS attributable to drug use (155). Most of these deaths
were reported in a few countries, with over 90% of them
occurring in Spain, France, Italy and Portugal. AIDS
mortality peaked in the mid-1990s and has decreased
substantially following the introduction and increased
coverage of HAART.
With the exception of Spain, Italy and, in particular,
Portugal, population mortality rates due to AIDS
attributable to drug injection are low. And, in many
countries, overdose mortality is considerably higher
than AIDS-related mortality among drug users (156). The
number of deaths from other causes (e.g. consequences
of other infectious diseases, violence, accidents) is
more difﬁcult to assess at present and there is a need to
improve data collection and estimation in this area (see
preceding section).
Suicide appears to be a frequent cause of death among
drug users. A literature review (Darke and Ross, 2002)
found that the suicide rate among heroin users was 14
times higher than that found in the general population.
Reducing drug-related deaths
The reduction of drug-related deaths is a goal of
most national drug strategies, but few countries have
adopted action plans or provided systematic guidance
on measures to be taken. However, in 2007, the United
Kingdom’s Department of Health issued new guidelines
on clinical management of drug misuse and dependence,
setting out speciﬁc actions for the prevention of drug-
related deaths.
The contribution that treatment, including substitution
along with psychosocial care and psychotherapy, can
make to reduce mortality among drug users was shown
in a prospective long-term study in Italy (Davoli et
al., 2007). The study was conducted among a cohort
of 10 454 heroin users entering public treatment
services from 1998 to 2001, and evaluated retention
in treatment and overdose mortality. The risk of death
among the cohort was, on average, increased by
a factor of 10 compared to the general population;
though, among drug users undergoing treatment,
the risk of death was four times that of the general
population, and those who had stopped treatment were
20 times more likely to die.
The targeted dissemination of information on overdose
risks and management via leaﬂets, brochures and
posters is common practice in most countries.
Furthermore, training workshops to increase knowledge
and skills in overdose management competence are
now reported from half of all Member States. This
training can address drug users and relatives, as well
as staff, and typically includes: information on speciﬁc
risks, including decreased tolerance after periods of
abstinence; the effects of polydrug use, in particular
concomitant alcohol use, and of using drugs when no
other person is present; and skills in ﬁrst aid. In Italy, a
combination of overdose response training with take-
home dispensing of naloxone is reported to be used
in half of the addiction care departments under public
health service coordination.
The proactive monitoring of the psychosocial wellbeing
of drug users, including of those in substitution
treatment, may have value as drug overdoses are in
many cases triggered by previous health or social
events, and rates of intentional overdose might be high
(Oliver et al., 2007).
A further challenge, in many countries, is that health and
social services are dealing with an ageing population
of long-term drug users, who may be more vulnerable
NB: The data are from a study based on a sample of 501 drug users
admitted for treatment for drug addiction during the period
1981–91. A total of 189 deaths were recorded up to 2003, of
which the cause of death could not be identiﬁed in 14 cases.
Source: Ødegard, E., Amundsen, E. J. and Kielland, K. B. (2007), ‘Fatal
overdoses and deaths by other causes in a cohort of Norwegian
drug abusers: a competing risk approach’, Drug and Alcohol
Dependence 89, pp. 176–82.
Figure 12: Known causes of death among a cohort of drug users
in Norway
Drug overdose Disease Suicide
Trauma Alcohol poisoning
(155) The year 2003 was taken as the most recent year for which information from almost all Member States regarding causes of death is available
through Eurostat. For detailed information on sources, numbers and computations see Table DRD-5 in the 2008 statistical bulletin.
(156) See Figure DRD-7 (part ii) in the 2008 statistical bulletin.
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to both drug overdose and a range of negative health
consequences. Drug injectors, in particular, may suffer from
high levels of somatic disease, notably chronic infections of
the liver, which further increase their vulnerability.
Elevated risk of drug-induced death on completion
of prison sentences or treatment
The risk of drug-induced death in the immediate period
after release from prison or on relapse after treatment is
substantially elevated, according to studies carried out in
Europe and elsewhere.
A recent study carried out in the United Kingdom (England
and Wales) compared the records of almost 49 000 prisoners
released during 1998–2000 with all deaths recorded up to
November 2003 (Farrell and Marsden, 2008). Of the 442
deaths that occurred among the sample during this period,
the majority (59%) were drug-related. In the year following
release, the drug-induced mortality rate was 5.2 per 1 000
men and 5.9 per 1 000 women. In the period immediately
after release, expected rates were exceeded by more than
10 times for women and more than eight times for men. All
female and 95% of male deaths that occurred during the
ﬁrst fortnight outside prison were drug-related, and could be
attributed to drug overdoses or, more generally, to substance
use disorders. Coroners’ records cited the involvement of
opioids in 95% of the drug-induced deaths, benzodiazepines
in 20%, cocaine in 14% and tricyclic antidepressants in 10%
of cases.
The VEdeTTE study in Italy (Davoli et al., 2007) observed a
death rate from overdose of one per 1 000 among heroin
users in treatment and 23 per 1 000 in the ﬁrst month after
treatment, corresponding to a risk of overdose death 27 times
higher in the ﬁrst month out of treatment, after adjustment for
possible confounders.
Despite the observed connection between drug-induced
deaths and prison release or treatment termination, few
countries are systematically investing in educating prisoners
or those in treatment on the risk of overdose. Continuity of
care and rehabilitation of drug users that are released from
prison are also undeveloped in many countries. Improvements
in these two areas could represent valuable opportunities to
prevent drug-related deaths.
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Introduction
The use of new psychoactive substances can have
important public health and policy implications, but
monitoring emerging trends is a considerable challenge.
New patterns of drug use are difﬁcult to detect
because, typically, they ﬁrst emerge at low levels, and
in speciﬁc localities or among restricted sub-groups of
the population. Few countries have monitoring systems
that are sensitive to this kind of behaviour and the
methodological difﬁculties presented by monitoring this
kind of drug use are considerable. Nonetheless, the
importance of identifying potential new threats is widely
recognised, and it is in direct response to this that the
European Union, through the Council decision on new
psychoactive substances, developed an early-warning
system that provides a quick-response mechanism to
the emergence of new psychoactive substances on the
European drug scene. Activities in support of the early-
warning system form an important part of the work of the
EMCDDA and ﬁt within a broader perspective of using a
wide variety of data sources to improve the timeliness and
sensitivity of the European drug monitoring system.
EU action on new psychoactive substances
The Council decision on new psychoactive substances (157)
establishes a mechanism for the rapid exchange of
information on new psychoactive substances that may pose
public health and social threats. It also provides for an
assessment of the risks associated with these new substances
in order that measures applicable in the Member States
for the control of narcotic and psychotropic substances
can also be applied to new substances. In May 2007,
a risk assessment of a new psychoactive substance BZP
(1-benzylpiperazine) was carried out by the extended
Scientiﬁc Committee of the EMCDDA, and a report was
submitted to the Council and the European Commission (158).
The risk assessment concluded that due to its stimulant
properties, risk to health and lack of medical beneﬁts,
there was a need to control BZP, but the control measures
should be appropriate to the relatively low risk posed by
the substance. In March 2008, the Council adopted a
decision deﬁning BZP as a new psychoactive substance
which is to be made subject to control measures and
criminal provisions. Member States have one year to take
the necessary measures, in accordance with their national
law, to submit BZP to control measures, proportionate
to the risks of the substance, and criminal penalties, as
provided for under their legislation complying with their
obligations under the 1971 United Nations Convention on
Psychotropic Substances.
In March 2007, the EMCDDA and Europol reported to the
Commission on the active monitoring of 1-(3-chlorophenyl)
piperazine (mCPP) (159). This report was produced for
information purposes only and concluded that ‘mCPP was
unlikely to become established as a recreational drug in
its own right’ due to its indistinct psychoactive properties
and some adverse effects. Since it appears that mCPP has
no particular appeal to users, it is likely that its market in
the European Union is driven by supply push rather than
demand pull.
During 2007, a total of 15 new psychoactive substances
were notiﬁed for the ﬁrst time through the early-warning
system to the EMCDDA and Europol. The group of newly
notiﬁed substances is diverse and, besides new synthetic
drugs, includes medicinal products and naturally occurring
substances. Nine of the newly reported compounds were
synthetic drugs similar to those listed in Schedules I and II
of the 1971 United Nations Convention on Psychotropic
Substances. They included substances from known
chemical groups such as phenethylamines, tryptamines
and piperazines, as well as substances with a less
common chemical make-up. The group is equally divided
between substances that have pronounced hallucinogenic
effects and those that exhibit predominantly stimulant
properties.
For the ﬁrst time, in 2007, three naturally occurring
substances have been reported through the information
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(157) Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances
(OJ L 127, 20.5.2005, p. 32).
(158) http://www.emcdda.europa.eu/publications/risk-assessments/bzp
(159) http://www.emcdda.europa.eu/html.cfm/index16775EN.html
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exchange mechanism; among them, Salvia divinorum, a
plant with potent psychoactive properties (160).
Internet — a marketplace for psychoactive
substances
The Internet offers a window on the world of the drug user
through online forums and chat rooms as well as the sites of
online shops selling psychoactive alternatives to controlled
substances. Information available can give insights into
different aspects of the online marketplace in drugs, for
example on the working methods of online shops; the
way that they respond to users’ demands, and new trends
among young people. To identify current developments in
the online drug market, the EMCDDA conducted a snapshot
study in early 2008, which surveyed 25 online shops. The
results of that study are presented here.
Online shops
There are reports of an increasing number of online
shops selling psychoactive alternatives to controlled
drugs such as LSD, ecstasy, cannabis and opioids. While
the substances offered for sale by the online shops are
often referred to as ‘legal highs’ or ‘herbal highs’, in
some European countries these drugs are covered by the
same laws as controlled drugs, and may incur the same
penalties.
Within the European Union, the majority of online shops
identiﬁed in the snapshot study are based in the United
Kingdom and the Netherlands and, to a lesser extent,
Germany and Austria. Online shops often specialise
in certain types of drug-related products, for example
some mainly sell drug paraphernalia, some specialise in
hallucinogenic mushrooms or ‘party pills’, while others
market a wide range of herbal, semi-synthetic and
synthetic substances.
Online shops based in Europe advertise over 200
psychoactive products. The most commonly encountered
‘legal highs’ are Salvia divinorum, kratom (Mitragyna
speciosa), Hawaiian baby woodrose (Argyreia nervosa),
hallucinogenic mushrooms (EMCDDA, 2006), and a
variety of ‘party pills’.
(160) See ‘New substances under control’.
New substances under control
Since January 2006, 12 countries have reported additions
or changes to their lists of controlled substances. mCPP
(1-(3-chlorophenyl)piperazine) has been added to the
list of controlled substances in six countries (Belgium,
Germany, Lithuania, Hungary, Malta, Slovakia) and BZP
(1-benzylpiperazine) has been added in four countries
(Estonia, Italy, Lithuania, Malta). Of these substances,
mCPP had been actively monitored by the EMCDDA
and Europol, and BZP had been the subject of a risk
assessment in 2007. Other substances being brought
under control in the period include the hallucinogens DOC
(4-chloro-2,5-dimethoxyamphetamine), DOI (4-iodo-2,5-
dimethoxyamphetamine) and bromo-dragonﬂy (bromo-
benzodifuranyl-isopropylamine) in Denmark and Sweden,
and ketamine in Estonia.
Various plants with psychoactive properties are also
being controlled. To this end, Belgium has restructured its
legislation on psychotropic substances to include a new
category that lists plants or parts of plants under control,
rather than just their psychoactive ingredients as before.
Among the plants placed on the list are khat (qat, Catha
edulis) and Salvia divinorum. Khat is now controlled
by 11 countries in Europe (a 2005 risk assessment in
the United Kingdom recommended against control). In
2006, Sweden added salvinorine-A, the main active
principle of Salvia divinorum, to its list; the plant has
also been put under control in Germany in 2008. In the
same period, Tabernanthe iboga has been added to the
list of controlled substances in France, following legal
control of the active ingredient, ibogaine, in Belgium,
Denmark and Sweden. Finally, in response to deaths
associated with hallucinogenic mushrooms, Ireland and the
Netherlands have both moved to close earlier loopholes
that had allowed sale and possession of fresh mushrooms
containing psilocin; in Ireland the law came into force
in January 2006, while in the Netherlands it is in the
parliamentary process at the time of writing.
For further information, a list of substances controlled
across the EU and Norway is presented in the ‘Substances
and classiﬁcations table’ in the European Legal Database
on Drugs (http://www.emcdda.europa.eu/publications/
legal-reports).
Internet study methodology
To obtain a snapshot, Internet searches were conducted in
January 2008 using multilingual keywords and the search
engine Google (http://www.google.com). A total of 68
EU-based online shops were identiﬁed selling various types
of ‘legal highs’. They were stratiﬁed according to their
country of origin. EU country code domains (e.g. ES, FR,
DE) or other indications of being EU-based (e.g. contact
address) were used for the identiﬁcation of the country of
origin. More than half of the shops (52%) were located
in the United Kingdom, 37% in the Netherlands, 6% in
Germany, 4% in Austria and 1% in other countries (e.g.
Ireland, Poland). A random sample of 25 online shops was
selected for detailed analysis. Sampling fractions in each
stratum (country of origin) were proportional to those of
the total sample of online shops. Online shops that sold
exclusively to the trade, rather than to the consumer, were
excluded as were those that sold only hallucinogenic
mushrooms.
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The substances offered for sale are advertised to have
effects similar to those of controlled drugs. Both Salvia
divinorum and Hawaiian baby woodrose, along with the
less frequently offered morning glory (Ipomoea violacea)
are described as producing hallucinogenic effects similar
to those of LSD. Kratom is often marketed as a substitute for
opioids, various preparations are offered as alternatives
to cannabis, and ‘party pills’ are sold as alternatives
to MDMA. The ‘party pills’ on offer may contain plant
material or semi-synthetic or synthetic substances.
The main ingredient of synthetic ‘party pills’ is often
benzylpiperazine (BZP), though the online shops appear to
have replacement substances ready for when BZP becomes
subject to control measures in the EU Member States. The
advertised prices of substances on offer vary from EUR 1
to EUR 11 for the equivalent of one dose.
GHB and its precursor GBL: follow-up
In Europe, gamma-hydroxybutyric acid (GHB) has been
under surveillance since 2000, when a risk assessment of
the substance was conducted under the terms of the 1997
joint action on new synthetic drugs (EMCDDA, 2002).
The addition of GHB to Schedule IV of the 1971 UN
Convention on Psychotropic Substances, in March 2001,
obliged all EU Member States to control the drug under
their legislation addressing psychotropic substances, and
new controls rapidly curtailed the previously open sale of
GHB.
GHB occurs naturally in the human body, but is also used
as a medicine and as a recreational drug. Non-medical
use of GHB surfaced on the recreational nightlife scene
in some parts of Europe, the USA and Australia during
the 1990s, speciﬁcally in nightclubs where many other
drugs were being commonly used. Concerns quickly arose
about the health risks associated with its use. In particular,
anxieties arose about the potential for surreptitiously
adding GHB to drinks (commonly referred to as ‘drink
spiking’) to facilitate sexual assault. However, there is a
lack of forensic evidence for this, and establishing it is
difﬁcult due to the narrow time window for detecting GHB
in body ﬂuids. However, the association of GHB with
drug-facilitated sexual assault may have contributed to a
relatively ‘negative image’ of the substance (EMCDDA,
2008c).
GBL
Concerns are now arising about reports of consumption
of gamma-butyrolactone (GBL), a precursor of GHB,
which is not a scheduled substance in any of the UN drug
control conventions. GBL is rapidly converted into GHB
in the body, and there is currently no readily available
toxicological test to determine which of the two substances
has been consumed.
GHB can be readily manufactured from GBL and
1,4-butanediol (1,4-BD), which are commonly and legally
used in many branches of industry (e.g. chemicals,
plastics, pharmaceuticals) and are thus available from
commercial suppliers. The commercial availability of
GBL has the potential to make this substance available to
drug trafﬁckers and consumers at levels of price and risk
much lower than those normally encountered in illicit drug
markets in the European Union. For example, the average
price of a 1 gram dose of GBL purchased in bulk on the
Internet varies from EUR 0.09 to EUR 2.
Health risks
Both GHB and GBL have a steep dose–response curve,
with rapid onset of symptoms, which greatly increases
the risks associated with illicit use. Nausea, vomiting
and various degrees of impaired consciousness are the
main adverse affects in most reported cases of GHB
intoxication. However, the frequent presence of other
drugs may complicate the clinical presentation. A Dutch
study of 72 GHB users reported that the majority had
passed out at least once while on GHB and some had
done so frequently (Korf et al., 2002). In a survey of GHB
and GBL users in the United Kingdom, adverse reactions
were reported to be more common in club settings than
in private homes (Sumnall et al., 2008). In London and
Barcelona, the patient proﬁle for GHB intoxications has
been described as mainly young and male, with the
majority presenting at weekends, usually with concomitant
consumption of alcohol or illicit drugs (Miro et al., 2002;
Wood et al., 2008).
Intoxications and emergencies associated with GHB
have been reported in the scientiﬁc literature and to the
EMCDDA since the late 1990s, albeit not systematically, in
Belgium, Denmark, Spain, Luxembourg, the Netherlands,
Finland, Sweden, the United Kingdom and Norway.
Although GHB is associated with only a very small
proportion of all drug intoxication emergencies requiring
hospital or ambulance emergency services, numbers
appear to have increased since 2000. In Amsterdam, in
2005, the proportion of requests for emergency assistance
that required transportation to hospital was higher for cases
related to GHB/GBL than to those involving other drugs.
In the United Kingdom, one London hospital emergency
department — with a catchment area that includes local
club venues which typically, but not exclusively, cater for
the gay club scene — recorded a total of 158 GHB and
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GBL presentations in 2006. While most of these patients
reported consumption of GHB, chemical analysis of
samples collected from nightclubs in the same catchment
area during the same time period found that over half
of the samples contained GBL rather than GHB. This
suggests that GBL use may be more common than was
previously thought (Wood et al., 2008).
Due to its rapid elimination from the body, it is difﬁcult to
establish GHB/GBL as a cause of intoxication or death.
Furthermore, there is an absence of an accurate and
comparable system for recording the number of deaths
and non-fatal emergencies related to the use of GHB and
its precursors.
Responses
Some Member States (Italy, Latvia, Sweden) have
chosen to control GBL (or GBL and the other precursor
1,4-BD) under drug control or equivalent legislation
and discussions about possible further controls are in
progress in the United Kingdom. In accordance with
Community legislation on control of precursors, GBL
and 1,4-BD are included in the list of non-controlled
substances for which voluntary monitoring measures to
prevent their diversion from licit industrial uses are in
place in all Member States.
Interventions for prevention and harm reduction in
response to the use of GHB/GBL are commonly provided
by national and community drugs projects that target
nightlife settings. These interventions usually consist
of training club staff and disseminating information
about the risks of using GHB and other drugs. Such
interventions often take place in conjunction with other
interventions related to ‘club drugs’ and use of alcohol
and drug combinations (EMCDDA, 2008e).
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